Conditions: Postoperative Pain
Keywords: Total knee arthroplasty Analgesia Pain management
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 297
Healthy volunteers: no

Brief summary:
The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect achieved following single dose injection femoral nerve block with liposome bupivacaine, and (2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be tested in Part 2.

Part 2: The primary objective of Part 2 is to compare the magnitude and duration of the analgesic effect of single injection femoral nerve block of a single dose level of liposome bupivacaine (selected from Part 1) with placebo (preservative-free normal saline).

Detailed description:
This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study in subjects undergoing primary unilateral total knee arthroplasty (TKA) under general or spinal anesthesia. Note: Bupivacaine cannot be used as the spinal anesthetic.

Part 1 During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be randomized to receive a single dose injection femoral nerve block with either one of three doses of liposome bupivacaine (67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance. Preservative-free normal saline will be added to the 67 mg and 133 mg doses of study drug to achieve a volume of 20 mL.

Part 2 In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately 90 liposome bupivacaine subjects and 90 placebo subjects) will receive a single dose injection femoral nerve block with the selected dose level of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance.

Arms:
arm 1: 5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively arm 2: 10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively arm 3: 20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively arm 4: 20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively arm 5: 20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively arm 6: 20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively

Interventions: intervention 1: Placebo intervention 2: EXPAREL 67 mg intervention 3: EXPAREL 133 mg intervention 4: EXPAREL 266 mg
Intervention descriptions: intervention 1: Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty intervention 2: 5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty intervention 3: 10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty intervention 4: 20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty

Protocol document:
Prot_000.pdf: 
Pacira Pharmaceuticals, Inc. 
 
 
EXPAREL 
Document: 
Clinical Study Protocol 
Official Title: 
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-
Controlled, Dose Ranging Study to Evaluate the Safety, Efficacy, and 
Pharmacokinetics of Single Injection Femoral Nerve Block With 
Liposome Bupivacaine for Postsurgical Analgesia in Subjects 
Undergoing Total Knee Arthroplasty 
NCT Number: 
NCT01683071 
Document Date: 
April 19, 2013 
 


Clinical Study Protocol
Amendment 2
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,
Dose-Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single
Injection Femoral Nerve Block with Liposome Bupivacaine for Postsurgical Analgesia
in Subjects Undergoing Total Knee Arthroplasty
Confidentiality Statement
The information contained in this document is confidential and the property of Pacira Pharmaceuticals, Inc.
It should not be reproduced, revealed, or sent to third parties other than Institutional Review Boards/Independent
Ethics Committees and the Investigator’s research support staff participating in the conduct of the study without
the prior written authorization of Pacira Pharmaceuticals, Inc.
Protocol No.:
402-C-323
EudraCT No.:
N/A
IND No.:
69,198
Study Phase:
2/3
Study Drug:
Liposome bupivacaine
Date:
19 April 2013 (Amendment 2)
04 September 2012 (Amendment 1)
03 August 2012 (original)
Study Sites:
Up to 40 sites in the United States
Sponsor:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
Tel: (858) 625-2424


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
2 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
SUMMARY OF CHANGES
Unless otherwise noted, the protocol clarifications and revisions stated below were made based
on discussion with the Principal Investigators.
Section 2 (Synopsis)

Methodology:
o
The second postsurgical rescue medication (PCA and/or opioid) text was changed
from: "The second rescue medication will be PCA-administered opioid (morphine
or hydromorphone). The PCA pump will be programmed to deliver either: (1)
on-demand morphine boluses of 1.5 mg with a lockout interval of 6 minutes and an initial
maximum hourly dose of 15 mg or (2) on-demand hydromorphone boluses of 0.2 mg
with a lockout interval of 10 minutes and an initial maximum hourly dose of 1.2 mg."
to: "The second rescue medication will be an on-demand PCA-administered opioid
(morphine or hydromorphone). The PCA pump will be programmed to deliver either
on-demand morphine or on-demand hydromorphone boluses at a dose and lockout
interval in accordance with the site's standard practice."
o
The opioid-related adverse events (ORAE) questionnaire was removed from the Part 2
study assessments as well as from the study endpoints as there is no validated outcomes
instrument available.
o
Text was clarified regarding follow-up procedures for discontinued subjects and the
analgesic use during the 72-hour observation period. The text was changed
from: "Subjects who do not receive adequate pain control with this regimen are to be
withdrawn from the study and followed for safety only. No other analgesic agents,
including non-steroidal anti-inflammatory agents (NSAIDs), are allowed during the
72-hour observation period."
to: "Subjects who do not achieve adequate pain control with this regimen are to be
withdrawn from the study and followed for AEs only. No other analgesic agents,
including non-steroidal anti-inflammatory agents (NSAIDs), are allowed during the
72-hour observation period or until the subject is withdrawn from the study, whichever is
sooner."

Eligibility Criteria:
o
Exclusion criterion #5 was changed
from: "Use of selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin
(Lyrica®), or duloxetine (Cymbalta®) within 3 days of surgery."
to: "Initiation of treatment with any of the following medications within 1 month of study
drug administration or if the medication(s) are being given to control pain: selective
serotonin reuptake inhibitors (SSRIs), selective norepinepherine reuptake inhibitors
(SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
3 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013

Eligibility Criteria (Cont.)
o
Exclusion criterion #8 was changed
from: "Contraindication to any of the pain-control agents planned for postsurgical use
(e.g., morphine, hydromorphone, oxycodone, bupivacaine)."
to: "Contraindication to hydromorphone, oxycodone, or bupivacaine."
o
The following exclusion criterion was added: "Use of dexmedetomidine HCl (Precedex®)
within 3 days of surgery."
Section 4 (List of Abbreviations)
SNRI and SSRI were added.
Table 1 (Time and Events Schedule of Study Procedures)

"Part 1 only" was added to the row for the predefined ORAE assessment.

ORAE was defined in the table footnote.
Sections 9, 10, 11, 12, and 13
The changes made in the Synopsis (listed above) were made to Sections 9 though 13.
Sections 10.3 (Removal of Subjects from Therapy or Assessment
Safety assessments (the neurological examination, cold test, 20-meter walk test, and collection of
a blood sample for pharmacokinetic analysis, if possible) were specified in the early termination
procedures.
Section 11.4 (Selection of Doses in the Study)
For clarification, "or placebo" was added to the end of the first sentence in the second paragraph.
Section 11.5.1 (Blinding Procedures)
The blinding procedures were modified.
Section 11.6.1 (Prior and Concomitant Therapy and Medications)
The text in this section was clarified and modified based on the changes made in the eligibility
criteria.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
4 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Section 11.6.2 (Permitted or Restricted Therapy and Medication During Surgery)
For completeness, the following text was added: "Prophylactic antiemetics or planned
postsurgical antiemetics given without regard to the subject's emesis needs is prohibited."
Section 11.6.3 (Permitted or Restricted Therapy and Medication After Surgery through
72 Hours After Surgery)
Dexmedetomidine HCl (Precedex) was added to the prohibited medications.
Section 13.6 (Additional Procedures at Withdrawal if Prior to 72 Hours)
For clarification, this section was added.
Section 18 (Appendices)
Minor revisions were made to some of the appendices.
"Part 1 only" was added to the ORAE questionnaire in Appendix 6.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
5 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
SIGNATURE PAGE
22 April 2013
Erol Onel, MD
Executive Medical Director
Date
23 April 2013
Gary Patou, MD
Chief Medical Officer
Date
23 April 2013
Patricia Mills, RN
Sr. Director, Drug Safety and
Pharmacovigilance
Date


Pacira Phar maceuticals, Inc. 
402-C-323 (TKA)
Liposo me Bupivacaine 
Clinical Stud y Protocol Amendment 2
Document No. 040-00171.006 
6 of 71 
PCDOC #138012
CONFIDENT IAL 
19 April 2013
2. 
SYNOPSIS
Na me of Sponsor/Co mpany:
Pacira Phar maceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Stud y Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Na me of Finished Product:
Liposo me Bupivacaine
Na me of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Title of Study: A Multicenter , Rando mized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging
Stud y to Evaluate the Safety, Efficacy, and Phar macokinetics of Single Injection Femoral Nerve Block with
Liposo me Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty
Principal Investigators: To be determined.
Study Center(s): Up to 40 sites in the United States.
Publications (Reference): None.
Objectives:
Primar y Objectives:
Part 1: The primar y objectives of Part 1 are to (1) evaluate three dose levels of liposo me bupivacaine versus
placebo with respect to the magnitude and duratio n of the analgesic effect achieved follo wing single dose
injection femoral nerve block with liposo me bupivacaine, and (2) select a single therapeutic dose of liposome
bupivacaine fro m the three dose levels to be tested in Part 2.
Part 2: The primar y objective of Part 2 is to compare the magnitude and duratio n of the analgesic effect of single
injection femoral nerve block of a single dose level of liposome bupivacaine (selected from Part 1) with placebo
(preservative-free nor mal saline for injection).
Secondar y Objectives:
The secondary objectives are to evaluate additional efficacy parameter s, characterize the p har maco kinetic (PK)
profile of liposo me bupivacaine when ad ministered as a femoral nerve block, and further assess the safety profile
of liposo me bupivacaine.
M ethodology:
This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging
stud y in subjects undergoing p rimar y unilateral total knee arthroplasty (TKA) under general or spinal anesthesia.
Note: Bupivacaine cannot be used as the spinal anesthetic.
On Day 1, eligible subjects will be randomized to receive a single dose of study drug administered in a blinded
manner within 2 hours prior to the surgical procedure as a femoral nerve block. At the conclusion of the block,
a femoral ner ve catheter is to be left in place and hep-locked (see “Postsur gical Rescue Medication” belo w).
Additionally, a patient-controlled analgesia (PCA) pump will be established prior to the completion of the
surgery. The PCA pump will not be loaded at this time. The use of fentanyl will be permitted during surgery.
However, intraoperative administration of morphine or any other analgesics (including intrathecal opioids), local
anesthetics, or anti-inflammatory agents is prohibited, unless needed to treat an adverse event (AE).
All subjects will be required to remain in the study site for a minimum of 72 hours after the end of surgery for
postsurgical assessments. The study staff will ensure adequate safety precautions are in place in order to prevent
falls (e.g., use of support devices during ambulation, such as a knee immobilizer and walker/crutches), as needed.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
7 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Methodology (Cont):
Part 1
During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be randomized to receive a
single dose injection femoral nerve block with either one of three doses of liposome bupivacaine (67, 133, or
266 mg) or placebo in 20 mL under ultrasound guidance. Preservative-free normal saline will be added to the
67 mg and 133 mg doses of study drug to achieve a volume of 20 mL.
After all subjects have completed the 72-hour assessments in Part 1, an analysis will be conducted in order to
select a single therapeutic dose from the three liposome bupivacaine dose levels tested. An unblinded dose
selection committee will review at least the results from the following assessments conducted during Part 1:
(1) the area under the curve (AUC) of the numeric rating scale (NRS) at rest (NRS-R) pain intensity scores
through 72 hours; (2) total postsurgical opioid consumption; (3) the time to first opioid rescue; and (4) safety
data. Based on a clinical evaluation of the data, the committee will determine the apparent efficacy and safety of
each of the three liposome bupivacaine dose levels tested and will recommend a dose level for Part 2 of the study.
Statistical significance will not be required in order to recommend a dose level for Part 2. The unblinded dose
selection committee also will recommend whether the sample size for Part 2 should be increased.
Part 2
In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately 90 liposome
bupivacaine subjects and 90 placebo subjects) will receive a single dose injection femoral nerve block with the
selected dose level of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo in 20 mL under ultrasound
guidance.
Postsurgical Rescue Medication
Subjects should only receive rescue medication upon request for pain control, as needed.
The first rescue medication will be intravenous (IV) hydromorphone 0.5 mg, which will be administered once via
bolus only. At this time, the PCA should be loaded with opioid (morphine or hydromorphone only).
The second rescue medication will be an on-demand PCA-administered opioid (morphine or hydromorphone).
The PCA pump will be programmed to deliver either on-demand morphine or on-demand hydromorphone
boluses at a dose and lockout interval in accordance with the site's standard practice. A continuous infusion
(background or basal rate) of morphine or hydromorphone is not permitted. If the subject’s pain is excessive or
pain control is inadequate, then the bolus dose may be adjusted according to local hospital practices; however,
adding a basal rate is prohibited. Once a subject is tolerating oral (PO) medication, PO immediate-release
oxycodone may be administered (but not more than 10 mg every 4 hours).
If a subject’s pain is inadequately controlled by opioids, a third rescue medication consisting of conventional
bupivacaine HCl at a concentration of 0.125% (1.25 mg/mL) at a rate of 8 mL per hour for up to 12 hours may be
administered via the previously placed femoral nerve catheter.
Subjects who do not achieve adequate pain relief with this regimen will be withdrawn from the study and
followed for AEs only. No other analgesic agents, including non-steroidal anti-inflammatory agents (NSAIDs),
are allowed during the 72-hour observation period or until the subject is withdrawn from the study, whichever is
sooner.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
8 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Methodology (Cont.)
Postsurgical Assessments: Postsurgical assessments will include pain intensity scores using the 0-10 point
NRS-R and NRS with activity (NRS-A) (where the prescribed activity is active knee flexion up to 45 degrees)
(see Appendix 1); use of supplemental opioid pain medication; neurological assessment (see Appendix 2);
cardiac assessment (i.e., ECG recordings); sensory function assessment (i.e., cold test); motor function
assessment (i.e., 20-meter walk test); vital signs; overall benefit of analgesia score (OBAS) questionnaire
(see Appendix 3); subject satisfaction with postsurgical pain control (see Appendix 4); physician satisfaction
with return of sensory/motor function (see Appendix 5); and an opioid-related AE questionnaire during Part 1
only (see Appendix 6). Adverse events will be recorded through Day 30. If a cardiac or neurological event
occurs during Part 1 or Part 2 of the study that the Investigator believes may be associated with high levels of
systemic bupivacaine, an unscheduled PK blood sample should be collected at the time that the event is noted.
Safety and efficacy assessments will be conducted at pre-specified time points after the end of surgery (defined as
the time of the last suture/staple).
A follow-up visit will be scheduled for all subjects on Day 30.
Pharmacokinetic Assessments (Part 1 only): Blood samples for PK analysis will be obtained from subjects at
specific sites during Part 1 of the study at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 36, 48, 60, and
72 hours after the beginning of study drug administration. Blood samples for PK analysis should be collected
even if the subject is not yet in surgery or is still in surgery. Placebo samples will be collected to maintain the
treatment double-blind but will not be analyzed. Samples from subjects receiving bupivacaine nerve block rescue
will not be analyzed. (Note: At time points when the PK and NRS pain intensity assessments coincide, the NRS
pain intensity assessments will be conducted before the blood draw.)
Number of Subjects (Planned):
Approximately 280 subjects are planned for enrollment in this study: 100 subjects (25 per treatment arm) in
Part 1 and 180 subjects (approximately 90 liposome bupivacaine subjects and 90 placebo subjects) in Part 2.
The number of subjects in Part 2 may be increased after review of the Part 1 data.
Eligibility Criteria:
Inclusion Criteria:
1.
Male or female, ≥18 years of age.
2.
Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.
3.
American Society of Anesthesiology (ASA) Physical Status 1, 2, or 3.
4.
Able to demonstrate motor function by performing a 20-meter walk unassisted with the optional use of a
4-legged walker, and sensory function by exhibiting sensitivity to cold.
5.
Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
9 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Exclusion Criteria:
1.
Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study
drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an
acceptable method of birth control. If of childbearing potential, must have a documented negative pregnancy
test within 24 hours before surgery.
2.
Planned concurrent surgical procedure (e.g., bilateral TKA).
3.
Use of any of the following medications within the times specified before surgery: long-acting opioid
medication, NSAIDs, or aspirin (except for low-dose aspirin used for cardioprotection or acetaminophen)
within 3 days, or any opioid medication within 24 hours.
4.
Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in
the postsurgical period for pain that is not strictly related to the TKA surgery and which may confound the
postsurgical assessments (e.g., significant pain from other joints including the non-index knee joint, chronic
neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery).
5.
Initiation of treatment with any of the following medications within 1 month of study drug administration or
if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective
norepinepherine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).
6.
Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
7.
Body weight < 50 kg (110 pounds) or a body mass index ≥40 kg/m2.
8.
Contraindication to hydromorphone, oxycodone, or bupivacaine.
9.
Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational
drug, whichever is longer, prior to study drug administration, or planned administration of another
investigational product or procedure during the subject’s participation in this study.
10. Previous participation in a liposome bupivacaine study.
11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol
within the past 2 years.
12. Failure to pass the urine drug screen.
13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator,
could interfere with study assessments or compliance.
14. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of
the skin or localized carcinoma in situ of the cervix.
15. Current or historical evidence of any clinically significant disease or condition, especially cardiovascular or
neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate
the subject’s postsurgical course.
16. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an
increased vulnerability to study drugs and procedures.
17. Subjects who are planned to receive Entereg® (alvimopan).
18. Subjects who will receive prophylactic antiemetics or planned postsurgical antiemetics given without regard
to the subject's emesis needs.
19. Use of dexmedetomidine HCl (Precedex®) within 3 days of surgery.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
10 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Test Product, Dose, Mode of Administration, and Lot Number:
Name: Liposome bupivacaine.
Active Ingredient: Bupivacaine 1.3%, 13.3 mg/mL.
Dosage: Single administration of 67, 133, or 266 mg. Preservative-free normal saline will be added to the 67 mg
and 133 mg doses of study drug to achieve a volume of 20 mL.
Lot Number: To be determined.
Mode of Administration: Ultrasound-guided femoral nerve block prior to the surgical procedure.
Reference Product, Dose, Mode of Administration, and Lot Number:
Name: Placebo (preservative-free normal saline for injection).
Dosage: Single administration in a volume of 20 mL.
Lot Number: To be determined.
Mode of Administration: Ultrasound-guided femoral nerve block prior to the surgical procedure.
Duration of Subject Participation in Study:
Each subject’s participation in this study could be up to 64 days (up to 30 days for the screening period and up to
34 days for post-dosing follow-up).
Efficacy Assessments:
The following efficacy measurements will be assessed at the times specified after the end of surgery:

Pain intensity scores using the NRS-R at baseline (prior to the nerve block), and 2, 4, 8, 12, 24, 36, 48,
60, and 72 hours, and at first request for rescue pain medication.

Pain intensity scores using the NRS-A (where the prescribed activity is actively flexing the involved
knee up to 45 degrees) at baseline (prior to the nerve block), and 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours,
and at first request for rescue pain medication.

Time of first opioid rescue.

Opioid use.

Conventional bupivacaine HCl use.

Sensory function assessment (i.e., cold test) at baseline, when the subject wakes up after surgery (general
anesthesia subjects only), and at 2, 4, 12, 24, 36, 48, 60, and 72 hours after surgery, or until the subject’s
sensitivity to cold is demonstrated on two consecutive evaluations.

Overall benefit of analgesia score questionnaire at 24, 48, and 72 hours.

Subject satisfaction with postsurgical pain control at 72 hours and Day 30 using a 5-point Likert scale.

Predefined treatment-emergent opioid-related AEs at 72 hours following surgery during Part 1 only.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
11 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Efficacy Endpoints:
The efficacy endpoints listed below will be assessed based on the efficacy measurements conducted at the
specified time points after the end of surgery.
Primary Endpoint
The primary efficacy endpoint is the AUC of the NRS-R pain intensity scores through 72 hours.
Secondary Endpoints
The following secondary endpoints will be analyzed using a hierarchical testing procedure.

Total postsurgical opioid consumption (in mg) through 72 hours.

Time to first opioid rescue.
Tertiary Endpoints

Total postsurgical opioid consumption (in mg) through 24, 36, 48, and 60 hours.

Overall benefit of analgesia score questionnaire at 24, 48, and 72 hours.

Subject satisfaction with postsurgical pain control at 72 hours and Day 30.

The NRS-R and NRS-A pain intensity scores at each assessed time point.

The AUC of the NRS-R pain intensity scores through 24, 36, 48, and 60 hours.

The AUC of the NRS-A pain intensity scores through 24, 36, 48, 60, and 72 hours.

The AUC of the NRS-R pain intensity scores from 24-48 and 48-72 hours.

Proportion of subjects who are pain free (defined as an NRS pain intensity score of 0 or 1) at each
assessed time point.

Proportion of subjects who receive the following rescue medication(s):
o
Subjects who receive no rescue medications (i.e., opioid or conventional bupivacaine HCl).
o
Subjects who only receive IV hydromorphone bolus.
o
Subjects who receive IV hydromorphone bolus and a second opioid medication.
o
Subjects who receive IV hydromorphone bolus, a second opioid medication, and conventional
bupivacaine HCl.

Proportion of subjects at each time point with sensitivity to cold in one of the dermatomes.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
12 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Pharmacokinetic Endpoints (Part 1 only):
Pharmacokinetic parameters will be estimated from plasma bupivacaine measurements using non-compartmental
analysis, based on the sampling schedule described above (at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12,
24, 36, 48, 60, and 72 hours after the beginning of study drug administration). The following parameters will be
determined:

Peak plasma concentration (Cmax).

Time to peak plasma concentration (Tmax).

Area under the plasma concentration versus time curve (AUC) from time 0 to the last collection time
after drug administration (AUC0-last).

Area under the plasma concentration versus time curve from time 0 extrapolated to infinity after drug
administration (AUC0-∞).

The apparent terminal elimination rate constant (λz).

The apparent terminal elimination half-life (t1/2el).
Safety Assessments:
The following safety measurements will be conducted at the specified time points:

Adverse events from the time of randomization through Day 30.

Vital signs (resting heart rate and blood pressure) at baseline, 30 minutes, 1 hour, and 2 hours after
surgery.

Neurological assessment at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48,
60, and 72 hours after surgery.

Cardiac assessment (i.e., ECG recordings) at baseline (beginning approximately 1 hour prior to study
drug administration) through the first 72 hours after study drug administration. Electrocardiogram
changes will be examined using the ECG data closest to the median Tmax from each dose group.

Motor function assessment (i.e., ability to perform a 20-meter walk, unassisted with the optional use of a
4-legged walker) at 24 hours and 72 hours after surgery and on Day 30.

Physician satisfaction with return of sensory/motor function at 72 hours and on Day 30.
Safety Endpoints:
The following safety endpoints will be assessed based on the safety measurements conducted at the specified time
points:

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through
Day 30.

Change from baseline in vital signs (resting heart rate and blood pressure) at each assessed time point.

Summary of neurological assessments (proportion of subjects who are oriented, and proportion of
subjects who have any of the neurologic events).

Change from baseline in ECG data closest to the median Tmax.

Proportion of subjects able to walk 20 meters, unassisted, at 24 hours, 72 hours, and on Day 30.

Rating of physician satisfaction with return of sensory/motor function at 72 hours and on Day 30.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
13 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Name of Sponsor/Company:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
(858) 625-2424
Individual Study Table Referring
to Part of the Dossier
Volume:
Page:
(For National Authority Use Only)
Name of Finished Product:
Liposome Bupivacaine
Name of Active Ingredient:
Bupivacaine, 13.3 mg/mL
Statistical Methods:
A comprehensive statistical analysis plan will be developed for this study.
The efficacy results from Part 1 and Part 2 will not be combined.
Part 1
At the end of Part 1, an unblinded dose selection committee will review at least the results from the following
assessments conducted during Part 1: (1) the AUC of the NRS-R pain intensity scores through 72 hours; (2) total
postsurgical opioid consumption; (3) the time to first opioid rescue, and (4) safety data. Based on a clinical
evaluation of the data, the committee will determine the apparent efficacy and safety of each of the three
liposome bupivacaine dose levels tested and will recommend a dose level to be tested during Part 2 of the study.
Descriptive summaries will be provided by treatment group. Each dose of liposome bupivacaine will be
compared to placebo using analysis of covariance (ANCOVA) with treatment as the main effect and the baseline
NRS-R pain intensity score as a covariate for AUC of the NRS-R pain intensity scores through 72 hours, using
analysis of variance (ANOVA) after a natural logarithm transformation for total postsurgical opioid consumption,
and using a log-rank test for time to first opioid rescue. Summary statistics will be provided by treatment group
for the safety assessments.
Adverse events and SAEs will be summarized by treatment group.
At the end of the study, descriptive summary statistics, without statistical tests, will be provided by treatment
group for the other efficacy endpoints.
Part 2
The efficacy results from Part 2 will not include data from Part 1. Descriptive summaries will be provided by
treatment group. Liposome bupivacaine will be compared to placebo using ANCOVA with treatment as the
main effect and the baseline NRS-R pain intensity score as a covariate for AUC of the NRS-R pain intensity
scores through 72 hours, using ANOVA after a natural logarithm transformation for total postsurgical opioid
consumption, and using a log-rank test for time to first opioid rescue. For analyzing the two secondary endpoints
a hierarchical testing procedure will be used. First the total postsurgical opioid consumption will be tested. If the
test is significant at the 0.05 level then, and only then, time to first opioid rescue will be tested. This result will
be declared statistically significant at the 0.05 significance level.
Safety data from Part 1 and Part 2 will be combined and summarized by treatment group.


Pacira Pharmaceuticals, Inc.
402-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
14 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Table 1.
Time and Events Schedule of Study Procedures
Abbreviations: AE = adverse event; d = day; min = minutes; NRS-A = numeric rating scale with activity; NRS-R = numeric rating scale at rest; OBAS = overall benefit of analgesia
score; OR = operating room; ORAEs = opioid-related adverse events; PCA = patient-controlled analgesia; PK = pharmacokinetic.
*
Postsurgical efficacy assessments will be conducted at the time points specified after the end of surgery.
1
Before study drug administration.
2
Measure vital signs (heart rate and blood pressure) after subject has rested in supine position for at least 5 minutes.
3
If the neurological assessment reveals a neurological event that the Investigator believes may be associated with high levels of systemic bupivacaine, an unscheduled PK blood
sample should be collected at the time that the event is noted.
4
Electrocardiogram testing should begin approximately 1 hour prior to study drug administration and continue through 72 hours after study drug administration.
Screen
Visit
Day-1 to
Day 11 15min 30min 1h
2h
4h
8h 12h 18h 24h 30h 36h 42h 48h 54h 60h 72h Day 30
Time Window
Within
30 days
±5
min
±5
min
±5
min
±15
min
±15
min
±30
min
±30
min ±1h ±1h ±1h ±1h ±2h ±2h ±2h ±2h ±4h
±4d
Obtain signed informed consent
X
Assess/confirm eligibility
X
X
Medical/surgical history
X
X
Demographics and baseline characteristics
X
Pregnancy test (for women of childbearing potential only)
X
Urine drug screen
X
Physical examination
X
Vital signs2
X
X
X
X
X
Perform neurological assessment3
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Perform cardiac assessment (electrocardiogram recordings)4
Perform sensory function assessment (cold test)5
X
X
X
X
X
X
X
X
X
Perform motor function assessment (20-meter walk test)
X
X
X
X
Randomize subject and prepare study drug
X
Administer study drug within 2 hours of surgery; record start and stop time
X
Record intraoperative opioids administered and dose
X
Place femoral nerve catheter and install PCA pump (prior to the
completion of surgery)
X
Conduct pain intensity assessments (NRS-R, NRS-A)6
X
X
X
X
X
X
X
X
X
X
Record times and amounts of rescue medication administered
Complete OBAS questionnaire
X
X
X
Part 1 only (specific sites): Collect scheduled PK blood sample7
X
X
X
X
X
X
X
X
X
X
X
X
X
Subject satisfaction with postsurgical pain control
X
X
Part 1 only Question subject re: predefined treatment-emergent ORAEs
X
Physician satisfaction with return of sensory/motor function
X
X
Record concomitant medications8
Record AEs (starting at randomization)9


Pacira Pharmaceuticals, Inc.
402-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
15 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
5
Sensory function will be assessed at baseline, when the subject wakes up after surgery (general surgery subjects only), and at 2, 4, 12, 24, 36, 48, 60, and 72 hours after the end
of surgery, or until the subject’s sensitivity to cold is demonstrated on two consecutive evaluations.
6
Also record NRS pain intensity scores at first request for rescue pain medication.
7
Collect blood samples for PK analysis from subjects at specific sites during Part 1 of the study at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours
after the beginning of study drug administration. Blood samples should be collected even if the subject is not yet in surgery or is still in surgery.
8
Instruct subject to discontinue prohibited medications. Record date/time of all medications starting 3 days prior to surgery through 72 hours after surgery. Record medications
administered for treatment of an AE through Day 30.
9
If a cardiac or neurological event occurs during Part 1 or Part 2 of the study that the Investigator believes may be associated with high levels of systemic bupivacaine, an
unscheduled PK blood sample should be collected at the time that the event is noted.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
16 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
3.
TABLE OF CONTENTS
TITLE PAGE...................................................................................................................................1
SUMMARY OF CHANGES...........................................................................................................2
SIGNATURE PAGE .......................................................................................................................5
2.
SYNOPSIS ...................................................................................................................6
3.
TABLE OF CONTENTS ...........................................................................................16
4.
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................20
4.1.
List of Abbreviations ..................................................................................................20
4.2.
Definition of Terms ....................................................................................................21
5.
ETHICS ......................................................................................................................22
5.1.
Institutional Review Board/Independent Ethics Committee ......................................22
5.2.
Ethical Conduct of the Study......................................................................................22
5.3.
Subject Information and Consent ...............................................................................22
6.
INVESTIGATORS AND STUDY ADMINISTRATION STRUCTURE.................23
7.
INTRODUCTION......................................................................................................24
7.1.
Indication ....................................................................................................................24
7.2.
EXPAREL (bupivacaine liposome injectable suspension).........................................24
7.3.
Summary of Human Experience with Liposome Bupivacaine...................................25
8.
OBJECTIVES.............................................................................................................26
8.1.
Primary Objectives .....................................................................................................26
8.2.
Secondary Objectives .................................................................................................26
9.
STUDY DESIGN AND PLAN ..................................................................................27
9.1.
Study Design...............................................................................................................27
9.1.1.
Duration of the Study and Subject Participation ........................................................29
9.1.2.
Study Stopping Rules .................................................................................................29
9.2.
Discussion of Study Design........................................................................................29
10.
STUDY POPULATION.............................................................................................31
10.1.
Inclusion Criteria ........................................................................................................31
10.2.
Exclusion Criteria.......................................................................................................31
10.3.
Removal of Subjects from Therapy or Assessment....................................................32
10.3.1.
Withdrawal Secondary to Adverse Events .................................................................32


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
17 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
10.3.2.
Voluntary or Study Investigator Withdrawal .............................................................33
11.
TREATMENTS..........................................................................................................34
11.1.
Treatment to be Administered ....................................................................................34
11.1.1.
Administration Technique ..........................................................................................34
11.1.2.
Study Drug Administration Considerations................................................................35
11.2.
Identity of Investigational Product(s).........................................................................35
11.2.1.
Description of Liposome Bupivacaine .......................................................................35
11.2.2.
Description of Reference Product...............................................................................35
11.2.3.
Description of Diluents...............................................................................................35
11.3.
Method of Assigning Subjects to Treatment ..............................................................36
11.3.1.
Randomization Scheme ..............................................................................................36
11.3.2.
Randomization Procedures .........................................................................................36
11.3.3.
Replacement of Subjects.............................................................................................36
11.4.
Selection of Doses in the Study..................................................................................36
11.5.
Blinding ......................................................................................................................37
11.5.1.
Blinding Procedures....................................................................................................37
11.5.2.
Unblinding Procedures ...............................................................................................37
11.6.
Prior and Concomitant Therapy and Medications......................................................38
11.6.1.
Prior and Concomitant Medications and Therapy......................................................38
11.6.2.
Permitted and Restricted Therapy or Medications During Surgery ...........................38
11.6.3.
Permitted and Restricted Therapy or Medications After Surgery through
72 Hours After Surgery ..............................................................................................39
11.7.
Treatment Compliance................................................................................................39
11.8.
Accountability of Study Drug.....................................................................................39
12.
STUDY ENDPOINTS AND MEASUREMENTS ....................................................41
12.1.
Efficacy Assessments .................................................................................................41
12.2.
Efficacy Endpoints......................................................................................................41
12.3.
Pharmacokinetic Measurements (Part 1 Only)...........................................................42
12.4.
Pharmacokinetic Endpoints ........................................................................................42
12.5.
Safety Assessments.....................................................................................................43
12.6.
Safety Endpoints.........................................................................................................43
12.7.
Appropriateness of Measures .....................................................................................44


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
18 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
13.
STUDY PROCEDURES............................................................................................45
13.1.
Instructions for Conducting Procedures and Measures ..............................................45
13.1.1.
Pain Intensity Assessments.........................................................................................45
13.1.2.
Overall Benefit of Analgesia Score Questionnaire.....................................................45
13.1.3.
Neurological Assessment............................................................................................45
13.1.4.
Cardiac Assessment (Electrocardiogram Recordings) ...............................................46
13.1.5.
Sensory Function Assessment (Cold Test).................................................................46
13.1.6.
Motor Function Assessment (20-Meter Walk Test)...................................................47
13.1.7.
Vital Signs ..................................................................................................................47
13.1.8.
Subject Satisfaction with Postsurgical Pain Control ..................................................47
13.1.9.
Physician Satisfaction with Sensory/Motor Function.................................................47
13.1.10.
Fall Prevention............................................................................................................47
13.2.
Screening Procedures..................................................................................................47
13.3.
Baseline Procedures (Day -1 to Day 1) ......................................................................48
13.4.
Intraoperative Procedures ...........................................................................................48
13.5.
Procedures After Surgery Through 72 Hours.............................................................49
13.6.
Additional Procedures at Withdrawal if Prior to 72 Hours ........................................50
13.7.
Postsurgical Visit (Day 30).........................................................................................50
14.
ADVERSE EVENT REPORTING ............................................................................51
14.1.
Adverse Events ...........................................................................................................51
14.1.1.
Definitions ..................................................................................................................51
14.1.2.
Recording Adverse Events .........................................................................................52
14.1.3.
Severity of Adverse Events ........................................................................................52
14.1.4.
Relationship of Adverse Events to Study Drug..........................................................52
14.1.5.
Outcome of Adverse Events.......................................................................................53
14.1.6.
Action Taken with Subject due to an Adverse Event.................................................53
14.2.
Serious Adverse Events ..............................................................................................54
14.2.1.
Definition of a Serious Adverse Event .......................................................................54
14.2.2.
Reporting Serious Adverse Events .............................................................................54
15.
STATISTICAL METHODS.......................................................................................56
15.1.
Study Hypothesis........................................................................................................56
15.2.
Study Endpoints..........................................................................................................56
15.3.
Determination of Sample Size....................................................................................56


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
19 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
15.4.
Analysis Populations ..................................................................................................57
15.5.
Handling Subject Dropouts and Discontinuations......................................................57
15.6.
Statistical Analyses.....................................................................................................57
15.6.1.
Baseline Characteristics..............................................................................................57
15.6.2.
Study Compliance.......................................................................................................57
15.6.3.
Efficacy Analyses .......................................................................................................57
15.6.4.
Pharmacokinetic Analyses..........................................................................................60
15.6.5.
Safety Analyses ..........................................................................................................60
15.7.
Significance Testing ...................................................................................................61
15.8.
Interim Analyses.........................................................................................................61
16.
REFERENCES ...........................................................................................................62
17.
INVESTIGATOR AGREEMENT .............................................................................63
18.
APPENDICES ............................................................................................................64
Appendix 1:
Subject’s Reported Pain (Numeric Rating Scale) ..................................................65
Appendix 2:
Neurological Assessment .......................................................................................66
Appendix 3:
Overall Benefit of Analgesia Score Questionnaire ................................................67
Appendix 4:
Subject Satisfaction with Postsurgical Pain Control (Likert Scale)......................68
Appendix 5:
Physician's Satisfaction with Return of Sensory/Motor Function (Likert
Scale)......................................................................................................................69
Appendix 6:
Opioid-Related Adverse Events Questionnaire......................................................70
Appendix 7:
Dermatome Map.....................................................................................................71
LIST OF TABLES
Table 1.
Time and Events Schedule of Study Procedures ........................................................14


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
20 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
4.
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
4.1.
List of Abbreviations
AE
Adverse event
ANOVA
Analysis of variance
ANCOVA
Analysis of covariance
ASA
American Society of Anesthesiologists
AUC
Area under the curve
AUC0-tlast
The area under the plasma concentration-time curve from the time
of administration to the time of the last quantifiable concentration
calculated using the lin/log trapezoidal rule
AUC0-∞
The area under the plasma concentration-time curve from the time
of administration extrapolated to infinity.
CFR
Code of Federal Regulations
CI
Confidence interval
Cmax
The maximum observed plasma concentration obtained directly
from the experimental data without interpolation
CRF
Case Report Form
ECG
Electrocardiogram
FDA
Food and Drug Administration
GCP
Good Clinical Practice
ICF
Informed consent form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
IRB
Institutional Review Board
MedDRA
Medical Dictionary for Regulatory Activities
NRS
Numeric rating scale
NRS-A
Numeric rating scale with activity
NRS-R
Numeric rating scale at rest
NSAIDs
Non-steroidal anti-inflammatory drugs
OBAS
Overall benefit of analgesia score
OR
Operating room


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
21 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
PCA
Patient-controlled analgesia
PK
Pharmacokinetic
PO
Oral
QTcB
The heart rate-corrected QT interval using Bazett's formula
QTcF
The heart rate-corrected QT interval using Fridericia's formula
SAE
Serious adverse event
SAP
Statistical analysis plan
SNRI
Selective norepinepherine reuptake inhibitors
SSRI
Selective serotonin reuptake inhibitors
λz
The apparent terminal elimination rate constant
t1/2el
The apparent terminal elimination half-life
TEAE
Treatment-emergent adverse event
TKA
Total knee arthroplasty
Tmax
The time to attain Cmax
US
United States (of America)
wWOCF
windowed Worst-Observation-Carried-Forward
4.2.
Definition of Terms
Pharmacokinetic terms are defined in Section 12.4.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
22 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
5.
ETHICS
5.1.
Institutional Review Board/Independent Ethics Committee
Prior to screening subjects into this study, the study site will obtain the approval of an
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that complies with the
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and/or the
United States (US) Food and Drug Administration (FDA) Title 21 Code of Federal Regulations
(CFR) Part 56. Attention is directed to the basic elements that are required to be incorporated
into the informed consent form (ICF) under 21 CFR Part 50.25 and ICH GCP.
5.2.
Ethical Conduct of the Study
This study will be conducted in accordance with the clinical research guidelines established by
the FDA Title 21 CFR, Parts 50, 54, 56, and 312, and the ICH GCP. Study documents will be
maintained in accordance with applicable regulations.
5.3.
Subject Information and Consent
Before a subject undergoes any study-specific screening procedures, the Investigator or designee
will thoroughly explain to the subject the purpose of the study, the associated procedures, and
any expected effects and potential adverse reactions. A copy of the IRB-approved ICF will be
provided to the subject, who will be given sufficient time and opportunity to inquire about the
details of the study and decide whether or not to participate. The subject, and the study staff with
whom he/she discusses the ICF, will sign and date the ICF. A photocopy of the signed ICF will
be given to the subject.
The Investigator will explain to the subject that he/she is completely free to decline entry into the
study and may withdraw from the study at any time, for any reason, without risking her medical
care. Similarly, the Investigator and/or Pacira Pharmaceuticals, Inc. (Pacira) will be free to
withdraw the subject at any time for safety or administrative reasons. Any other requirements
necessary for the protection of the human rights of the subject will also be explained, according
to the current ICH GCP (E6) and the Declaration of Helsinki (1964, and as amended through
2000 [Edinburgh]).


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
23 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
6.
INVESTIGATORS AND STUDY ADMINISTRATION
STRUCTURE
Information regarding the investigators, sites, laboratories, and other service providers is
available upon request to the IRB/ECs and regulatory agencies.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
24 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
7.
INTRODUCTION
7.1.
Indication
Liposome bupivacaine was developed to extend pain relief with a single dose administration
without the use of indwelling catheters and to decrease the requirement for supplemental opioid
medications. It is indicated for use as an analgesic injected into the surgical site for postsurgical
pain relief. This study will explore the safety, efficacy, and pharmacokinetic (PK) profile of
liposome bupivacaine when administered via a femoral nerve block.
Effective postsurgical pain control is a critical element in subject recovery following surgery,
as the majority of subjects may experience significant pain, particularly in the first few days.
Improved postsurgical pain management contributes to better healing, faster subject
mobilization, shortened hospital stays, and reduced healthcare costs (American Society of
Anesthesiologists Task Force on Pain Management 1995).
7.2.
EXPAREL (bupivacaine liposome injectable suspension)
Bupivacaine is one of the longer-acting local anesthetics, but even so it has a limited duration of
action after local administration, usually reported as less than 8 hours. EXPAREL® (Pacira
Pharmaceuticals, Inc., San Diego, California) is a bupivacaine liposome injectable suspension.
It consists of microscopic spherical, multivesicular liposomes (DepoFoam® drug delivery
system), organized in a honeycomb-like structure comprising numerous non-concentric internal
aqueous chambers containing a bupivacaine base at a concentration of 13.3 mg/mL. Each
chamber is separated from adjacent chambers by lipid membranes. The lipids (phospholipids,
cholesterol, and triglycerides) are naturally occurring or close analogs of endogenous lipids.
Bupivacaine is slowly released from the DepoFoam particles by a complex mechanism involving
reorganization of the barrier lipid membranes and subsequent diffusion of the drug over an
extended period of time. A small amount of extra-liposomal bupivacaine (i.e., not bound within
the DepoFoam particles) enables liposome bupivacaine to have a similar onset of action to
standard bupivacaine.
EXPAREL (liposome bupivacaine) was approved by the US FDA in 2011 for administration into
the surgical site to produce postsurgical analgesia. The active ingredient (bupivacaine) and
inactive ingredient (DepoFoam) of EXPAREL are each contained, though separately, in
FDA-approved products:

Bupivacaine HCl solution, a well-characterized anesthetic/analgesic, with more than
35 years of use in the US.

DepoFoam, a liposomal extended-release formulation contained in the marketed products
DepoCyt® (1999) and DepoDur® (2004). The form of DepoFoam used in each of the
three products – DepoCyt, DepoDur, and liposome bupivacaine – has a slightly different
mixture of lipid components. However, unlike the other two products, EXPAREL
employs a novel lipid excipient (dierucoylphosphatidylcholine [DEPC]) in its
formulation.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
25 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
7.3.
Summary of Human Experience with Liposome Bupivacaine
Pacira has completed 21 clinical studies and 1 observational follow-up study to investigate
liposome bupivacaine. Across these studies, over 1300 human subjects received liposome
bupivacaine at doses ranging from 9 mg to 665 mg administered by various routes: local
infiltration into the surgical wound, subcutaneous, perineural, and epidural. The product
generally has been well tolerated and in active comparator studies reported adverse events
(AEs) occurred at a similar rate as the corresponding bupivacaine HCl controls.
Two nerve block studies have been completed. SKY0402-002 was a Phase 1 dose escalation
study conducted to evaluate the safety, pharmacodynamics, and pharmacokinetics of liposome
bupivacaine. A total of 37 healthy subjects were administered liposome bupivacaine
perineurally for unilateral ankle block in healthy male volunteers (24 subjects received liposome
bupivacaine and 12 subjects received bupivacaine HCl). The incidence and types of adverse
events experienced were similar across treatment groups. All AEs were mild or moderate in
severity; those related to liposome bupivacaine were mild in severity. There were no serious
adverse events (SAEs), deaths, or discontinuations due to adverse events.
SKY0402-C-203 was a Phase 2 nerve block study was performed in which three doses of
liposome bupivacaine (155, 199, and 310 mg) were compared to bupivacaine HCl (125 mg) in
a bunionectomy. A total of 38 patients received liposome bupivacaine. Liposome bupivacaine
was well tolerated and several doses demonstrated statistically significant separation from
bupivacaine HCl using multiple efficacy measures at multiple time points throughout the
72 hours; a PK curve also was defined.
In doses up to 665 mg, no adverse safety signal attributed to either the central nervous system
or cardiovascular system was reported with liposome bupivacaine. Adverse events that are
occasionally reported with high doses of standard bupivacaine solution have not been
observed. In two rigorous QTc studies, liposome bupivacaine did not cause significant QTc
prolongation even at the highest dose evaluated.
The robust nature of the efficacy results in both pivotal studies (SKY0402-C-316 and SKY0402-
C-317) was demonstrated across subgroups of patients with various prognostic features and
across demographic subgroups.
Following the NDA submission of EXPAREL (liposome bupivacaine), numerous clinical
studies were initiated in which liposome bupivacaine was administered via various routes of
administration (including infiltration into the transversus abdominis plane [TAP] and
intraoperative wound infiltration or instillation); final results are not available at this time.
Please refer to the Investigator’s Brochure for additional information regarding the completed
studies. Please see the EXPAREL Full US Prescribing Information for safety information
regarding the use of EXPAREL (liposome bupivacaine) in the setting of wound infiltration.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
26 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
8.
OBJECTIVES
8.1.
Primary Objectives
Part 1: The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome
bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect
achieved following single dose injection femoral nerve block with liposome bupivacaine, and
(2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be
tested in Part 2.
Part 2: The primary objective of Part 2 is to compare the magnitude and duration of the analgesic
effect of single injection femoral nerve block of a single dose level of liposome bupivacaine
(selected from Part 1) with placebo (preservative-free normal saline for injection).
8.2.
Secondary Objectives
The secondary objectives are to evaluate additional efficacy parameters, characterize the PK
profile of liposome bupivacaine when administered as a femoral nerve block, and further assess
the safety profile of liposome bupivacaine.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
27 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
9.
STUDY DESIGN AND PLAN
9.1.
Study Design
This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled,
dose-ranging study in subjects undergoing primary unilateral total knee arthroplasty (TKA)
under general or spinal anesthesia. Note: Bupivacaine cannot be used as the spinal anesthetic.
On Day 1, eligible subjects will be randomized to receive a single dose of study drug
administered within 2 hours prior to the surgical procedure as a femoral nerve block. Study drug
administration will be performed in a blinded manner (see Section 11.5.1). At the conclusion of
the block, a femoral nerve catheter is to be left in place and hep-locked (see “Postsurgical Rescue
Medication” below). Additionally, a patient-controlled analgesia (PCA) pump will be
established prior to the completion of the surgery. The PCA pump will not be loaded at this time.
The use of fentanyl will be permitted during surgery. However, intraoperative administration of
morphine or an y other analgesics (including intrathecal opioids), local anesthetics, or anti-
inflammatory agents is prohibited, unless needed to treat an AE.
All subjects will be required to remain in the study site for a minimum of 72 hours after the end
of surgery for postsurgical assessments. The study staff will ensure adequate safety precautions
are in place in order to prevent falls (e.g., use of support devices during ambulation, such as a
knee immobilizer and walker/crutches) as needed.
Part 1
During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be
randomized to receive a single dose injection femoral nerve block with either one of three doses
of liposome bupivacaine (67, 133, or 266 mg) or placebo in 20 mL under ultrasound guidance.
Preservative-free normal saline will be added to the 67 mg and 133 mg doses of study drug to
achieve a volume of 20 mL.
After all subjects have completed the 72-hour assessments in Part 1, an analysis will be
conducted in order to select a single therapeutic dose from the three liposome bupivacaine dose
levels tested. An unblinded dose selection committee will review at least the results from the
following assessments conducted during Part 1: (1) the area under the curve (AUC) of the
numeric rating scale (NRS) at rest (NRS-R) pain intensity scores through 72 hours; (2) total
postsurgical opioid consumption; (3) the time to first opioid rescue; and (4) safety data. Based
on a clinical evaluation of the results the committee will determine the apparent efficacy and
safety of each of the three liposome bupivacaine dose levels tested and will recommend a dose
level for Part 2 of the study. Statistical significance will not be required in order to recommend a
dose level for Part 2. The unblinded dose selection committee also will recommend whether the
sample size for Part 2 should be increased.
Part 2
In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately
90 liposome bupivacaine subjects and 90 placebo subjects) will receive a single dose injection
femoral nerve block with the selected dose of liposome bupivacaine (i.e., 67, 133, or 266 mg) or
placebo in 20 mL under ultrasound guidance.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
28 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Postsurgical Rescue Medication
Subjects should only receive rescue medication upon request for pain control, as needed.
First Rescue Medication (IV Hydromorphone)
The first rescue medication will be intravenous (IV) hydromorphone 0.5 mg, which will be
administered once via bolus only. At this time, the PCA should be loaded with opioid (morphine
or hydromorphone only).
Second Rescue Medication (PCA and/or PO Opioid)
The second rescue medication will be an on-demand PCA-administered opioid (morphine or
hydromorphone). The PCA pump will be programmed to deliver either on-demand morphine or
on-demand hydromorphone boluses at a dose and lockout interval in accordance with the site's
standard practice. A continuous infusion (background or basal rate) of morphine or
hydromorphone is not permitted. If the subject’s pain is excessive or pain control is inadequate,
then the bolus dose may be adjusted according to local hospital practices; however, adding a
basal rate is prohibited.
Once a subject is able to tolerate oral (PO) medication, PO immediate-release oxycodone may be
administered (but not more than 10 mg every 4 hours).
Third Rescue Medication (Conventional Bupivacaine HCl)
If a subject’s pain is inadequately controlled by opioids, a third rescue, a femoral nerve block,
consisting of conventional bupivacaine HCl at a concentration of 0.125% (1.25 mg/mL) at a rate
of 8 mL per hour for up to 12 hours may be administered via the previously placed femoral nerve
catheter.
Subjects who do not receive adequate pain control with this regimen are to be withdrawn from
the study and followed for AEs only. No other analgesic agents, including non-steroidal anti-
inflammatory agents (NSAIDs), are allowed during the 72-hour observation period.
Postsurgical Assessments
Postsurgical assessments will include pain intensity scores using the 0-10 point NRS-R and
NRS with activity (NRS-A) (where the prescribed activity is active knee flexion up to
45 degrees) (see Appendix 1); use of supplemental opioid pain medication; neurological
assessment (see Appendix 2); cardiac assessment [i.e., ECG recordings]; sensory function
assessment [i.e., cold test]; motor function assessment [i.e., 20-meter walk test]; vital signs;
overall benefit of analgesia score (OBAS) questionnaire (see Appendix 3); subject satisfaction
with postsurgical pain control (see Appendix 4); physician satisfaction with return of
sensory/motor function (see Appendix 5); and an opioid-related AE questionnaire during Part 1
only (see Appendix 6). Adverse events will be recorded through Day 30. If a cardiac or
neurological event occurs during Part 1 or Part 2 of the study that the Investigator believes may
be associated with high levels of systemic bupivacaine, an unscheduled PK blood sample should
be collected at the time that the event is noted.
Safety and efficacy assessments will be conducted at pre-specified time points after the end of
surgery (defined as the time of last suture/staple). A follow-up visit will be scheduled for all
subjects on Day 30.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
29 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Pharmacokinetic Assessments (Part 1 only)
Blood samples for PK analysis will be obtained from subjects at specific sites during Part 1 of
the study at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours
after the beginning of study drug administration. Blood samples for PK analysis should be
collected even if the subject is not yet in surgery or is still in surgery. Placebo samples will be
collected to maintain the treatment double-blind but will not be analyzed. Samples from subjects
receiving bupivacaine nerve block rescue will not be analyzed. (Note: At time points when the
PK and NRS pain intensity assessments coincide, the NRS pain intensity assessments will be
conducted before the blood draw.)
Unscheduled blood samples also may be collected during Part 1 or Part 2 of the study if a cardiac
or neurological event occurs that the Investigator believes may be associated with high levels of
systemic bupivacaine.
9.1.1.
Duration of the Study and Subject Participation
Each subject’s participation in this study could be up to 64 days (up to 30 days for the screening
period and up to 34 days for post-dosing follow-up).
9.1.2.
Study Stopping Rules
No formal stopping rules are planned for this study. If, however, Pacira, the Investigator, or
officials from regulatory authorities discover conditions during the study that indicate that the
study or study site should be terminated, this action may be taken after Pacira has consulted with
appropriate regulatory authorities and notified the Investigator(s).
9.2.
Discussion of Study Design
Liposome bupivacaine is approved for infiltration into a surgical wound. This multicenter,
randomized, double-blind, parallel-group study is a comparison of the efficacy and safety of
liposome bupivacaine to placebo when administered as a femoral nerve block in subjects
undergoing unilateral TKA. The double blind study design is intended to avoid potential bias
resulting from subject or Investigator knowledge of the assigned treatment.
Total knee arthroplasty is a frequently performed surgical procedure that causes postsurgical pain
of considerable intensity and duration. Standard analgesia following TKA often includes IV and
PO opioids postoperatively. Therefore, TKA was selected as an appropriate pain model for
investigating a sustained-release formulation of bupivacaine, which has the potential to
overcome the limitation reported in previous studies with regard to the duration of the analgesic
effect obtained with commercially-available products.
During Part 1, subjects will receive a single dose femoral nerve block with one of three dose
levels of liposome bupivacaine (67, 133, or 266 mg). An unblinded dose selection committee
will review study data, determine the apparent efficacy and safety of each of the three liposome
bupivacaine dose levels tested, and recommend a dose level to be tested during Part 2 of the
study. In Part 2 of the study, subjects will receive a single dose injection femoral nerve block
with the selected dose of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
30 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
All subjects will receive an opioid (morphine, hydromorphone, and/or oxycodone) and
conventional bupivacaine HCl, as needed, to control breakthrough postsurgical pain.
Neurological and cardiac assessments will be conducted to rule out bupivacaine toxicity related
to high plasma exposure. Additionally, sensory and motor function assessments will be
conducted in order to test for restoration of nerve function.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
31 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
10.
STUDY POPULATION
10.1.
Inclusion Criteria
Subjects eligible for study entry must meet all of the following criteria:
1. Male or female, ≥18 years of age.
2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.
3. American Society of Anesthesiology (ASA) Physical Status 1, 2, or 3.
4. Able to demonstrate motor function by performing a 20-meter walk, unassisted with the
optional use of a 4-legged walker, and sensory function by exhibiting sensitivity to cold.
5. Able to provide informed consent, adhere to the study visit schedule, and complete all
study assessments.
10.2.
Exclusion Criteria
A subject will not be eligible for the study if he/she meets any of the following criteria:
1. Currently pregnant, nursing, or planning to become pregnant during the study or within
1 month after study drug administration. Female subjects must be surgically sterile or at
least 2 years menopausal, or using an acceptable method of birth control. If of child-
bearing potential, must have a documented negative pregnancy test within 24 hours
before surgery.
2. Planned concurrent surgical procedure (e.g., bilateral TKA).
3. Use of any of the following medications within the times specified before surgery:
long-acting opioid medication, NSAIDs, or aspirin (except low-dose aspirin used for
cardioprotection or acetaminophen) within 3 days, or any opioid medication within
24 hours.
4. Concurrent painful physical condition or concurrent surgery that may require analgesic
treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not
strictly related to the surgical site administered study treatment, and which may confound
the postsurgical assessments (e.g., significant pain from other joints including the non-
index knee joint, chronic neuropathic pain, prior contralateral TKA, concurrent foot
surgery).
5. Initiation of treatment with any of the following medications within 1 month of study
drug administration or if the medication(s) are being given to control pain: selective
serotonin reuptake inhibitors (SSRIs), selective norepinepherine reuptake inhibitors
(SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®).
6. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
7. Body weight < 50 kilograms (110 pounds) or a body mass index ≥40 kg/m2.
8. Contraindication to hydromorphone, oxycodone, or bupivacaine.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
32 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
9. Administration of an investigational drug within 30 days or 5 elimination half-lives of
such investigational drug, whichever is longer, prior to study drug administration, or
planned administration of another investigational product or procedure during the
subject’s participation in this study.
10. Previous participation in a liposome bupivacaine study.
11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription
medicine(s), or alcohol within the past 2 years.
12. Failure to pass the urine drug screen.
13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of
the Investigator, could interfere with study assessments or compliance.
14. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or
squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
15. Current or historical evidence of any clinically significant disease or condition, especially
cardiovascular or neurological conditions that, in the opinion of the Investigator, may
increase the risk of surgery or complicate the subject’s postsurgical course.
16. Significant medical conditions or laboratory results that, in the opinion of the
Investigator, indicate an increased vulnerability to study drugs and procedures.
17. Subjects who are planned to receive Entereg® (alvimopan).
18. Subjects who will receive prophylactic antiemetics or planned postsurgical antiemetics
given without regard to the subject's emesis needs.
19. Use of dexmedetomidine HCl (Precedex®) within 3 days of surgery.
10.3.
Removal of Subjects from Therapy or Assessment
Every reasonable effort should be made to maintain subject compliance and participation in the
study. Reasons for discontinuation of any subject from the study will be recorded.
Subjects who withdraw from the study postsurgically should be followed for AEs . All AEs that
occur through Day 30 after surgery must be recorded. If a subject who withdraws from the study
has an ongoing AE, every effort must be made to follow such events until satisfactory resolution
is obtained, or further follow-up is otherwise no longer warranted.
Safety assessments performed during the early termination visit should include the neurological
examination, cold test, 20-meter walk test, and collection of a blood sample for PK analysis, if
possible.
10.3.1.
Withdrawal Secondary to Adverse Events
If a subject experiences an AE that renders him/her incapable of continuing with the remaining
study assessments, then he/she will be discontinued from further participation in the study.
A final evaluation should be performed so that the subject’s study participation can be terminated
in a safe and orderly manner (see Section 10.3).


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
33 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
10.3.2.
Voluntary or Study Investigator Withdrawal
Subjects are free to discontinue from the study at any time, without prejudice to future treatment.
Nevertheless, subjects will be encouraged to complete at least the study safety assessments.
In addition, a subject may be discontinued from the study if he/she refuses to comply with study
procedures. Reasons for discontinuation from the study will be recorded.
If a subject is discontinued by the Investigator or voluntarily withdraws from the study after
receiving liposome bupivacaine, he/she should be followed for AEs (see Section 10.3). A final
evaluation should be performed so that the subject can be terminated in a safe and orderly
manner.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
34 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
11.
TREATMENTS
11.1.
Treatment to be Administered
Study Drug
Subjects will receive a single dose injection femoral block with either one of three doses of
liposome bupivacaine (67, 133, or 266 mg) or placebo (preservative-free normal saline) in 20 mL
volume under ultrasound guidance according to the randomization schedule. Preservative-free
normal saline will be added to the 67 mg and 133 mg doses of study drug to achieve a volume of
20 mL (i.e., 15 mL of saline will be added to the 67 mg dose [5 mL] of liposome bupivacaine
and 10 mL of saline will be added to the 133 mg dose [10 mL]). Study drug administration will
be performed by study personnel who are NOT involved with protocol-specific, postsurgical
assessments.
Rescue Medication
Subjects should only receive rescue medication upon request, as needed.
The first rescue medication will consist of IV hydromorphone 0.5 mg, which will be
administered once via bolus only. At this time, the PCA should be loaded with opioid (morphine
or hydromorphone only).
The second rescue medication will consist of an on-demand PCA-administered opioid (morphine
or hydromorphone). The PCA pump will be programmed to deliver either on-demand morphine
or on-demand hydromorphone boluses at a dose and lockout interval consistent with the site's
standard practice. A continuous infusion (background or basal rate) of morphine or
hydromorphone is not permitted. If the subject’s pain is excessive or pain control is inadequate,
then the bolus dose may be adjusted according to local hospital practices; however, adding a
basal rate is prohibited. Once the subject is tolerating PO medication, PO immediate-release
oxycodone may be administered (but not more than 10 mg every 4 hours).
If a subject’s pain is inadequately controlled by opioids, a third rescue, a femoral nerve block,
consisting of conventional bupivacaine HCl at a concentration of 0.125% (1.25 mg/mL) at a rate
of 8 mL per hour for up to 12 hours will be administered via the previously placed femoral nerve
catheter.
No other analgesic agents, including NSAIDs, are allowed during the 72-hour observation period
or until the subject is withdrawn from the study, whichever is sooner. Subjects who do not
achieve adequate pain relief with this regimen will be withdrawn from the study and followed for
AEs per Section 10.3.
11.1.1.
Administration Technique
Study drug (liposome bupivacaine or placebo) will be administered under ultrasound guidance
by the anesthesiologist into the femoral nerve as described below (adopted from Mariano 2009).
Patients will have their femoral nerve located by ultrasound guidance alone. The recommended
method is as follows: With a linear array transducer in a sterile sleeve, the femoral nerve will be
identified in a transverse (short-axis) view at the inguinal crease. In a transverse view, the


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
35 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
internal appearance of the peripheral nerve bundle is a mixture of hypoechoic neural tissue
(fascicles) and hyperechoic connective tissue (perineurium and epineurium). Once the optimal
image of the femoral nerve is obtained, a local anesthetic skin wheal will be raised lateral to the
ultrasound transducer. A needle will be inserted through the skin wheal and directed medially in
plane beneath the ultrasound transducer toward the femoral nerve. The study drug (20 mL) will
be injected posterior to the femoral nerve via the needle. A flexible epidural-type catheter will
then be placed through the length of the needle and advanced 5 cm beyond the needle tip. Once
the catheter has been inserted, the needle itself will be withdrawn over the catheter. The catheter
tip position will be assessed by injecting 1 mL of air via the catheter under ultrasound guidance
with the appearance of hyperechoic air bubbles posterior to the femoral nerve confirming proper
catheter placement (and replaced, if necessary). Because the in-plane ultrasound-guided needle
placement technique effectively “tunnels” the catheter in a lateral-to-medial direction under the
transducer, the catheter will not be tunneled further. The catheter will be secured with sterile
liquid adhesive, a clear occlusive dressing, and an anchoring device to affix the catheter hub to
the subject. After negative aspiration, 2 mL of normal saline will be injected via the catheter to
help ensure future patency.
11.1.2.
Study Drug Administration Considerations
Since there is a potential risk of severe adverse effects associated with the administration of
bupivacaine, the study site must be equipped to manage subjects with any evidence of cardiac
toxicity.
Administration of additional local anesthetics including bupivacaine or lidocaine is prohibited
except where specified for spinal anesthesia or rescue. Bupivacaine cannot be used as the spinal
anesthetic. Liposome bupivacaine may not be administered to a subject if it has been held in a
syringe for more than 4 hours after preparation. In order to prevent the study drug from settling,
gently inverting and re-inverting the syringe several times prior to administration is
recommended.
11.2.
Identity of Investigational Product(s)
11.2.1.
Description of Liposome Bupivacaine
Liposome bupivacaine is formulated as a sterile, non-pyrogenic, white to off-white,
preservative-free, homogeneous suspension of bupivacaine encapsulated into multivesicular
lipid-based particles (the DepoFoam drug delivery system). Bupivacaine is present at a
nominal concentration of 13.3 mg/mL. Liposome bupivacaine will be provided in 20 mL,
1.3% (13.3 mg/mL) single-use, clear glass vials.
11.2.2.
Description of Reference Product
Placebo will consist of preservative-free normal saline for injection and will be supplied by the
study sites. Subjects in the placebo group will receive 20 mL of placebo.
11.2.3.
Description of Diluents
Preservative-free normal saline for injection will be added to the 67 mg (5 mL) and 133 mg
(10 mL) doses of study drug to achieve a volume of 20 mL.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
36 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
11.3.
Method of Assigning Subjects to Treatment
11.3.1.
Randomization Scheme
In Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be randomized to
receive a single dose injection femoral block with either one of three doses of liposome
bupivacaine (67, 133, or 266 mg) or placebo.
In Part 2 of the study, approximately 180 subjects (randomized 1:1, resulting in approximately
90 liposome bupivacaine subjects and 90 placebo subjects) will be randomized to receive single
dose injection femoral nerve block with the selected dose level (i.e., 67, 133, or 266 mg liposome
bupivacaine) or placebo.
The randomization code will be generated by a centralized randomization system, which will
also be used to communicate subject randomizations to study sites. All randomized subjects will
have both a unique subject identifier and a unique random code identifier. No subject or random
code identifiers are to be reused once assigned.
11.3.2.
Randomization Procedures
Once a subject is identified as being qualified for the study per the eligibility criteria (see
Section 10.1 and Section 10.2), and is at the study site for surgery, the research pharmacist or
designee will contact the centralized randomization service to obtain a randomization assignment
(4-digit random code identifier). The subject will be considered randomized into the study once
the assignment is received.
11.3.3.
Replacement of Subjects
Subjects who are randomized but are withdrawn from the study before receiving study drug or
do not undergo the planned surgical procedure may be replaced. Once assigned, subject numbers
will not be reused; subjects enrolled to replace those who withdraw will be assigned a unique
subject number and randomized to treatment according to the procedures outlined above.
11.4.
Selection of Doses in the Study
During the clinical development of liposome bupivacaine, single doses ranging from 9 mg to
665 mg were safely administered via various routes. Pharmacokinetic studies have shown that
because liposome bupivacaine releases bupivacaine gradually as the lipid structure breaks down,
administration of liposome bupivacaine 266 mg results in a maximum plasma concentration
equivalent to that seen with standard bupivacaine 100 mg. Based on this experience, a similar
maximum total dose was deemed appropriate for this study.
During Part 1 of the current study, subjects will receive a single dose femoral nerve block with
one of three dose levels of liposome bupivacaine (67, 133, or 266 mg) or placebo. During Part 2
of the study, subjects will receive a single dose injection femoral nerve block with the selected
dose level of liposome bupivacaine (i.e., 67, 133, or 266 mg) or placebo.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
37 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
11.5.
Blinding
11.5.1.
Blinding Procedures
Liposome bupivacaine and placebo are visually distinguishable; therefore, to maintain the
double-blind study design, the Principal Investigator and any study personnel involved in
protocol-specific postsurgical assessments will remained blinded to treatment assignment.
Only unblinded study personnel who are NOT involved with protocol-specific, postsurgical
assessments may prepare or administer the study drug. Staff members conducting study-specific,
postsurgical assessments and the subjects will remain blinded to the assigned treatment
throughout the study. If a subject experiences an SAE, Pacira will not automatically unblind the
subject’s treatment, unless it is necessary to manage treatment of the SAE. Expedited SAEs will
be unblinded by Pacira for regulatory reporting purposes.
Unblinded randomization assignments will be provided via a randomization system. At each
site, only the individual(s) who are identified in the randomization system to receive unblinded
randomization assignments will be responsible for preparing study drug.
Site surveys suggest that study sites will vary in their standard (and feasible) procedures for
preparing sterile study drug in a blinded fashion. Therefore, each site will be responsible for
providing their written blinding procedures for study drug preparation, transportation, and
administration that will ensure that the blind is maintained throughout each of these steps.
This documentation will be made available to Pacira for review before the site enrolls a subject
into the study. Assignment of blinded and unblinded responsibilities regarding the preparation of
study drug should take into account that liposome bupivacaine may not be held in a syringe
for more than 4 hours after preparation for administration.
The presurgical administration of study drug will be recorded using the minimal amount of
information necessary to avoid unblinding staff who will be participating in blinded procedures.
No crossover will be permitted between the blinded and unblinded study site personnel during
the study period. The assignment of site monitors will also be segregated. Blinded monitors will
review case report forms (CRFs), clinic charts, and all other study-related documents that do not
disclose the allocation of study treatment. Care should be taken in recording and review of
operating room records to not record information in an unblinded fashion. Pharmacy or any
other clinic records providing unblinded information (e.g., randomization, study drug
preparation, study drug accountability, study drug administration) will be reviewed by
specialized unblinded monitors who will notify Pacira of treatment noncompliance.
11.5.2.
Unblinding Procedures
Subject treatment assignments should not be unblinded during the study by blinded study
personnel. The Investigator will have the ability to unblind a subject if he or she feels that
subject safety warrants such unblinding. However, the Investigator should discuss the safety
issues with the Medical Monitor before attempting such unblinding, if possible. Any unblinding
will be documented through immediate notification of the Pacira study team and the Investigator.
Any accidental unblinding events (i.e., through mishaps in the operating room or
miscommunication among study staff) must be reported to Pacira immediately.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
38 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Only designated staff at Pacira will have the option to unblind treatment assignment through the
randomization system, which will be designed to document such a transaction and notify the lead
member of each functional group that such a transaction occurred.
Any incidence(s) of unblinding will be noted in the clinical study report with a full discussion of
the events leading to the decision to unblind.
11.6.
Prior and Concomitant Therapy and Medications
11.6.1.
Prior and Concomitant Medications and Therapy
Permitted Prior Medications and Therapy

Low-dose aspirin for cardioprotection.

Acetaminophen use is permitted up to the time of surgery.
Restricted Prior Medications and Therapy

Systemic glucocorticosteroids are not permitted within 1 month of enrollment into this
study.

Initiation of treatment with any of the following medications within 1 month of study
drug administration or if the medication(s) are being given to control pain is not
permitted: SSRIs, SNRIs, gabapentin, pregabalin (Lyrica), or duloxetine (Cymbalta).

Long-acting opioid medications, NSAIDs, or aspirin (except for low-dose aspirin used
for cardioprotection or acetaminophen) are not permitted within 3 days of study drug
administration.

Dexmedetomidine HCl (Precedex) use is not permitted within 3 days of surgery.

No opioid medications are permitted within 24 hours of study drug administration.
Concomitant medications
All medications taken within 3 days of study drug administration and up to 72 hours after the end
of surgery or until the subject is withdrawn from the study, whichever is sooner, will be recorded
on the CRF. Any medications administered in association with AEs occurring during the study
will be recorded through Day 30.
11.6.2.
Permitted and Restricted Therapy or Medications During Surgery
Permitted

Short and ultra-short acting opioids (e.g., fentanyl) will be allowed during surgery.
Restricted

Bupivacaine cannot be used as the spinal anesthetic.

No agents are to be admixed with liposome bupivacaine (e.g., epinephrine,
dexamethasone, and clonidine).


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
39 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013

Lidocaine and other local anesthetics will not be permitted to be locally administered
during the surgery because they are known to interact with liposome bupivacaine
resulting in the displacement of bupivacaine and elevated plasma levels.

Intrathecal opioids.

The use of opioids other than fentanyl (e.g., morphine, hydromorphone HCl),
acetaminophen, ketorolac, or other NSAIDs will not be permitted intraoperatively except
for emergency use to treat an AE.

Entereg (alvimopan) use is prohibited.

Prophylactic antiemetics or planned postsurgical antiemetics given without regard to the
subject's emesis needs is prohibited.
11.6.3.
Permitted and Restricted Therapy or Medications After Surgery through
72 Hours After Surgery
Permitted

Rescue medication use is permitted as described in Section 11.
Restricted

No other analgesics are permitted within 72 hours after surgery.

Entereg (alvimopan) use is prohibited.

Prophylactic antiemetics or planned postsurgical antiemetics given without regard to the
subject's emesis needs.

Dexmedetomidine HCl (Precedex) use is prohibited.
For study purposes, it is important to standardize pain management modalities during the first
72 hours following study drug administration. Therefore, the study staff must adhere closely to
the treatment options and requirements noted in the protocol. After 72 hours, the analgesic
regimen may be adjusted for each subject individually, as deemed appropriate by the physician
responsible for the postsurgical care.
All concomitant medication will be recorded through 72 hours after the end of surgery or until
the subject is withdrawn from the study, whichever is sooner.
11.7.
Treatment Compliance
Not applicable, since study drug (liposome bupivacaine or placebo) will be administered
intraoperatively.
11.8.
Accountability of Study Drug
Any shipment of liposome bupivacaine for the study will contain an investigational drug
transmittal and receipt form to assist the Investigator or designee (e.g., pharmacist) in
maintaining current and accurate inventory records. At a minimum, the Investigator or designee
will maintain accurate records demonstrating dates and units of drug received, lot numbers,
subjects to whom drug was administered, and accounts of any drug destroyed accidentally or


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
40 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
deliberately. The Investigator must retain vials containing used, unused, or expired liposome
bupivacaine for return or destruction, as instructed by Pacira, following confirmation of drug
accountability data by a study monitor. A record of drug return or destruction will be maintained
and provided to Pacira. Inventory records must be readily available for inspection by the study
monitor and/or appropriate regulatory authorities at any time. A copy of the inventory records,
drug accountability information, and notice of return or destruction will be returned to Pacira at
the end of the study. Only authorized personnel identified by the Investigator will have the
ability to access and administer the drug.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
41 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
12.
STUDY ENDPOINTS AND MEASUREMENTS
12.1.
Efficacy Assessments
The following efficacy measurements will be conducted at the times specified after the end of
surgery:

Pain intensity scores using the NRS-R at baseline (prior to the nerve block) and 2, 4, 8,
12, 24, 36, 48, 60, and 72 hours, and at first request for rescue pain medication
(Appendix 1).

Pain intensity scores using the NRS-A (where the prescribed activity is actively flexing
the involved knee up to 45 degrees) at baseline (prior to the nerve block) and 2, 4, 8, 12,
24, 36, 48, 60, and 72 hours, and at first request for rescue pain medication (Appendix 1).

Time of first opioid rescue.

Opioid use.

Conventional bupivacaine HCl use.

Sensory function assessment (i.e., cold test) at baseline, when the subject wakes up after
surgery (general surgery subjects only), and at 2, 4, 12, 24, 36, 48, 60, and 72 hours after
surgery, or until the subject’s sensitivity to cold is demonstrated on two consecutive
evaluations.

Overall benefit of analgesia score questionnaire at 24, 48, and 72 hours (Appendix 3).

Subject satisfaction with postsurgical pain control at 72 hours and Day 30 using a 5-point
Likert scale (Appendix 4).

Predefined treatment-emergent opioid-related AEs at 72 hours following surgery during
Part 1 only (Appendix 6).
12.2.
Efficacy Endpoints
The efficacy endpoints listed below will be assessed based on the efficacy measurements
conducted at the specified time points after the end of surgery.
Primary Endpoint
The primary efficacy endpoint is the AUC of the NRS-R pain intensity scores through 72 hours.
Secondary Endpoints
The following secondary endpoints will be analyzed using a hierarchical testing procedure:

Total postsurgical opioid consumption (in mg) through 72 hours.

Time to first opioid rescue.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
42 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Tertiary Endpoints

Total postsurgical opioid consumption (in mg) through 24, 36, 48, and 60 hours.

Overall benefit of analgesia score questionnaire at 24, 48, and 72 hours.

Subject satisfaction with postsurgical pain control at 72 hours and Day 30.

The NRS-R and NRS-A pain intensity scores at each assessed time point.

The AUC of the NRS-R pain intensity scores through 24, 36, 48, and 60 hours.

The AUC of the NRS-A pain intensity scores through 24, 36, 48, 60, and 72 hours.

The AUC of the NRS-R pain intensity scores from 24-48 and 48-72 hours.

Proportion of subjects who are pain free (defined as an NRS pain intensity score of
0 or 1) at each assessed time point.

Proportion of subjects who receive the following rescue medication(s):
o
Subjects who receive no rescue medications (i.e., opioid or conventional bupivacaine
HCl).
o
Subjects who only receive IV hydromorphone bolus.
o
Subjects who receive IV hydromorphone bolus and a second opioid medication.
o
Subjects who receive IV hydromorphone bolus, a second opioid medication, and
conventional bupivacaine HCl.

Proportion of subjects at each time point with sensitivity to cold in one of the
dermatomes.
12.3.
Pharmacokinetic Measurements (Part 1 Only)
Blood samples for PK analysis will be obtained from subjects at specific sites during Part 1
of the study at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours
after the beginning of study drug administration. Blood samples for PK analysis should be
collected even if the subject is not yet in surgery or is still in surgery. Placebo samples will be
collected to maintain the treatment double-blind but will not be analyzed. Samples from
subjects receiving bupivacaine nerve block rescue will not be analyzed. (Note: At time points
when the PK and NRS pain intensity assessments coincide, the NRS pain intensity assessments
will be conducted before the blood draw.)
12.4.
Pharmacokinetic Endpoints
Pharmacokinetic parameters are to be estimated from the plasma bupivacaine concentration-time
profiles by non-compartmental analysis and are to include the following:
AUC0-tlast
The area under the plasma concentration-time curve from the time of
administration to the time of the last quantifiable concentration calculated using
the lin/log trapezoidal rule.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
43 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
AUC0-∞
The area under the plasma concentration-time curve from the time of
administration extrapolated to infinity. The residual area from the time of the last
quantifiable concentration (Ctlast) to infinity is to be calculated using the
approximation: AUCt-∞= Ct last/ λz.
Cmax
The maximum observed plasma concentration obtained directly from the
experimental data without interpolation.
Tmax
The time to attain Cmax.
λz
The apparent terminal elimination rate constant determined by log-linear
regression of the terminal log-linear segment of the plasma concentration-time
curve.
t1/2el 
The apparent terminal elimination half-life calculated as 0.693/λz.
12.5.
Safety Assessments
The following safety assessments will be conducted at the times specified:

Adverse events from the time of randomization through Day 30.

Vital signs (resting heart rate and blood pressure) at baseline, 30 minutes, 1 hour, and
2 hours after surgery.

Neurological assessment at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 18, 24,
30, 36, 42, 48, 60, and 72 hours after surgery (see Appendix 2).

Cardiac assessment (i.e., ECG recordings) at baseline (beginning approximately 1 hour
prior to study drug administration) through 72 hours after study drug administration.
Electrocardiogram changes will be examined using the ECG data closest to the median
Tmax from each dose group.

Motor function assessment (i.e., ability to perform a 20-meter walk, unassisted with the
optional use of a 4-legged walker) at 24 hours, 72 hours, and on Day 30.

Physician satisfaction with return of sensory/motor function at 72 hours and on Day 30
(see Appendix 5).
12.6.
Safety Endpoints
The following safety endpoints will be assessed based on the safety measurements conducted at
the specified time points:

Incidence of TEAEs and SAEs through Day 30.

Change from baseline in vital signs (resting heart rate and blood pressure) at each
assessed time point.

Summary of neurological assessments (proportion of subjects who are oriented, and
proportion of subjects who have any of the neurological events).

Change from baseline in ECG data closest to the median Tmax.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
44 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013

Proportion of subjects able to walk 20 meters, unassisted, at 24 hours, 72 hours, and on
Day 30.

Rating of physician satisfaction with return of sensory/motor function at 72 hours and
Day 30.
12.7.
Appropriateness of Measures
Endpoints selected for this study were based on validated methodologies and other well
established clinical measurements used in peer-reviewed studies in both the peer reviewed
literature and at regulatory authorities.
The neurological and cardiac safety assessments are based on the known signs and symptoms
associated with systemic bupivacaine toxicity. The motor and sensory function assessments are
standard tests to determine restoration of nerve function.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
45 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
13.
STUDY PROCEDURES
A time and events schedule for all study procedures is provided in Table 1.
13.1.
Instructions for Conducting Procedures and Measures
With the exception of the PK assessments (which will be conducted after the beginning of study
drug administration), all assessments conducted after baseline will be timed from the end of
surgery. Day 1 is defined as the day on which study drug is administered. The beginning of
surgery is defined as the time of the first incision. The end of surgery is defined as the time of
the last suture/staple. Postsurgical is defined as after the end of surgery.
Subjects will be hospitalized for at least 72 hours after surgery; therefore, postsurgical analgesia
and collection of study data through the primary endpoint will take place under the supervision
of study staff.
13.1.1.
Pain Intensity Assessments
Pain intensity will be assessed using the NRS-R followed by the NRS-A (see Appendix 1).
To assess pain intensity at rest (NRS-R), the subject will assume a resting position that does not
exacerbate his or her postsurgical pain. The subject will rest in this position for at least
5 minutes before responding to the following question, “On a scale of 0 to 10, where 0 = no pain
and 10 = worst possible pain, how much pain are you having right now?” The subject’s
response will be recorded.
The subject’s pain intensity will be assessed with activity (NRS-A). The prescribed activity is
active knee flexion up to 45 degrees. The subject will respond to the following question, “On a
scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having
right now?” The subject’s response will be recorded.
Note: At time points when the NRS pain intensity assessments coincide, the NRS-R will be
conducted before the NRS-A. At time points when the NRS pain intensity assessment(s) and a
PK assessment coincide, the NRS assessment will be conducted before the blood draw.
Additionally, if ice or passive extenders are used, these must be stopped at least 15 minutes prior
to the NRS pain intensity assessments. If subjects are in immobilizers, these must be removed at
least 15 minutes prior to the NRS pain intensity assessments.
13.1.2.
Overall Benefit of Analgesia Score Questionnaire
The OBAS questionnaire (Lehmann 2010) will be completed at 24, 48, and 72 hours
(see Appendix 3).
13.1.3.
Neurological Assessment
A neurological assessment will be conducted at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8,
12, 18, 24, 30, 36, 42, 48, 60, and 72 hours after surgery. The examination will include the
subject's orientation. Additionally, the subject will be asked whether s/he is experiencing any
numbness and tingling of the mouth and lips, a metallic taste, blurred vision, tremors, or
twitching (see Appendix 2). If the neurological assessment reveals a neurological event that the


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
46 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Investigator believes may be associated with high levels of systemic bupivacaine, an
unscheduled PK blood sample should be collected at the time that the event is noted.
13.1.4.
Cardiac Assessment (Electrocardiogram Recordings)
Digital 12-lead holter ECGs will be recorded using the Mortara Instrument Digital H12+™ECG
continuous recorder (Mortara Instrument, Inc., Milwaukee, Wisconsin), which will continuously
record all 12 leads simultaneously from baseline through approximately 72 hours after drug
administration. The ECG signal will be recorded on compact flash memory cards provided to
the sites. The subject’s unique identification number and demographic information will be
recorded for each card. Without knowledge of subject treatment assignment, a central laboratory
will generate a 10-second, 12-lead digital ECG at each time point specified in the protocol.
If targeted ECG time points are artifactual and of poor quality, the central laboratory will capture
analyzable 10-second ECGs as close as possible to the targeted time points.
Digital ECGs will be transmitted by the central laboratory and processed via its validated data
management system, EXPERT. Interval duration measurements will first be obtained by trained
analysts using the proprietary validated electronic caliper system applied on a computer screen
utilizing the method of Global Median Beat. The Global Median Beat is created by an
algorithm, where one representative beat for each of the 12 leads is selected and superimposed,
creating a single superimposed (Global Median) beat. Trained analysts will then review for
correct interval duration measurement (IDM) caliper placement and adjudicate the pre-placed
algorithm calipers as necessary. A cardiologist will then verify the interval durations and
perform the morphology analysis, noting any T-U wave complex that suggests an abnormal form
compatible with an effect on cardiac repolarization.
On-screen measurements of the HR, PR, QRS, and QT interval durations will be performed and
derived variables RR, QTcF, and QTcB will be calculated using the following formulae:
QTcB = QT/√RR
QTcF = QT/3√RR
RR = 60/HR
Each fiducial point (onset of P wave, onset of Q wave, offset of S wave, and offset of T wave)
will be marked. The original ECG waveform and such annotations will be saved separately in
XML format for independent review.
Electrocardiogram changes in RR, PR, QRS, QT, QTcF, and QTcB will be examined at the time
closest to the median Tmax.
13.1.5.
Sensory Function Assessment (Cold Test)
For the sensory function assessment, the subject’s sensitivity to cold in the innervated
dermatomes (L2, L3) (see Appendix 7) will be assessed at baseline, when the subject wakes up
after surgery (general surgery subjects only), and at 2, 4, 12, 24, 36, 48, 60, and 72 hours after
surgery, or until the subject’s sensitivity to cold has returned in two consecutive evaluations.
The subject's skin will be wiped with ice or an alcohol pad. The subject will then be asked,
"Does this feel cold - yes or no?"


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
47 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
13.1.6.
Motor Function Assessment (20-Meter Walk Test)
Each subject's ability to perform a 20-meter walk, unassisted with the optional use of a 4-legged
walker, on a level surface will be assessed at baseline (during screening) and postsurgically at
24 hours, 72 hours, and on Day 30.
Subjects will be transported to the start of the course by wheelchair, assisted into a standing
position, and instructed to walk from end-to-end at their own pace while attempting to cover
20 meters with or without using a four-leg walker. The following standardized limited
encouragement from the staff should be offered: "You're doing well" or "Keep up the good
work." The outcome of the test will be recorded as either "yes" (the subject was able to walk the
full 20 meter distance) or "no" (the subject was unable to walk the full 20 meter distance).
13.1.7.
Vital Signs
Vital signs (heart rate and blood pressure) will be assessed after the subject has rested in a supine
position for at least 5 minutes and before the NRS assessments when the assessments coincide.
The subject will remain in a supine position during the assessment.
13.1.8.
Subject Satisfaction with Postsurgical Pain Control
The subject’s satisfaction with postsurgical pain control will be assessed at 72 hours and Day 30
using the Likert Scale (see Appendix 4).
13.1.9.
Physician Satisfaction with Sensory/Motor Function
The physician’s satisfaction with return of sensory/motor function will be assessed at 72 hours
and on Day 30 using a Likert scale (see Appendix 5).
13.1.10.
Fall Prevention
The study staff must ensure adequate safety precautions are in place in order to prevent falls
(e.g., use of a knee immobilizer and walker/crutches during ambulation, as needed).
Additionally, the study staff must be educated regarding possible continuous peripheral nerve
block-induced muscle weakness and necessary fall precautions.
13.2.
Screening Procedures

Explain study purpose and procedures.

Obtain signed ICF.

Assess eligibility.

Record relevant medical/surgical history, demographics, and baseline characteristics.

Measure vital signs (heart rate and blood pressure) after subject has rested for at least
5 minutes in the supine position.

Record concomitant medications taken within 3 days prior to surgery.

Test ability of subject to perform 20-meter walk, unassisted with the optional use of a
4-legged walker, per Section 13.1.6.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
48 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
13.3.
Baseline Procedures (Day -1 to Day 1)

Confirm eligibility.

Update relevant medical/surgical history.

Perform urine pregnancy test for women of childbearing potential before study drug
administration.

Perform urine drug screen.

Perform physical examination.

Measure vital signs (heart rate and blood pressure) after subject has rested for at least
5 minutes in the supine visit.

Record subject’s baseline assessment of pain intensity using the NRS-R followed by the
NRS-A (see Appendix 1).

Perform neurological assessment (see Appendix 2).

Start 12-lead digital ECG recording approximately 1 hour prior to study drug
administration.

Perform sensory function assessment (cold test).

Part 1 only: Collect baseline blood sample for PK analysis (specific sites only).

Record concomitant medications taken within 3 days prior to surgery.

Randomize subject and prepare study drug (Day 1).

Administer study drug according to the randomization schedule within 2 hours prior to
the surgical procedure.

Record start and stop time of study drug administration.

At the conclusion of the block, place and hep-lock the femoral nerve catheter.

Record AEs starting after subject randomization.
13.4.
Intraoperative Procedures

Install the PCA pump (unloaded) prior to the completion of the surgery.

Record start and stop times of surgery.

Record intraoperative opioids administered.

Perform ECG recordings.

Part 1 only: Collect blood samples for PK analysis (specific sites only) per Section 12.3.
(Blood samples for PK analysis should be collected even if the subject is not yet in
surgery or is still in surgery.)

Record concomitant medications.

Record AEs and any treatment(s) for the events.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
49 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013

If a cardiac or neurological event occurs during Part 1 or Part 2 of the study that the
Investigator believes may be associated with high levels of systemic bupivacaine, an
unscheduled PK blood sample should be collected at the time that the event is noted.
13.5.
Procedures After Surgery Through 72 Hours
Part 1 Only

Question subject regarding the predefined treatment-emergent opioid-related AEs at
72 hours after surgery (see Appendix 6).

Collect scheduled blood samples for PK analysis at specific sites only per Section 12.3.
Parts 1 and 2

Administer rescue medication for breakthrough pain per Section 11.

Load PCA pump with morphine or hydromorphone if IV hydromorphone 0.5 mg × 1
bolus is administered.

Record date, time, and amount of all rescue medication administered (IV hydromorphone
bolus, PCA opioid, oxycodone, and/or conventional bupivacaine HCl) through 72 hours
after surgery.

Record subject’s assessment of pain intensity using the NRS-R followed by the NRS-A
at the following time points: 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours after surgery and at
first request for rescue pain medication, if applicable (see Appendix 1).

Perform neurological assessment at 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 18, 24, 30,
36, 42, 48, 60, and 72 hours after surgery per Section 13.1.3 (see Appendix 2).

Perform cardiac assessment (i.e., 12-lead digital ECG recordings) through 72 hours after
study drug administration.

Perform sensory function assessment (i.e., cold test) when the subject wakes up after
surgery (general anesthesia subjects only), and at 2, 4, 12, 24, 36, 48, 60, and 72 hours
after surgery, or until the subject’s sensitivity to cold has returned to the baseline level in
two consecutive evaluations per Section 13.1.5.

Perform motor function assessment (i.e., ability of subject to perform a 20-meter walk,
unassisted with the optional use of a 4-legged walker) at 24 hours and 72 hours per
Section 13.1.6.

Measure vital signs (heart rate and blood pressure) after subject has rested for at least
5 minutes in the supine position at 30 minutes, 1 hour, and 2 hours after surgery.

Complete OBAS questionnaire (see Appendix 3) at 24, 48, and 72 hours after surgery.

Obtain overall rating of subject satisfaction with postsurgical pain control using the
Likert scale at 72 hours after surgery (see Appendix 4).

Record AEs and any treatment(s) for the events.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
50 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013

If a cardiac or neurological event occurs during Part 1 or Part 2 of the study that the
Investigator believes may be associated with high levels of systemic bupivacaine, an
unscheduled PK blood sample should be collected at the time that the event is noted.

Record concomitant medications.

Assess physician's satisfaction with return of sensory/motor function using a Likert scale
(see Appendix 5).
13.6.
Additional Procedures at Withdrawal if Prior to 72 Hours

Perform neurological assessment per Section 13.1.3 (see Appendix 2).

Perform sensory function assessment (i.e., cold test) unless the subject’s
sensitivity to cold has returned to the baseline level in two consecutive
evaluations per Section 13.1.5.

Perform motor function assessment (i.e., ability of subject to perform a 20-meter
walk, unassisted with the optional use of a 4-legged walker) per Section 13.1.6.

Collect blood sample for PK analysis, if possible.
13.7.
Postsurgical Visit (Day 30)

Obtain overall rating of subject satisfaction with postsurgical pain control using the
Likert scale (see Appendix 4).

Test ability of subject to perform a 20-meter walk, unassisted with the optional use of a
4-legged walker, per Section 13.1.6.

Assess physician's satisfaction with return of sensory/motor function using a Likert scale
(see Appendix 5).

Record AEs and any treatment(s) for the events.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
51 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
14.
ADVERSE EVENT REPORTING
Consistent with the current regulatory guidance provided by the US CFR and the ICH GCP,
AEs and SAEs are defined in Section 14.1.1 and Section 14.2.1, respectively.
The concepts of AEs and SAEs represent regulatory instruments used to evaluate and monitor
the safety of clinical study subjects. Therefore, these terms only apply in light of their regulatory
definition. The term serious, in a regulatory sense, does not necessarily mean severe. The SAE
concept is used primarily to identify, during the conduct of the study, those SAEs that may
require expedited reporting to regulatory authorities.
14.1.
Adverse Events
14.1.1.
Definitions
Definition of Adverse Event (AE): Any untoward medical occurrence associated with the use of
a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse
experience) can be any unfavorable and unintended sign (e.g., abnormal laboratory finding),
symptom, or disease temporally associated with the use of a drug, without any judgment about
causality. An AE can arise from any use of the drug (e.g., off-label use in combination with
another drug) and from any route of administration, formulation, or dose, including an overdose.
An AE can be any unfavorable and unintended change in a body structure or body function.
Adverse events include any clinically significant deterioration of a subject’s medical status.
The AE may involve any organ or system and can be represented by the new onset or
deterioration of a disease, a syndrome, a symptom, a physical sign, as well as by findings and
results of instrumental examinations and laboratory tests. Any medically relevant and untoward
change after the subject is randomized, including frequency or pattern changes for a fluctuating
condition (e.g., migraine) is considered an AE.
An AE that occurs after randomization and before the start of the study drug administration is
identified as a pretreatment AE (PTAE). An AE that occurs after the administration of the study
treatment is considered a TEAE. All AEs must be recorded and reported accordingly, whether
they appear causally related to the study drug or not. Adverse events will be followed until the
outcome is known or until the end of the study.
Definition of Adverse Reaction: Any AE caused by a drug. Adverse reactions are a subset of all
suspected adverse reactions for which there is reason to conclude that the drug caused the event.
Definition of Suspected Adverse Reaction: Any AE for which there is a reasonable possibility
that the drug caused the AE. For the purposes of IND safety reporting, ‘reasonable possibility’
means there is evidence to suggest a causal relationship between the drug and the AE.
A suspected adverse reaction implies a lesser degree of certainty about causality than adverse
reaction, which means any AE caused by a drug. Suspected adverse reactions are a subset of all
AEs for which there is a reasonable possibility that the drug caused the event.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
52 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
14.1.2.
Recording Adverse Events
It is the responsibility of the Investigator to document all AEs (i.e., PTAEs and TEAEs) with an
onset after the subject is randomized. For the purpose of this study, all AEs that occur through
Day 30 after surgery must be recorded regardless of whether or not they are considered related to
study drug. Whenever feasible, AE terms should be documented as medical diagnoses (highest
possible level of integration); otherwise, the AEs should be reported separately as individual
signs or symptoms. Only one AE per line should be recorded in the AE CRF; for example, an
AE of nausea and vomiting should be listed as two separate events: the event of nausea and the
event of vomiting. If a diagnosis is established after symptoms are recorded on the AE CRF,
the diagnosis should be recorded and the symptoms collapsed (removed; i.e., lined through and
initialed). Whenever possible, abnormal laboratory results should be reported as their clinical
corollary (e.g., low potassium should be recorded as hypokalemia).
All AEs will be followed through progression and regression of their severity. For example,
if an AE is reported as mild in severity but changes to moderate, the AE of mild will have an
outcome of changed AE characteristic and the AE will be re-entered. The AE with a moderate
severity must have the same start date as the mild event stop date. If the AE then becomes mild,
the AE with a moderate severity will have an outcome of changed AE characteristic and the AE
will be re-entered with a severity of mild; the start date of the mild AE must be the same as the
stop date of the moderate AE.
Any condition noted before the subject is randomized will be listed as Medical History and is
considered a pre-existing condition. If a pre-existing condition changes (i.e., becomes more
severe or more frequent), at any time after randomization, or after study drug administration, it is
considered an AE. Note: A change in treatment for a pre-existing condition (e.g., new high
blood pressure medication), does not necessarily indicate an AE.
Information recorded on the AE CRF will include the AE term, the date and time of onset,
severity, seriousness, relationship to study drug, action taken with study drug, action taken for
the AE, and the outcome of the AE, including the date and time of resolution, if applicable.
14.1.3.
Severity of Adverse Events
In general, the severity of an AE should be categorized using the following guidelines:
Mild:
An AE that is easily tolerated by the subject, causing minimal
discomfort and not interfering with everyday activities.
Moderate:
An AE that is discomforting and interferes with normal everyday
activities.
Severe:
An AE that prevents normal everyday activities.
14.1.4.
Relationship of Adverse Events to Study Drug
The Investigator will assess the relationship of the AE to study drug after careful medical
consideration on a case-by-case basis. General guidelines are provided below:
Not Related:
A causal relationship between the study drug and the AE can be
easily ruled out (e.g., based on the temporal sequence, absence of


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
53 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
a reasonable pathophysiological mechanism, or direct evidence of
actual cause).
Related:
There is reason to conclude that the drug caused the event (i.e., there
is a reasonable possibility based on evidence to suggest that the drug
caused the event).
14.1.5.
Outcome of Adverse Events
The Investigator will assess the outcome of the AE after careful medical consideration, on a
case-by-case basis. General guidelines are provided below:
Recovered/Resolved:
The event resolved and the subject recovered from the AE.
Recovered/Resolved
with Sequelae:
The initial event resolved, but has a continuing abnormal condition
as a result of the AE.
Not Recovered/
Not Resolved:
At the time of last assessment, the event was ongoing, with an
undetermined outcome. Note: ongoing AEs are not to be considered
resolved as a result of death.
Recovering/Resolving:
At the time of last assessment, the event was decreasing in
frequency, severity, etc., and a resolution was expected.
Fatal:
The AE directly caused death.
Unknown:
There was an inability to access the subject or the subject’s records
to determine the outcome (e.g., subject withdrew consent or was
lost to follow-up).
14.1.6.
Action Taken with Subject due to an Adverse Event
The Investigator will provide any actions taken regarding the subject (e.g., treatment, diagnostic
tests, laboratory tests, or therapy) for each reported AE.

None.

Medication.

Non-pharmaceutical therapy. (The specific therapy used must be recorded in the
CRF.)

Discontinued from study.

Other. (The specific action taken must be recorded.)


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
54 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
14.2.
Serious Adverse Events
14.2.1.
Definition of a Serious Adverse Event
Definition of a Serious Adverse Event (SAE): An AE is considered “serious” if, in the view of
either the Investigator or Sponsor, it results in any of the following outcomes:

Death1.

A life-threatening adverse event2.

Inpatient hospitalization or prolongation of existing hospitalization3.

A persistent or significant incapacity4.

Congenital anomaly/birth defect.

Medically significant5.
1Death: Any event resulting in a subject’s death must be reported as an SAE. However, death,
in and of itself, is not an AE; it is an outcome. The cause of death is the AE. Therefore, the
Investigator should make every effort to obtain and document the cause of death for all subjects
who die during the study. If, despite all efforts, the cause of death remains unknown, the AE
should be documented as an “unspecified fatal event.”
2Life-threatening: An AE is considered life-threatening if, in the view of either the Investigator
or Sponsor, its occurrence places the subject at immediate risk of death. It does not include an
AE that had it occurred in a more severe form might have caused death.
3Hospitalization: It should be noted that hospitalization, in and of itself, does not represent an
SAE. It is the AE leading to the subject’s hospitalization that becomes “serious” when it
requires inpatient care. Consequently, an SAE should not be reported in case of preplanned
hospitalizations for a pre-existing condition that did not worsen during the study. However,
any medical condition that delays a subject’s discharge from the hospital (i.e., prolonged
hospitalization) or requires the subject to be readmitted should be reported as an SAE.
4Persistent or significant incapacity: A substantial disruption of a person’s ability to conduct
normal life functions.
5Medically Significant: Important medical events that may not result in death, be life-
threatening, or require hospitalization, may be considered serious when, based upon appropriate
medical judgment, they may jeopardize the subject and may require medical or surgical
intervention to prevent one of the outcomes listed in this definition. Examples of such medically
significant events include allergic bronchospasm requiring intensive treatment in an emergency
room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization,
or the development of drug dependency or drug abuse.
14.2.2.
Reporting Serious Adverse Events
Any SAE or death that occurs at any time after randomization through Day 30, whether or not
related to study drug, must be reported by the Investigator or designee to Pacira Drug Safety or
designee by telephone or fax within 24 hours of discovery. Telephone contact information for
Pacira Drug Safety/designee can be found in the regulatory binder.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
55 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Investigators should not wait to receive additional information to fully document the event
before notifying Pacira Drug Safety or designee of the SAE. The telephone or fax report should
be followed by a full written summary using the SAE Form detailing relevant aspects of the SAE
in question. Where applicable, information from relevant hospital records and autopsy reports
should be obtained and all subject-identifying information redacted prior to forwarding to Pacira
Drug Safety or designee. In the event of a fatal or life-threatening SAE, any required follow-up
must be provided to Pacira Drug Safety or designee immediately. The Investigator will follow
all SAEs until resolved or the condition stabilizes and further follow-up is not warranted.
If the Investigator is made aware of any SAEs after Day 30, these should also be reported to
Pacira Drug Safety or designee provided the SAE is considered related to study drug. The site
would then provide a completed SAE form within 1 business day and the event would be
followed until resolution, or until adequate stabilization is met.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
56 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
15.
STATISTICAL METHODS
A comprehensive statistical analysis plan (SAP) will be developed for this study. A separate
SAP will be developed for the analysis of the ECG results.
15.1.
Study Hypothesis
Part 1
The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine
versus placebo with respect to the magnitude and duration of the analgesic effect achieved
following single dose injection femoral nerve block with liposome bupivacaine, and (2) select a
single therapeutic dose of liposome bupivacaine from the three dose levels tested.
Part 2
The primary null hypothesis is:
H0: The means of the AUC of the NRS-R pain intensity scores through 72 hours are not
different between the liposome bupivacaine and placebo groups.
The alternative hypothesis is:
HA: The mean AUC of the NRS-R pain intensity scores through 72 hours for the
liposome bupivacaine group is less than for the placebo group.
15.2.
Study Endpoints
The endpoints to be assessed in this study are listed in Section 12.2 (Efficacy Endpoints),
Section 12.4 (PK Endpoints) and Section 12.6 (Safety Endpoints).
15.3.
Determination of Sample Size
Part 1
The sample size for Part 1 of the study was not based on formal statistical power calculations.
Part 2
A study population of approximately 180 subjects is planned with approximately 90 subjects in
each treatment group (liposome bupivacaine and placebo). The sample size was estimated based
on the results of a Phase 3 hemorrhoidectomy study of liposome bupivacaine versus placebo
where the mean (standard deviation) AUC of the NRS-R pain intensity scores through 72 hours
was 141 (101) and 202 (104) for the liposome bupivacaine and placebo groups, respectively.
A two-group t-test with 0.05 two-sided significance level will have > 97% power to detect a
difference in means of 61, assuming that the common standard deviation is 104, when the sample
size in each group is 90.
After the data from Part 1 are evaluated, the sample size for Part 2 may be increased.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
57 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
15.4.
Analysis Populations
The following analysis sets are planned:
Safety: The safety analysis set will include all subjects who receive study drug and will be based
on actual treatment received.
Efficacy: The efficacy analysis set will include all subjects in the safety analysis set who undergo
the planned surgery and will be based on randomized treatment, regardless of actual treatment
received.
Pharmacokinetic: The PK analysis set will include all subjects in the safety analysis set who
receive liposome bupivacaine, provide sufficient samples to allow for calculation of PK
parameters required for analysis, and who do not receive conventional bupivacaine HCl
postsurgically.
15.5.
Handling Subject Dropouts and Discontinuations
For the calculation of AUC of NRS pain intensity scores through any of the time periods, the
following methods will be used for imputing missing data:
Missing scores before the first non-missing score will be replaced by the median score at the
missing time point from other subjects in the same treatment group. Missing scores after the last
non-missing score will be replaced by the last non-missing score (last observation carried
forward). Linear interpolation will be used to replace missing scores between two non-missing
scores. Subjects who have no pain scores after surgery will have the missing scores replaced by
the median score at the missing time point from other subjects in the same treatment group.
Additional methods for dealing with missing data will be described in the SAP.
15.6.
Statistical Analyses
15.6.1.
Baseline Characteristics
Demographic and baseline characteristics will be summarized by treatment group, separately for
Part 1 and Part 2.
15.6.2.
Study Compliance
The percentage of subjects in each analysis set and the percentage who fail to complete the study
(as well as the reasons for discontinuation) will be displayed by treatment group, separately for
Part 1 and Part 2.
15.6.3.
Efficacy Analyses
All efficacy analyses will be based on randomized treatment, regardless of actual treatment
received.
Efficacy data for Part 1 and Part 2 will be analyzed separately.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
58 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
15.6.3.1
Primary Efficacy Measure
The primary efficacy measure in this study is the AUC of the NRS-R pain intensity scores
through 72 hours.
Handling of Subjects Requiring Rescue Medication
For AUC of the NRS-R and NRS-A pain intensity scores, prior to analysis the windowed Worst-
Observation-Carried-Forward (wWOCF) imputation method will be applied. For subjects who
take rescue pain medication, their pain intensity scores recorded within the window of controlled
type of rescue medication (6 hours for oxycodone, 4 hours for morphine, and 2 hours for IV
hydromorphone) will be replaced by the ‘worst’ observation. For subjects who require a rescue
with conventional bupivacaine HCl, the window will be from the start of the bupivacaine
infusion until the end of the infusion plus 12 hours. All pain scores within that window will be
replaced by the ‘worst’ observation. The worst observation will be the highest score in the time
interval from the end of surgery up to the time prior to taking their first rescue pain medication.
Note that pain intensity scores in the window that are higher than the worst value prior to rescue
pain medication will not be overwritten. If no pain intensity score is available prior to the first
rescue pain medication, the worst observation from all available measurements will be used
instead.
Part 1
For AUC of the NRS-R pain intensity scores through 72 hours, each dose of liposome
bupivacaine will be compared to placebo using analysis of covariance (ANCOVA) with
treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. Based
on the model, the difference between each dose of liposome bupivacaine and placebo will be
estimated along with the 2-sided 95% confidence interval (CI).
Part 2
For AUC of the NRS-R pain intensity scores through 72 hours, liposome bupivacaine will be
compared to placebo using ANCOVA with treatment as the main effect and the baseline NRS-R
pain intensity score as the covariate. Based on the model, the difference between the treatment
groups will be estimated along with the 2-sided 95% CI.
15.6.3.2
Secondary Efficacy Measures
The secondary efficacy measures for Part 2 of this study are:

Total postsurgical opioid consumption through 72 hours

Time to first opioid rescue.
These efficacy measures will be analyzed using a hierarchical fixed-sequence stepwise testing
procedure. To protect the Type 1 error rate, the testing will be performed in a sequentially
rejective fashion. First the total postsurgical opioid consumption through 72 hours will be tested.
If the test of opioid consumption is significant at the two-sided 0.05 level then, and only then,
the time to first opioid rescue will be tested. Each test will be declared positive at the two-sided
0.05 significance level.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
59 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
For total postsurgical opioid consumption, opioid medications will be converted to a morphine
equivalent amount. All opioids administered through72 hours will be included in the analysis.
Prior to analysis, the natural logarithm transformation will be applied to the total amount. To test
for significant differences between liposome bupivacaine and placebo an analysis of variance
(ANOVA) with treatment as the main effect will be used. Based on the model, liposome
bupivacaine will be compared to placebo and a two-sided 95% CI about the differences will be
presented.
The time from end of surgery to the first use of an opioid rescue through 72 hours after surgery
will be summarized with medians and Kaplan-Meier estimates. A log-rank test will be used to
compare liposome bupivacaine to placebo.
15.6.3.3
Tertiary Efficacy Measures
Continuous Measures of Efficacy
For AUC of pain intensity scores, missing data will be imputed as described in Section 15.5 and
fully described in the SAP.
For total postsurgical opioid consumption, opioid medications will be converted to a morphine
equivalent amount. All opioids administered through the specified time period will be included
in the analysis. Prior to analysis, the natural logarithm transformation will be applied to the total
amount.
Part 1
At the end of the study, summary statistics for each measure will be shown at each time point by
treatment group. No statistical tests will be performed.
Part 2
Summary statistics for each measure will be shown at each time point by treatment group.
To test for significant differences between liposome bupivacaine and placebo with respect to
continuous measures of efficacy, an ANOVA with treatment as the main effect or ANCOVA
with treatment as the main effect and the baseline value as the covariate will be used. Based on
the model, liposome bupivacaine will be compared to placebo and two-sided 95% CIs about the
differences will be presented.
Categorical Measures of Efficacy
Part 1
At the end of the study, the proportion of subjects in each category will be calculated and
summarized at each time point by treatment group. No statistical tests will be performed.
Part 2
The proportion of subjects in each category will be calculated and summarized at each time point
by treatment group. A chi-square test or Cochran-Mantel-Haenszel test will be used to compare
liposome bupivacaine to placebo.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
60 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
15.6.4.
Pharmacokinetic Analyses
Part 1
Pharmacokinetic parameters will be estimated from the PK analysis set, using plasma drug
concentration-time profiles, where appropriate, by non-compartmental analysis.
Actual sampling time will be used for all calculations of the PK parameters. If there is any doubt
in the actual time a sample was taken, then the scheduled time will be used.
Descriptive statistics will be used to summarize the PK parameters.
Part 2
Not applicable.
15.6.5.
Safety Analyses
All safety analyses will be based on actual treatment received.
15.6.5.1
Adverse Events
Adverse events from Part 1 and Part 2 will be shown separately and combined.
Adverse event verbatim terms will be mapped to preferred terms and related system organ class
using the Medical Dictionary for Regulatory Activities (MedDRA). All summaries of AEs will
only include TEAEs. Events that start prior to the start of study drug administration will be
identified in listings only. Incidence rates of TEAEs and the proportion of subject prematurely
withdrawn from the study due to a TEAE will be shown for each treatment group. Incidence
rates also will be displayed for each treatment group for study drug-related TEAEs and by
severity. Incidence rates of SAEs also will be shown for each treatment group. All incidence
rates will be categorized and displayed by system organ class and preferred term.
15.6.5.2
Vital Signs
Descriptive statistics for each vital sign for baseline and change from baseline at each time point
will be summarized for each treatment group, for Part 1 and Part 2 separately and combined.
15.6.5.3
Proportion of Subjects Able to Walk 20 Meters, Unassisted
The proportion of subjects able to walk 20 meters, unassisted with the optional use of a four-
legged walker, at 24 hours, 72 hours, and Day 30 will be summarized for each treatment group,
for Part 1 and Part 2 separately and combined. For Part 2, the proportion in each of the liposome
bupivacaine group will be compared to the placebo group using a chi-square test.
15.6.5.4
Rating of Physician’s Satisfaction with Return of Sensory/Motor Function
The physician’s satisfaction with return of sensory/motor function will be summarized for each
treatment group, for Part 1 and Part 2 separately and combined. For Part 2, a Cochran-Mantel-
Haenszel test will be used to compare liposome bupivacaine to placebo.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
61 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
15.6.5.5
Neurological Assessments
The proportion of subjects who are oriented at each time point will be summarized for each
treatment group, for Part 1 and Part 2 separately and combined. The proportion of subjects who
have at least one of the neurologic events will be summarized for each treatment group, for
Part 1 and Part 2 separately and combined.
15.7.
Significance Testing
All tests will be two-sided and based on a significance level of 0.05.
15.8.
Interim Analyses
After all subjects have completed, or discontinued from, Part 1 of the study, an unblinded dose
selection committee will review at least the results of the primary efficacy measure and the two
secondary efficacy measures and safety data. The committee will determine the apparent
efficacy and safety of each of the three liposome bupivacaine dose levels tested and will
recommend a dose level for Part 2 of the study.
The committee also will run sample size estimates based on the results (mean differences and
variances) of the primary efficacy measures and make a recommendation for Part 2 of the study.
However, the sample size for Part 2 will not be fewer than 90 subjects per treatment arm.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
62 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
16.
REFERENCES
American Society of Anesthesiologists Task Force on Pain Management. Practice guidelines
for acute pain management in the postoperative setting: A report by the American Society
for Anesthesiologist Task Force on Pain Management Acute Pain Section. Anesthesiology.
1995;82:1071-1081.
EXPAREL Full Prescribing Information, October 2011.
Lehmann N, Joshi GP, Dirkmann D, et al. Development and longitudinal validation of the
overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument.
Br J Anasth. 2010;105(4):511-518. Epub 2010 Aug 6.
Mariano ER, Loland VJ, Sandhu NS, Bellars RH, Bishop ML, Afra R, Ball ST, Meyer RS,
Maldonado RC, Ilfeld BM. Ultrasound guidance versus electrical stimulation for femoral
perineural catheter insertion. J Ultrasound Med. 2009; 28:1453-60.
EXPAREL Investigator’s Brochure, Edition 15, 09 July 2012.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
63 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
17.
INVESTIGATOR AGREEMENT
Printed Name of Investigator:
Printed Title/Position:
Printed Institution Address:
I have reviewed this protocol (including Appendices) and agree:

To assume responsibility for the proper conduct of the study at this site;

To conduct the study in compliance with this protocol, with any future amendments,
and with any other study conduct procedures provided by Pacira Pharmaceuticals,
Inc. (Pacira) or designee. I also agree to comply with Good Clinical Practice and all
regulatory requirements;

Not to implement any changes to the protocol without agreement from Pacira or
designee and prior review and written approval from the Independent Ethics
Committee, except where it is necessary to eliminate an immediate hazard to the
subjects or for administrative aspects of the study (where permitted by applicable
regulatory requirements);

That I am thoroughly familiar with the appropriate use of the investigational
product(s), as described in this protocol, and with other relevant information
(e.g., the Investigator’s Brochure);

To ensure that all persons assisting me with the conduct of this study are adequately
informed about the investigational product(s) and about their study-related duties and
functions as described in this protocol;

That I am aware that regulatory authorities may require Investigators to disclose all
information about significant ownership interests and/or financial ties related to the
Sponsor and/or the investigational product(s). Consequently, I agree to disclose all
such significant financial information to Pacira and to update this information
promptly if any relevant changes occur during the course of the study through 1 year
following completion of the study. I also agree that any information regarding my
significant financial interest related to Pacira and/or the investigational product(s)
will be disclosed to the regulatory authorities by Pacira.
Signature of Investigator
Date


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol
Document No. 040-00171.006
64 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
18.
APPENDICES


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
65 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 1:
Subject’s Reported Pain (Numeric Rating Scale)
Note: Subjects will be evaluated for pain using the NRS-R followed by the NRS-A (where the
prescribed activity is active knee flexion up to 45 degrees) at baseline, 2, 4, 8, 12, 24, 36,
48, 60, and 72 hours after surgery.
Pain Intensity Scale
On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, circle the number that best
describes how much pain you are having right now. (Circle one number only.)
0
1
2
3
4
5
6
7
8
9
10
No pain
Worst
possible pain


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
66 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 2:
Neurological Assessment
A neurological assessment will be conducted at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8,
12, 18, 24, 30, 36, 42, 48, 60, and 72 hours after surgery.
The examination will include the subject's orientation.

Is the subject oriented?
Yes
No
Not Assessable
Additionally, the subject will be asked the following questions:

Do you have numbness of the lips, the tongue, or around the mouth?
Yes
No

Do you have a metallic taste in your mouth?
Yes
No

Are you having problems with your hearing?
Yes
No

Are you having problems with your vision?
Yes
No

Are your muscles twitching?
Yes
No
If the subject answers "yes" to any of these questions, the event should be recorded as an AE.
If the neurological assessment reveals a neurological event that the Investigator believes may be
associated with high levels of systemic bupivacaine, an unscheduled PK blood sample should be
collected at the time that the event is noted.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
67 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 3:
Overall Benefit of Analgesia Score Questionnaire
Note: The OBAS questionnaire will be completed at 24, 48, and 72 hours after surgery.
Please rate your current pain at rest on a scale between
0=minimal pain and 4=maximum imaginable pain
2. Please grade any distress and bother from vomiting in the past 24 h
(0=not at all to 4=very much)
3. Please grade any distress and bother from itching in the past 24 h
(0=not at all to 4=very much)
4. Please grade any distress and bother from sweating in the past 24 h
(0=not at all to 4=very much)
5. Please grade any distress and bother from freezing in the past 24 h
(0=not at all to 4=very much)
6. Please grade any distress and bother from dizziness in the past 24 h
(0=not at all to 4=very much)
7. How satisfied are you with your pain treatment during the past 24 h
(0=not at all to 4=very much)


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
68 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 4:
Subject Satisfaction with Postsurgical Pain Control (Likert
Scale)
Note: The subject's satisfaction with postsurgical pain control will be conducted at 72 hours after
surgery and on Day 30.
Please circle the number below that best describes your overall satisfaction with the pain
medication you received after surgery. (Circle one number only.)
1. Extremely dissatisfied
2. Dissatisfied
3. Neither satisfied nor dissatisfied
4. Satisfied
5. Extremely satisfied


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
69 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 5:
Physician's Satisfaction with Return of Sensory/Motor
Function (Likert Scale)
Note: The physician’s satisfaction with return of sensory/motor function will be assessed at
72 hours after surgery and on Day 30
Please circle the number below that best describes your overall satisfaction with the subject's
return of sensory/motor function. (Circle one number only.)
1. Extremely dissatisfied
2. Dissatisfied
3. Neither satisfied nor dissatisfied
4. Satisfied
5. Extremely satisfied


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
70 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 6:
Opioid-Related Adverse Events Questionnaire
The opioid-related adverse events questionnaire will be completed at 72 hours after surgery
during Part 1 only. The subject will be asked the questions below.
Since your operation, have you had:

Itching all over your body?
Yes
No

Excessive tiredness?
Yes
No

Difficulty breathing?
Yes
No

Did you need a postsurgical bladder catheter?
Yes
No

Vomiting?
Yes
No

Need for medicine to prevent vomiting?
Yes
No

Constipation?
Yes
No

Confusion?
Yes
No

Delirium?
Yes
No
If the subject answers "Yes" to any of these questions, the event should be recorded as an AE.


Pacira Pharmaceuticals, Inc.
402-C-323 (TKA)
Liposome Bupivacaine
Clinical Study Protocol Amendment 2
Document No. 040-00171.006
71 of 71
PCDOC #138012
CONFIDENTIAL
19 April 2013
Appendix 7:
Dermatome Map
For the sensory function assessment, the subject’s sensitivity in the innervated dermatomes (L2,
L3) will be assessed at baseline, when the subject wakes up after surgery, and at 2, 4, 12, 24, 36,
48, 60, and 72 hours after surgery, or until the subject’s sensitivity to cold has returned in two
consecutive evaluations.
The subject's skin will be wiped with ice or an alcohol pad. The subject will then be asked,
"Does this feel cold - yes or no?"


Site-Specific Addendum to
Clinical Study Protocol Amendment 1
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,
Dose-Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single
Injection Femoral Nerve Block with Liposome Bupivacaine for Postsurgical Analgesia
in Subjects Undergoing Total Knee Arthroplasty
Confidentiality Statement
The information contained in this document is confidential and the property of Pacira Pharmaceuticals, Inc.
It should not be reproduced, revealed, or sent to third parties other than Institutional Review Boards/Independent
Ethics Committees and the Investigator’s research support staff participating in the conduct of the study without
the prior written authorization of Pacira Pharmaceuticals, Inc.
Protocol No.:
402-C-323
EudraCT No.:
N/A
IND No.:
69,198
Study Phase:
2/3
Study Drug:
Liposome bupivacaine
Date:
14 January 2013
Study Site:
Site 001
Investigator:
Tim I. Melson, MD
Sponsor:
Pacira Pharmaceuticals, Inc.
10450 Science Center Drive
San Diego, CA 92121
Tel: (858) 625-2424


Pacira Pharmaceuticals, Inc.
402-C-323
EXPAREL
Site-Specific Addendum to Clinical Study Protocol Amendment 1
CONFIDENTIAL
14 January 2013
DOCUMENT NO. 040-00171.005
2 of 4
PCDOC #137765
SIGNATURE PAGE
14 January 2013
Erol Onel, MD
Executive Medical Director
Date
14 January 2013
Gary Patou, MD
Chief Medical Officer
Date
14 January 2013
George Wagner
Executive Director, Regulatory Affairs
Date


Pacira Pharmaceuticals, Inc.
402-C-323
EXPAREL
Site-Specific Addendum to Clinical Study Protocol Amendment 1
CONFIDENTIAL
14 January 2013
DOCUMENT NO. 040-00171.005
3 of 4
PCDOC #137765
Pharmacokinetic Assessments
Per protocol amendment 1, blood samples for pharmacokinetic (PK) analysis are to be collected
from subjects at specific sites during Part 1 of the study at baseline, 15 minutes, 30 minutes, and
1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours after the beginning of study drug administration.
Per this protocol addendum, additional blood draws for PK analysis may be collected from a
subset of up to 20 subjects across two or more WIRB sites at 84, 96, 120, 144, 168 hours after
the beginning of study drug administration, and on Day 10. The exact timing of the extra blood
draws may be modified based on a review of the data by an unblinded statistician and
pharmacokineticist. After a subject has been discharged from the hospital, the blood samples
may be collected on an outpatient basis at the site or by a home healthcare agency designated by
the study staff.


Pacira Pharmaceuticals, Inc.
402-C-323
EXPAREL
Site-Specific Addendum to Clinical Study Protocol Amendment 1
CONFIDENTIAL
14 January 2013
DOCUMENT NO. 040-00171.005
4 of 4
PCDOC #137765
INVESTIGATOR AGREEMENT
Printed Name of Investigator:
Printed Title/Position:
Printed Institution Address:
I have reviewed this protocol (including Appendices) and agree:

To assume responsibility for the proper conduct of the study at this site;

To conduct the study in compliance with this protocol, with any future amendments,
and with any other study conduct procedures provided by Pacira Pharmaceuticals,
Inc. (Pacira) or designee. I also agree to comply with Good Clinical Practice and all
regulatory requirements;

Not to implement any changes to the protocol without agreement from Pacira or
designee and prior review and written approval from the Independent Ethics
Committee, except where it is necessary to eliminate an immediate hazard to the
subjects or for administrative aspects of the study (where permitted by applicable
regulatory requirements);

That I am thoroughly familiar with the appropriate use of the investigational
product(s), as described in this protocol, and with other relevant information
(e.g., the Investigator’s Brochure);

To ensure that all persons assisting me with the conduct of this study are adequately
informed about the investigational product(s) and about their study-related duties and
functions as described in this protocol;

That I am aware that regulatory authorities may require Investigators to disclose all
information about significant ownership interests and/or financial ties related to the
Sponsor and/or the investigational product(s). Consequently, I agree to disclose all
such significant financial information to Pacira and to update this information
promptly if any relevant changes occur during the course of the study through 1 year
following completion of the study. I also agree that any information regarding my
significant financial interest related to Pacira and/or the investigational product(s)
will be disclosed to the regulatory authorities by Pacira.
Signature of Investigator
Date


 
 
Site-Specific Addendum to 
Clinical Study Protocol Amendment 1 
 
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 
Dose-Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single 
Injection Femoral Nerve Block with Liposome Bupivacaine for Postsurgical Analgesia 
in Subjects Undergoing Total Knee Arthroplasty 
 
 
 
 
 
Confidentiality Statement 
The information contained in this document is confidential and the property of Pacira Pharmaceuticals, Inc.  
It should not be reproduced, revealed, or sent to third parties other than Institutional Review Boards/Independent 
Ethics Committees and the Investigator’s research support staff participating in the conduct of the study without 
the prior written authorization of Pacira Pharmaceuticals, Inc. 
 
 
Protocol No.:  402-C-323 
EudraCT No.: N/A 
IND No.: 69,198 
Study Phase: 2/3 
 
Study Drug: Liposome bupivacaine 
Date: 14 January 2013  
Study Site:   Site 005 
Investigator: Harold S. Minkowitz, MD 
Sponsor: Pacira Pharmaceuticals, Inc. 
10450 Science Center Drive 
San Diego, CA  92121 
Tel: (858) 625-2424 


Pacira Pharmaceuticals, Inc. 
402-C-323 
EXPAREL 
Site-Specific Addendum to Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL 
 
14 January 2013 
DOCUMENT NO. 040-00171.004 
2 of 4 
PCDOC #137677 
 
SIGNATURE PAGE  
 
 
 
 
 
 
 
 
14 January 2013 
 
 Erol Onel, MD 
Executive Medical Director  
Date 
 
 
 
 
14 January 2013 
 
Gary Patou, MD 
Chief Medical Officer 
 
Date 
 
 
 
 
14 January 2013 
 
George Wagner 
Executive Director, Regulatory Affairs 
 
Date 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 
EXPAREL 
Site-Specific Addendum to Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL 
 
14 January 2013 
DOCUMENT NO. 040-00171.004 
3 of 4 
PCDOC #137677 
Pharmacokinetic Assessments  
Per protocol amendment 1, blood samples for pharmacokinetic (PK) analysis are to be collected 
from subjects at specific sites during Part 1 of the study at baseline, 15 minutes, 30 minutes, and 
1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours after the beginning of study drug administration.   
Per this protocol addendum, additional blood draws for PK analysis may be collected from a 
subset of up to 20 subjects across two or more WIRB sites at 84, 96, 120, 144, 168 hours after 
the beginning of study drug administration, and on Day 10.  The exact timing of the extra blood 
draws may be modified based on a review of the data by an unblinded statistician and 
pharmacokineticist.  After a subject has been discharged from the hospital, the blood samples 
may be collected on an outpatient basis at the site or by a home healthcare agency designated by 
the study staff.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 
EXPAREL 
Site-Specific Addendum to Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL 
 
14 January 2013 
DOCUMENT NO. 040-00171.004 
4 of 4 
PCDOC #137677 
INVESTIGATOR AGREEMENT 
 
Printed Name of Investigator: 
 
Printed Title/Position: 
 
Printed Institution Address: 
 
 
 
 
 
I have reviewed this protocol (including Appendices) and agree: 
• 
To assume responsibility for the proper conduct of the study at this site; 
• 
To conduct the study in compliance with this protocol, with any future amendments, 
and with any other study conduct procedures provided by Pacira Pharmaceuticals, 
Inc. (Pacira) or designee.  I also agree to comply with Good Clinical Practice and all 
regulatory requirements; 
• 
Not to implement any changes to the protocol without agreement from Pacira or 
designee and prior review and written approval from the Independent Ethics 
Committee, except where it is necessary to eliminate an immediate hazard to the 
subjects or for administrative aspects of the study (where permitted by applicable 
regulatory requirements);  
• 
That I am thoroughly familiar with the appropriate use of the investigational 
product(s), as described in this protocol, and with other relevant information 
(e.g., the Investigator’s Brochure); 
• 
To ensure that all persons assisting me with the conduct of this study are adequately 
informed about the investigational product(s) and about their study-related duties and 
functions as described in this protocol; 
• 
That I am aware that regulatory authorities may require Investigators to disclose all 
information about significant ownership interests and/or financial ties related to the 
Sponsor and/or the investigational product(s).  Consequently, I agree to disclose all 
such significant financial information to Pacira and to update this information 
promptly if any relevant changes occur during the course of the study through 1 year 
following completion of the study.  I also agree that any information regarding my 
significant financial interest related to Pacira and/or the investigational product(s) 
will be disclosed to the regulatory authorities by Pacira. 
 
Signature of Investigator 
Date 
 

SAP_001.pdf: 
Pacira Pharmaceuticals, Inc. 
EXPAREL 
 
Document: 
Statistical Analysis Plan 
Official Title: 
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- 
Controlled, Dose Ranging Study to Evaluate the Safety, Efficacy, and 
Pharmacokinetics of Single Injection Femoral Nerve Block With 
Liposome Bupivacaine for Postsurgical Analgesia in Subjects 
Undergoing Total Knee Arthroplasty 
NCT Number: 
NCT01683071 
Document Date: 
December 09, 2013 


 
 
 
 
 
 
STATISTICAL ANALYSIS PLAN 
 
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging Study 
to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single Injection Femoral Nerve Block with 
Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty 
 
 
 
Protocol No.: 402-C-323 
IND No.: 69,198 
Study Phase: 2/3 
Study Drug: Liposome Bupivacaine 
Date/Version: 09 December 2013 – Amendment 3 
27 June 2013 – Amendment 2 
1 February 2013 - Amendment 1 
12 October 2012 - Original 
Prepared by: Janice Lookabaugh, MPH 
Statistician, Consultant 
 
Sponsor: Pacira Pharmaceuticals, Inc. 
10450 Science Center Drive 
San Diego, CA 92121 
Telephone: (858) 625-2424 
Fax: (858) 625-0804 
 
 
 
 
 
 
Confidentiality Statement 
The information contained in this document is confidential and the property of Pacira Pharmaceuticals, Inc. It should 
not be reproduced, revealed, or sent to third parties other than Institutional Review Boards/Independent Ethics 
Committees and the Investigator’s research support staff participating in the conduct of the study without the prior 
written authorization of Pacira Pharmaceuticals, Inc. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 2 of 152 
09 December 2013 
 
 
 
SIGNATURE PAGE 
 
Erol Onel, MD 
Executive Medical Director 
09 December 2013 
Date 
Gary Patou, MD 
Chief Medical Officer 
09 December 2013 
Date 
George M. Wagner 
Executive  Director, Regulatory Affairs and 
Pharmacovigilance 
09 December 2013 
Date 
Janice Lookabaugh, MPH 
Statistician Consultant 
09 December 2013 
Date 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 3 of 152 
09 December 2013 
 
 
 
SUMMARY OF CHANGES 
 
The changes made to the statistical analysis plan are as follows: 
• 
Minor formatting and spelling corrections were made throughout. 
• 
In Section 7.1.2 and Section 7.6.2.2 a note was added to clarify how combination 
opioids would be used in the imputation of NRS pain intensity scores. 
• 
The table in Section 7.1.2 and in Section 7.6.2.2 had additional medications added to 
be consistent with what has been recorded in the clinical database. 
• 
In Section 7.6.2.1 one sensitivity analysis of the primary efficacy variable was added. 
• 
In Section 7.6.2.2 a clarification was added for how to calculate total dose of fentanyl 
when administered transdermally. 
• 
In Section 7.6.2.3 a plot for cold sensitivity was added. 
• 
In Section 7.7.2 an analysis of unbound bupivacaine was added. 
• 
In Section 7.8.4 the description of transfusions was changed from intraoperatively or 
postsurgically to after study drug administration. 
• 
Tables and listings were added or changed to be consistent with the above changes. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 4 of 152 
09 December 2013 
 
 
 
TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................................... 1 
SIGNATURE PAGE ....................................................................................................................... 2 
SUMMARY OF CHANGES ........................................................................................................... 3 
TABLE OF CONTENTS ................................................................................................................ 4 
1. 
LIST OF ABBREVIATIONS ...................................................................................... 6 
2. 
INTRODUCTION ........................................................................................................ 8 
3. 
STUDY OBJECTIVES ................................................................................................ 9 
4. 
STUDY OVERVIEW ................................................................................................ 10 
5. 
DEFINITIONS ........................................................................................................... 12 
6. 
ANALYSIS SETS ...................................................................................................... 13 
7. 
STATISTICAL METHODS OF ANALYSIS ............................................................ 14 
7.1. 
General Principles ...................................................................................................... 14 
7.1.1. 
Calculation of AUC of NRS ....................................................................................... 14 
7.1.2. 
Imputation of NRS Pain Intensity Scores ................................................................... 15 
7.1.3. 
Handling Missing Values ........................................................................................... 16 
7.1.4. 
Multiplicity Adjustments ............................................................................................ 18 
7.1.5. 
By-Center Analyses .................................................................................................... 18 
7.2. 
Subject Disposition ..................................................................................................... 18 
7.3. 
Description of Demographics and Baseline Characteristics ....................................... 18 
7.4. 
Prior and Concomitant Medication ............................................................................. 19 
7.5. 
Measurements of Treatment Compliance ................................................................... 19 
7.6. 
Efficacy Analysis ....................................................................................................... 19 
7.6.1. 
Efficacy Variables ...................................................................................................... 19 
7.6.2. 
Methods of Analysis ................................................................................................... 20 
7.7. 
Pharmacokinetic Analyses .......................................................................................... 24 
7.7.1. 
Pharmacokinetic Parameter Calculation Methods ...................................................... 24 
7.7.2. 
Pharmacokinetic Concentrations and Variables ......................................................... 25 
7.8. 
Safety Analyses. ......................................................................................................... 26 
7.8.1. 
Adverse Events. .......................................................................................................... 26 
7.8.2. 
Laboratory Parameters ............................................................................................... 26 
7.8.3. 
Vital Signs .................................................................................................................. 26 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 5 of 152 
09 December 2013 
 
 
7.8.4. 
Other Safety Parameters ............................................................................................. 26 
7.9. 
Interim Analysis ......................................................................................................... 27 
8. 
SAMPLE SIZE CALCULATIONS ........................................................................... 29 
9. 
REFERENCES ........................................................................................................... 30 
10. 
LAYOUT OF TABLES, LISTINGS, AND FIGURES ............................................. 31 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 6 of 152 
09 December 2013 
 
 
1. 
LIST OF ABBREVIATIONS 
 
AE 
Adverse event 
ANCOVA 
Analysis of covariance 
ANOVA 
Analysis of variance 
ASA 
American Society of Anesthesiologists 
ATC 
Anatomic therapeutic chemical 
AUC 
Area under the curve 
AUC(0-inf) 
Area under the plasma concentration versus time curve from 
time 0 extrapolated to infinity after drug administration 
AUC(0-last) 
Area under the plasma concentration versus time curve from 
time 0 to the last collection time after drug administration 
BLOQ 
Below the limit of quantification 
CI 
Confidence interval 
Cmax 
The maximum observed plasma concentration obtained 
directly from the experimental data without interpolation 
%CV 
Coefficient of variation 
CRF 
Case report form 
CSR 
Clinical study report 
eCRF 
Electronic case report form 
ECG 
Electrocardiogram 
EMA 
European Medicines Agency 
FDA 
Food and Drug Administration 
ICH 
International Conference on Harmonisation 
IV 
Intravenous 
λz 
Apparent terminal elimination rate constant 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 7 of 152 
09 December 2013 
 
 
 
LOCF 
Last observation carried forward 
LS 
Least squares 
MedDRA 
Medical Dictionary for Regulatory Activities 
NRS 
Numeric rating scale 
NRS-A 
Numeric rating scale with activity 
NRS-R 
Numeric rating scale at rest 
OBAS 
Overall benefit of analgesia score 
ORAE 
Opioid-related adverse event 
PCA 
Patient-controlled analgesia 
PK 
Pharmacokinetic 
PO 
Oral 
SAP 
Statistical analysis plan 
SD 
Standard deviation 
SOC 
System organ class 
TEAE 
Treatment-emergent adverse event 
TKA 
Total knee arthroplasty 
Tmax 
Time to maximum concentration 
t½ 
Half-life calculated from the apparent terminal elimination 
rate 
WHO-DD 
World Health Organization Drug Dictionary 
wWOCF 
Windowed worst observation carried forward 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 8 of 152 
09 December 2013 
 
 
 
 
2. 
INTRODUCTION 
This statistical analysis plan (SAP) describes the planned statistical analysis and reporting of 
the clinical study 402-C-323 titled “A Multicenter, Randomized, Double-Blind, Parallel- 
Group, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Efficacy, and 
Pharmacokinetics of Single Injection Femoral Nerve Block with Liposome Bupivacaine for 
Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty”. 
The structure and content of this SAP provides sufficient detail to meet the requirements 
identified by the US Food and Drug Administration (FDA), European Medicines Agency 
(EMA), and International Conference on Harmonisation (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use: Guidance on Statistical Principles in Clinical 
Trials [1].  All work planned and reported for this SAP will follow internationally accepted 
guidelines, published by the American Statistical Association [2] and the Royal Statistical 
Society [3], for statistical practice. 
The purposes of this SAP are to: 
• 
Outline the types of analyses and presentations of data that will form the basis for 
drawing conclusions to the study objectives and hypotheses outlined in the 
protocol. 
• 
Explain in detail how the data will be handled and analyzed, adhering to 
commonly accepted standards and practices for Good Statistical Practice. 
The planned analyses identified in this SAP may be included in clinical study reports (CSRs), 
regulatory submissions, or future manuscripts. Also, post-hoc exploratory analyses not 
necessarily identified in this SAP may be performed to further examine study data. Any post- 
hoc, or unplanned, exploratory analyses performed will be clearly identified as such in the 
final CSR. 
The following documents were reviewed in preparation of this SAP: 
• 
Protocol 402-C-323 Amendment 2 issued on 19 April 2013. 
• 
Case report forms (CRFs) for Protocol 402-C-323. 
• 
ICH Guidance on Statistical Principles for Clinical Trials (E9). 
The reader of this SAP is encouraged to also read the clinical study protocol and other 
identified documents for details on the planned conduct of this study.  Operational aspects 
related to collection and timing of planned clinical assessments are not repeated in this SAP 
unless relevant to the planned analyses. 
A separate SAP will be written for the analysis of electrocardiogram (ECG) data. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 9 of 152 
09 December 2013 
 
 
 
 
3. 
STUDY OBJECTIVES 
Part 1: The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome 
bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect 
achieved following single dose injection femoral nerve block with liposome bupivacaine, and 
(2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be 
tested in Part 2. 
Part 2: The primary objective of Part 2 is to compare the magnitude and duration of the 
analgesic effect of single injection femoral nerve block of a single dose level of liposome 
bupivacaine (selected from Part 1) with placebo (preservative-free normal saline for 
injection). 
The secondary objectives are to evaluate additional efficacy parameters, characterize the 
pharmacokinetic (PK) profile of liposome bupivacaine when administered as a femoral nerve 
block, and further assess the safety profile of liposome bupivacaine. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 10 of 152 
09 December 2013 
 
 
 
 
4. 
STUDY OVERVIEW 
This is a Phase 2/3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, 
dose-ranging study in subjects undergoing primary unilateral total knee arthroplasty (TKA) 
under general or spinal anesthesia. 
On Day 1, eligible subjects will be randomized to receive a single dose of study drug 
administered within 2 hours prior to the surgical procedure as a femoral nerve block. 
All subjects will be required to remain in the study site for a minimum of 72 hours after the 
end of surgery for postsurgical assessments. 
Part 1 
During Part 1 of the study, approximately 100 subjects (25 per treatment arm) will be 
randomized to receive a single dose injection femoral nerve block with either one of three 
doses of liposome bupivacaine (67, 133, or 266 mg) or placebo in 20 mL under ultrasound 
guidance.  Preservative-free normal saline will be added to the 67 mg and 133 mg doses of 
study drug to achieve a volume of 20 mL. 
After all subjects have completed the 72-hour assessments in Part 1, an analysis will be 
conducted in order to select a single therapeutic dose from the three liposome bupivacaine 
dose levels tested. The dose selected was 266 mg. 
Part 2 
In Part 2 of the study, approximately 180 subjects (approximately 90 liposome bupivacaine 
and 90 placebo subjects) will receive a single dose injection femoral nerve block with the 
selected dose of liposome bupivacaine (i.e., 266 mg) or placebo in 20 mL under ultrasound 
guidance. 
Postsurgical Rescue Medication 
Subjects should only receive rescue medication upon request for pain control, as needed. 
First Rescue Medication (IV Hydromorphone) 
The first rescue medication will be intravenous (IV) hydromorphone 0.5 mg, which will be 
administered once via bolus only. 
Second Rescue Medication (PCA and/or PO Opioid) 
The second rescue medication will be a patient-controlled analgesia (PCA) pump 
administered opioid (morphine or hydromorphone). The PCA pump will be programmed to 
deliver either: (1) on-demand morphine or (2) on-demand hydromorphone boluses at a dose 
and lockout interval in accordance with the site’s standard practice.  If a subject’s pain is 
excessive or pain control is inadequate, then the bolus dose may be adjusted according to 
local hospital practices. 
Once a subject is able to tolerate oral (PO) medication, PO immediate-release oxycodone may 
be administered (but not more than 10 mg every 4 hours). 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 11 of 152 
09 December 2013 
 
 
 
Third Rescue Medication (Conventional Bupivacaine HCl) 
If a subject’s pain is inadequately controlled by opioids, a third rescue, a femoral nerve block, 
consisting of conventional bupivacaine HCl at a concentration of 0.125% (1.25 mg/mL) at a 
rate of 8 mL per hour for up to 12 hours may be administered via the previously placed 
femoral nerve catheter. 
Postsurgical Assessments 
Postsurgical assessments will include pain intensity scores using the 0-10 point numeric rating 
scale (NRS) at rest (NRS-R) and NRS with activity (NRS-A) (where the prescribed activity is 
active knee flexion up to 45 degrees); use of supplemental opioid pain medication; 
neurological assessment; cardiac assessment (i.e., ECG recordings); sensory function 
assessment (i.e., cold test); motor function assessment (i.e., 20-meter walk test); vital signs; 
overall benefit of analgesia score (OBAS) questionnaire; subject satisfaction with postsurgical 
pain control; physician satisfaction with return of sensory/motor function; and an opioid- 
related adverse events (ORAEs) questionnaire in Part 1 only.  Adverse events (AEs) will be 
recorded through Day 30.  If a cardiac or neurological event occurs during Part 1 or Part 2 of 
the study that the Investigator believes may be associated with high levels of systemic 
bupivacaine, an unscheduled PK blood sample should be collected at the time that the event is 
noted. 
Safety and efficacy assessments will be conducted at pre-specified time points after the end of 
surgery.  A follow-up visit will be scheduled for all subjects on Day 30. 
See Table 1 in the protocol for the times of each of the assessments. 
Pharmacokinetic Assessments (Part 1 only) 
Blood samples for PK analysis will be obtained from subjects at specific sites during Part 1 of 
the study at baseline, 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 36, 48, 60, an 72 hours 
after the beginning of study drug administration. 
At two sites, there was an addendum to the protocol that allowed for additional blood draws 
for PK analysis from up to 20 subjects at 84, 96, 120, 144, 168 hours after study drug 
administration, and on Day 10. 
Unscheduled blood samples also may be collected during Part 1 or Part 2 of the study if a 
cardiac or neurological event occurs that the Investigator believes may be associated with 
high levels of systemic bupivacaine. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 12 of 152 
09 December 2013 
 
 
 
 
 
5. 
DEFINITIONS 
The terms study site and center are used interchangeably. 
Time 0 is defined as the start time of study drug administration for the PK analyses, and as the 
end time of surgery for the efficacy analyses. 
Study day: Day 1 is defined as the day study drug is administered. Positive study days will be 
measured forward in time from Day 1, with Day 2 being the calendar day immediately 
following the day study drug is administered.  Day -1 is the calendar day immediately 
preceding the day study drug is administered and negative study days will be measured 
backward from Day -1. 
Study visits and time points will be determined from the scheduled times as reported on the 
electronic CRFs (eCRFs) for the summarization and analysis of data that are shown by time 
point, unless otherwise specified. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 13 of 152 
09 December 2013 
 
 
 
 
6. 
ANALYSIS SETS 
The safety analysis set will include all subjects who receive study drug and will be based on 
actual treatment received. 
The efficacy analysis set will include all subjects in the safety analysis set who undergo the 
planned surgery and will be based on randomized treatment, regardless of actual treatment 
received. 
The PK analysis set will include all subjects in the safety analysis set who receive liposome 
bupivacaine, provide sufficient samples to allow for calculation of PK parameters required for 
analysis, and who do not receive conventional bupivacaine HCl postsurgically. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 14 of 152 
09 December 2013 
 
 
 
 
 
7. 
STATISTICAL METHODS OF ANALYSIS 
7.1. 
General Principles 
Descriptive statistics (the number of subjects [n], mean, standard deviation [SD], median, 
minimum, and maximum) will be used to summarize continuous variables.  Means and 
medians will be presented to one more decimal place than the recorded data. Standard 
deviations will be presented to two more decimal places than the recorded data.  Minimum 
and maximum values will be presented using the same number of decimal places as the 
recorded data.  Percentages will be presented to one decimal place. 
In addition, for PK parameters, geometric means and between-subject coefficient of variations 
(%CV) will be presented. 
Frequency distributions (number [n] and percentage of subjects [%]) will be used to 
summarize categorical or qualitative variables.  In general, the denominator for the percentage 
calculation will be based upon the total number of subjects in the study population for the 
treatment groups, unless otherwise specified. 
All statistical tests will be performed against a two-sided alternative hypothesis with a 
significance level of 5% (α = 0.05), and all confidence intervals (CIs) calculated will be 
two-sided 95% CIs.  All tests will be declared to be statistically significant if the calculated 
p-value is ≤ 0.05 unless specified otherwise.  Tests for binomial proportions will be conducted 
(1) using a normal approximation whenever each classification cell for each group to be 
compared contains expected cell counts of 5 or more subjects, or (2) using an exact method 
whenever any one classification cell for any one group to be compared contains expected cell 
counts of fewer than 5 subjects. 
All analyses will be performed using SAS® Software version 9.2 or later. 
Pharmacokinetic parameters will be derived using noncompartmental methods with 
WinNonlin Professional Version 5.2 or later (Pharsight Corp., Cary, North Carolina). 
For the listings, subjects will be listed under their randomized treatment, regardless of actual 
treatment received.  Subjects who are randomized but do not receive study drug will be 
included in the listings with the treatment group identified as “Liposome bupivacaine xx mg, 
Not Treated” or “Placebo, Not Treated”, depending on their randomized treatment. 
 
7.1.1. 
Calculation of AUC of NRS 
Area under the curve (AUC) will be calculated using the trapezoidal method with the actual 
NRS pain intensity scores reported by the subject.  Missing values will be imputed as 
described in Section 7.1.3.  The time points “Baseline” and “First Rescue” will not be 
included in the calculation of AUC. However, “First Rescue” might be used for imputation 
purposes as described in Section 7.1.2. Time 0 NRS score will be set to a score of 0.  Actual 
times, not scheduled times, when available will be used in the calculations.  Linear 
interpolation will be used to calculate the pain intensity score at the end of an interval. For 
72 hours, as an example, if the actual time is prior to 72 hours post-dose then the actual time 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 15 of 152 
09 December 2013 
 
 
 
and the reported score will be used.  In addition, the reported score will be carried forward to 
72 hours.  If the actual time is after 72 hours then linear interpolation between the 60-hour and 
72-hour scores will be used to calculate the score at 72 hours and the time will be set to 72. 
The linear interpolation will be performed after missing pain scores are imputed as discussed 
is Section 7.1.2. 
 
7.1.2. 
Imputation of NRS Pain Intensity Scores 
For calculation of AUC of NRS pain intensity scores, the windowed worst observation carried 
forward (wWOCF) and last observation carried forward (LOCF) imputation procedure will be 
used as follows: 
a) Windowed worst observation carried forward for rescue medications 
For subjects who take a rescue medication, their NRS scores recorded within the window 
of controlled type of rescue medication (see the table below for the windows for the 
planned rescue medications) will be replaced by the ‘worst’ observation. The worst 
observation will be the highest score in the time interval from Time 0 to up to the time 
prior to taking the first rescue medication. The NRS score at the first rescue will be 
included in this calculation.  Note that NRS scores in the window that are higher than the 
worst value prior to rescue medication will not be overwritten.  If no NRS score is 
available prior to the first rescue the worst observation from all available NRS scores will 
be used instead. 
 
Medication 
Route 
Window Used to Impute NRS 
Oxycodone 
PO 
6 hours 
Oxycontin (MS Contin) 
PO 
6 hours 
Morphine 
IV 
4 hours 
Hydromorphone (Dilaudid) 
IV 
2 hours 
Hydromorphone (Dilaudid) 
PO 
4 hours 
Fentanyl 
IV 
6 hours 
Fentanyl 
Transdermal 
Start of administration until the end 
of the administration plus 6 hours 
Hydrocodone 
PO 
6 hours 
Bupivacaine HCl 
Perineural 
12 hours 
Bupivacaine HCl 
Infusion 
Start of the infusion until the end of 
the infusion plus 12 hours 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 16 of 152 
09 December 2013 
 
 
 
Ropivacaine 
Start of the infusion until the end of 
the infusion plus 12 hours 
Meperidine 
IV 
4 hours 
Ultram 
PO 
6 hours 
IV = intravenous; PO = oral. 
If unplanned rescue medications are given then the window will be determined post-hoc prior to breaking 
the blind. If a combination opioid is given then the window will be determined by the opioid part of the 
medication. Opioids given postsurgically with an indication like ‘anesthesia maintenance’ will not be 
included for imputation purposes. 
 
b) Missing scores before the first non-missing score will be replaced by the median score 
at the missing time point from the other subjects in the same treatment group. 
c) Missing scores after the last non-missing score will be replaced by the LOCF. 
d) Missing scores between two non-missing scores will not be replaced (i.e., linear 
interpolation will be used). 
Subjects who have no pain intensity scores recorded after surgery will have the missing scores 
replaced by the median score at each time point from all subjects in the same treatment group. 
7.1.3. 
Handling Missing Values 
Surgery Date or Time 
It is expected that all necessary information on surgery (start and stop date and time) and 
postsurgery rescue medication (start dates and times, doses, frequency) will be complete. 
Any such information that is missing and cannot be obtained through query resolution may be 
imputed, on a case-by-case basis, in a conservative manner that minimizes bias. For example, 
if pain medication taken on Day 1 has no time of administration recorded, the imputed time 
will be the end of surgery. 
PCA Pump Interval Data 
For some subjects, individual doses from the PCA pump were not collected. For some 
subjects the individual doses were not collected for the whole 72 hours and for some it was 
not collected for parts of the 72 hours. For these data the intervals during which medication 
was delivered via the PCA pump are known.  So what was entered in the database was the 
medication, the start date and time of the interval, the stop date and time of the interval, and 
the total dose received. 
For these cases, for purposes of imputing pain scores using the wWOCF imputation, it will be 
assumed that a dose was given at the beginning of the interval, a dose was given at the end of 
the interval, and a dose was given in the middle of the interval. 
For these cases, for purposes of calculating the total postsurgical opioid consumption through 
the various time intervals, it will be assumed that the total dose was given at the beginning of 
the interval. 
Rescue Pain Medication 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 17 of 152 
09 December 2013 
 
 
 
For calculation of the total rescue pain medication usage (morphine equivalent) by time point, 
if a subject is discontinued early (e.g., dies, withdraws consent, is withdrawn from the study, 
or is lost to follow-up) before the end of the time interval (e.g., 24 hours after study drug 
administration), his or her total rescue pain medication usage through the time interval will be 
a projected amount.  For example, if a subject discontinues early at 6 hours after surgery, the 
projected amounts through 24 hours will be actual amount + average amount (actual amount/6 
hours) multiplied by the number of hours remaining in the time interval (24-6). 
Adverse Event or Concomitant Medications Dates or Times 
For AEs or concomitant medications with missing or partially missing start/stop date/time, the 
following imputation rules will be applied: 
For partial start date/time: 
• If the year is unknown, then the date will not be imputed and will be assigned a 
missing value. 
• If the month is unknown, then: 
i) 
If the year matches the year of the dose of study drug date, then the month and 
day of the dose of study drug date will be imputed. 
ii) 
Otherwise, ‘January’ will be assigned. 
• If the day is unknown, then: 
i) 
If the month and year match the month and year of the dose of study drug date, 
then the day of the dose of study drug date will be imputed. 
ii) 
Otherwise, ‘01’ will be assigned. 
• If the time is unknown, then: 
i) 
If the date (day, month, and year) match the date of the dose of study drug date, 
then the time of the dose of study drug time will be imputed. 
ii) 
Otherwise, “00’ will be assigned. 
For partial stop date/time: 
• If the year is unknown, then the date will not be imputed and will be assigned a missing 
value. 
• If the month is unknown, then ‘December’ will be assigned. 
• If the day is unknown, then the last day of the month will be assigned. 
• If the time is unknown, then the last time of the day will be assigned. 
If the above rules for stop dates result in an illogical date with regards to the dates the subject is 
in the study, then the stop date will be replaced with the subject’s date of completion/ 
withdrawal. Further, should the above rules not result in the most conservative date, then the 
imputed value may be replaced by a date that will lead to a more conservative analysis. 
Should this situation arise, specific details will be provided in the derived dataset specification 
documentation or documented in the derived analysis data set program using comments. 
AE Severity or Relationship to Study Drug 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 18 of 152 
09 December 2013 
 
 
 
If severity of an AE is not reported, then for tables of AEs by severity, the event will be 
classified as ‘Severe’.  If relationship to study drug is not reported for an AE, then for tables 
of study-drug related AEs, the event will be classified as related. 
Time to Event Time 
For calculating time to an event when only the hour, and not the minutes, are reported for the 
time of the event, then the minutes will be set to zero. 
 
7.1.4. 
Multiplicity Adjustments 
Part 1 
The purpose of Part 1 of the study is to select a dose for use in Part 2. Therefore, no alpha- 
level adjustments for multiple comparisons between the three doses and placebo will be made. 
Part 2 
Since no multiple comparisons of the primary efficacy variable will be made, no alpha- 
adjustments will be made. 
Also, since there is only one primary efficacy variable and all other efficacy variables are 
considered secondary, no alpha-adjustments for the primary response variable will be made. 
There are two secondary efficacy variables that will be analyzed using a hierarchical fixed- 
sequence stepwise testing procedure (See Section 7.6.1). The two secondary efficacy 
variables will only be analyzed if the prmary efficacy variable is statistically significant at the 
two-sided 0.05 significance level. To protect the Type 1 error rate, the testing will be 
performed in a sequentially rejective fashion.  First, the total postsurgical opioid consumption 
through 72 hours will be tested.  If the test of opioid consumption is significant at the two- 
sided 0.05 level then, and only then, the time to first opioid rescue will be tested. Each test 
will be declared positive at the two-sided 0.05 significance level. 
 
7.1.5. 
By-Center Analyses 
Up to 40 sites/centers will enroll subjects in this study.  The primary efficacy results will be 
summarized by site but site will not be included in any models. 
 
7.2. 
Subject Disposition 
The number and percentage of subjects who are in each analysis set, who completed the 
study, and who discontinued early from the study, along with reasons for early withdrawal, 
will be summarized by treatment group and for all subjects, separately for Part 1 and Part 2. 
In addition, the same summary will be produced by site for Part 2. 
 
7.3. 
Description of Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized by treatment group and for all 
subjects, separately for Part 1 and Part 2 for the safety analysis set and efficacy analysis set. 
The variables to be included in the summary are age, gender, ethnicity, race, American 
Society of Anesthesiologists (ASA) physical status class, height (cm), and weight (kg). 
Conversions between units for height and weight will use the following formulas: 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 19 of 152 
09 December 2013 
 
 
 
Weight (kg) = weight (lb) / 2.2046226 
Height (cm) = height (in) / 2.54. 
7.4. 
Prior and Concomitant Medication 
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO-DD) and will be classified according to the default anatomical therapeutic 
chemical (ATC) classification system code and preferred term. 
Prior medications are defined as medications with a stop date/time prior to study drug 
administration.  Concomitant medications are defined as medications taken after the start of 
study drug administration (i.e., started prior to the start of study drug administration and 
continued after or started after the start of study drug administration). 
Prior and concomitant medications will be summarized using n (%) of subjects by treatment 
group and for all subjects and by ATC class and preferred term separately for Part 1 and 
Part 2 for the safety analysis set. Subjects may have more than one medication per ATC 
category and preferred term.  At each level of subject summarization, a subject will be 
counted once if he/she reports one or more medications at that level. 
The tables of concomitant medications will not include rescue pain medications. 
 
7.5. 
Measurements of Treatment Compliance 
Study drug administration will be summarized by treatment group, separately for Part 1 and 
Part 2 for the safety analysis set.  The variables to be included are duration of injection and 
volume of study drug administered. Surgery will be summarized by treatment group, 
separately for Part 1 and Part 2 for the efficacy analysis set. The variables to be included in 
the summary are length of surgery (end time minus start time, in minutes), type of anesthesia, 
and incision length. 
 
7.6. 
Efficacy Analysis 
All summaries of the efficacy variables will use the efficacy analysis set, which will be based 
on randomized treatment, and will be summarized separately for Part 1 and Part 2. 
 
7.6.1. 
Efficacy Variables 
The primary efficacy variable is the AUC of the NRS-R pain intensity scores through 
72 hours. 
Secondary efficacy variables are: 
• Total postsurgical opioid consumption (in mg) through 72 hours. 
• Time to first opioid rescue. 
Tertiary efficacy variables are (the order of these variables has been changed from the order in 
the protocol to reflect how they will be discussed in the CSR): 
• The NRS-R and NRS-A pain intensity scores at each assessed time point. 
• The AUC of the NRS-R pain intensity scores through 24, 36, 48, and 60 hours. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 20 of 152 
09 December 2013 
 
 
 
• The AUC of the NRS-A pain intensity scores through 24, 36, 48, 60, and 72 hours. 
• The AUC of the NRS-R pain intensity scores from 24-48 and 48-72 hours. 
• Proportion of subjects who are pain free (defined as an NRS pain intensity score of 0 
or 1) at each assessed time point. 
• Total postsurgical opioid consumption (in mg) through 24, 36, 48, and 60 hours. 
• Proportion of subjects who receive the following rescue medication(s): 
• Subjects who receive no rescue medications (i.e., opioid or conventional 
bupivacaine HCl). 
• Subjects who only receive IV hydromorphone bolus. 
• Subjects who receive IV hydromorphone bolus and a second opioid 
medication. 
• Subjects who receive IV hydromorphone bolus, a second opioid medication, 
and conventional bupivacaine HCl. 
• Overall benefit of analgesia score questionnaire at 24, 48, and 72 hours. 
• Subject satisfaction with postsurgical pain control at 72 hours and Day 30. 
• Time to sensitivity to cold (listed in the protocol as proportion of subjects at each time 
point with sensitivity to cold on one of the dermatomes). 
• Incidence of predefined treatment-emergent ORAEs (diffuse pruritus, overt respiratory 
depression, urinary retention as measured by need for postsurgical bladder 
catheterization, constipation, sedation, confusion, delirium, vomiting, or need for 
antiemetic medication) at 72 hours (Part 1 only). 
 
7.6.2. 
Methods of Analysis 
7.6.2.1 Primary Efficacy Variable 
The primary efficacy variable is the AUC of the NRS-R pain intensity scores through 
72 hours using the wWOCF + LOCF imputation method described in Section 7.1.2. 
Each dose of liposome bupivacaine (Part 1) and the one dose of liposome bupivacaine (Part 2) 
will be compared to placebo using analysis of covariance (ANCOVA) with treatment as the 
main effect and the baseline NRS-R pain intensity score as the covariate.  Based on the 
model, the least squares (LS) means, LS mean difference between the two treatment groups, 
95% CI for the LS mean difference(s) between liposome bupivacaine and placebo, and 
p-value will be reported. 
For Part 2, descriptive statistics of the primary efficacy variable will also be shown by site. 
Sensitivity Analyses of the Primary Efficacy Variable 
For Part 2 a sensitivity analysis will be performed. 
The sensitivity analysis will exclude subjects who had interval data for opioid 
consumption. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 21 of 152 
09 December 2013 
 
 
 
7.6.2.2 Secondary Efficacy Variables 
The secondary efficacy variables for this study are: 
• Total postsurgical opioid consumption through 72 hours. 
• Time to first opioid rescue. 
For total postsurgical opioid consumption, opioid medications will be converted to a 
morphine equivalent amount (see the table below).  The converted amounts will be totaled for 
each subject and used in the analysis. When fentanyl is given transdermally the total amount, 
prior to conversion, will be calculated as the start date/time of administration until the end 
date/time of administration or end date/time of 72 hours after surgery, whichever is sooner, 
multiplied by the dose.  Projected amounts, for subjects who discontinue early, will be 
calculated as described in Section 7.1.3. 
 
 
Medication 
Unit 
Route 
Conversion (Multiplication) 
Factor 
Oxycodone 
mg 
PO 
0.5 
Oxycontin 
mg 
PO 
0.5 
Morphine 
mg 
IV 
1 
Hydromorphone 
(Dilaudid) 
mg 
IV 
6.7 
Hydromorphone 
(Dilaudid) 
mg 
PO 
1.3 
Fentanyl 
mcg 
IV 
0.1 
Fentanyl 
mcg 
Transdermal 
0.5 
Hydrocodone 
mg 
PO 
0.33 
IV = intravenous; PO = oral. 
If unplanned rescue medications are administered, then the conversion factor will be determined post-hoc 
prior to breaking the blind. If a combination opioid is administered then the opioid portion of the 
medication will be converted and included in the calculations. Opioids given postsurgically with an 
indication like ‘anesthesia maintenance’ will not be included in the calculation of total opioids. 
 
Prior to analysis, the natural logarithm transformation will be applied to the total amount. 
When total amount of opioids used is 0, the result will be changed to the lesser of 1 or 0.5 of 
the smallest total amount observed in the study prior to being transformed with the natural 
logarithm.  To test for significant differences between each liposome bupivacaine dose and 
placebo (Part 1) and between the one liposome bupivacaine dose and placebo (Part 2), an 
analysis of variance (ANOVA) with treatment as the main effect will be used. Based on the 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 22 of 152 
09 December 2013 
 
 
 
model, the LS means, LS mean difference between the two treatment groups, 95% CI for the 
LS mean difference(s) between liposome bupivacaine and placebo, and p-value will be 
reported. 
For the analysis of time to first opioid rescue, time to first opioid rescue will be computed in 
hours as the date/time of the first opioid rescue minus the date/time of the end of surgery.  If a 
subject is not administered an opioid, the time to first administration will be censored at 
72 hours after surgery or at the time of last follow-up, whichever is earliest.  Time of last 
follow-up will be defined as the later of (1) the last pain assessment, (2) the start time of the 
last rescue or concomitant medication, or (3) the start time of the last AE. 
Time to first opioid rescue will be analyzed by the Kaplan-Meier method.  The n (%) of 
subjects administered an opioid as well as the n (%) of censored observations will be 
presented for each treatment group.  In addition, Kaplan-Meier estimates in terms of the 
median and its 95% CI, and the 25th and 75th percentiles will be presented for each treatment. 
Log-rank tests will be used to compare each dose of liposome bupivacaine (Part 1) and the 
one dose of liposome bupivacaine (Part 2) to placebo. 
For Part 2, the efficacy measures will be analyzed using a hierarchical fixed-sequence 
stepwise testing procedure. To protect the Type 1 error rate, the testing will be performed in a 
sequentially rejective fashion.  First, the total postsurgical opioid consumption through 
72 hours will be tested.  If the test of opioid consumption is significant at the two-sided 
0.05 level then, and only then, the time to first opioid rescue will be tested.  Each test will be 
declared positive at the two-sided 0.05 significance level. 
7.6.2.3 Tertiary Efficacy Variables 
For Part 1, no statistical tests will be performed on any of the tertiary efficacy variables.  Only 
descriptive statistics will be shown for each treatment. 
For Part 2, the following describes the statistical analyses to be performed. 
 
NRS-R, NRS-A, and AUC of Pain Intensity Scores 
For the tertiary efficacy variables NRS-R, NRS-A, and the AUCs of the NRS-R and NRS-A 
pain intensity scores, the same analyses as those for the primary efficacy variable will be 
performed, except that the baseline NRS-A score will be used as the covariate for all variables 
using the NRS-A. 
 
Proportion of Subjects Who are Pain Free 
Pain free is defined as an NRS-R pain intensity score of 0 or 1. The number and percentage 
of subjects who are pain free will be summarized by treatment group for each time point. A 
chi-square test will be used to compare liposome bupivacaine to placebo. 
 
Total Postsurgical Opioid Consumption Through 24, 36, 48, and 60 Hours 
For the tertiary efficacy variables total opioid consumption through each of the time periods, 
the same analysis as that for the secondary efficacy variable of total opioid consumption 
through 72 hours will be performed. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 23 of 152 
09 December 2013 
 
 
 
Subjects Who Receive Rescue Medication 
The category of ‘Subjects who receive no rescue medication’ is defined as subjects who 
report not taking any medication on the four Rescue Medication eCRFs. 
The category of ‘Subjects who only receive the IV hydromorphone bolus’ is defined as 
subjects who report taking IV hydromorphone (or other opioid medications) on the First 
Rescue Medication eCRF and report not taking a medication on either of the Second Rescue 
Medication eCRFs or on the Third Rescue Medication eCRF. 
The category of ‘Subjects who receive the IV hydromorphone bolus and a second opioid 
medication’ is defined as subjects who report taking IV hydromorphone (or other opioid 
medication) on the First Rescue Medication eCRF and who report taking a medication on 
either of the Second Rescue Medication eCRFs and report not taking a medication on the 
Third Rescue Medication eCRF. 
The category of ‘Subjects who receive the IV hydromorphone bolus, a second opioid 
medication, and conventional bupivacaine HCl’ is defined as subjects who report taking IV 
hydromorphone (or other opioid medication) on the First Rescue Medication eCRF, who 
report taking a medication on either or both of the Second Rescue Medication eCRFs, and 
bupivacaine HCl on the Third Rescue Medication eCRF. 
The number and percentage of subjects who are in each of the above categories will be 
summarized by treatment group.  A chi-square test will be used to compare liposome 
bupivacaine to placebo for each of the categories. 
 
Overall Benefit of Analgesia Score Questionnaire 
The OBAS is calculated as follows: 
1. Add all of the scores of questions one to six. 
2. To this number, add four. 
3. Subtract the score of question seven from this number. 
Summary statistics will be provided by treatment group at each time point.  A Wilcoxon Rank 
Sum test will be used to compare liposome bupivacaine to placebo. 
 
Subject Satisfaction with Postsurgical Pain Control 
Subjects will rate their satisfaction with postsurgical pain control as Extremely dissatisfied, 
Dissatisfied, Neither satisfied nor dissatisfied, Satisfied, or Extremely satisfied at 72 hours 
and on Day 30.  The categories will be summarized by treatment group at each time point. 
A Wilcoxon Rank Sum test will be used to compare liposome bupivacaine to placebo. 
 
Time to Sensitivity to Cold 
Once a subject reports sensitivity to cold on two consecutive evaluations the subject will no 
longer be tested.  The time to sensitivity to cold will be defined as the time of the first of two 
consecutive evaluations when the subject reports sensitivity to cold.  Time to sensitivity to 
cold will be calculated from the end of surgery.  If a subject never reports sensitivity to cold 
or never reports sensitivity to cold on two consecutive evaluations then the time will be 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 24 of 152 
09 December 2013 
 
 
 
censored at 72 hours after the end of surgery or at the time of the last follow-up, whichever is 
earliest. Time of last follow-up will be defined as the later of (1) the last pain assessment, (2) 
the start time of the last rescue or concomitant medication, or (3) the start time of the last AE. 
Time to sensitivity to cold will be analyzed by the Kaplan-Meier method.  The n (%) of 
subjects with sensitivity to cold as well as the n (%) of censored observations will be 
presented for each treatment group.  In addition, Kaplan-Meier estimates in terms of the 
median and its 95% CI, and the 25th and 75th percentiles will be presented for each treatment 
group.  For Part 2, a log-rank test will be used to compare liposome bupivacaine to placebo. 
A plot of the responses to cold sensitivity will be produced for Part 1 and Part 2 separately. 
The x-axis will show the scheduled hours post-op.  The y-axis will be the subject number. An 
‘X’ will be plotted for responses of ‘Yes’ and an ‘O’ will be plotted for responses of ‘No’. 
Figures should be created by site and treatment, combining sites with few subjects, in order to 
show about 20 subjects per figure. 
 
Incidence of Predefined Treatment-Emergent Opioid-Related AEs 
The determination of whether a subject had a treatment-emergent ORAE will be based solely 
on responses on the Predefined Treatment-Emergent ORAEs eCRF.  This was collected in 
Part 1 only The number and percentage of subjects who have at least one ORAE will be 
summarized by treatment group.  A chi-square test will be used to compare liposome 
bupivacaine to placebo. 
The number and percentage of subjects who have each of the ORAEs will also be summarized 
by treatment group, although no statistical tests will be performed. 
 
7.7. 
Pharmacokinetic Analyses 
7.7.1. 
Pharmacokinetic Parameter Calculation Methods 
Part 1 
Pharmacokinetic parameters will be calculated by noncompartmental analysis method from 
concentration-time data using WinNonlin Professional (Version 5.2 or later) following these 
guidelines: 
• Actual sampling times relative to study drug administration will be used for all 
calculations of the PK parameters.  If there is any doubt as to the actual time a sample 
was taken, then the scheduled time will be used. Descriptive statistics will be used to 
summarize the PK parameters. 
• There will be no imputation of missing data. 
For the calculation of AUCs from PK concentrations, concentration below the limit of 
quantification (BLOQ) will be handled as follows: 
• Pre-dose values will be set to zero. 
• All remaining BLOQ values will be set to missing. 
Pharmacokinetic parameters will be estimated according to the following guidelines: 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 25 of 152 
09 December 2013 
 
 
t
 
• The maximum observed plasma concentration (Cmax) will be obtained directly from the 
concentration-time data. 
• Time to maximum concentration (Tmax) is the time at which Cmax is observed. 
• The apparent terminal elimination rate constant (λZ) will be estimated at terminal phase by 
linear regression after log-transformation of the concentrations: 
• Only those data points that are judged to describe the terminal log-linear decline will 
be used in the regression. 
• A minimum number of three data points in the terminal phase will be used in 
calculating λz with the line of regression starting at any post-Cmax data point (Cmax 
should not be part of the regression slope) and including Clast, tlast. 
• The adjusted correlation coefficient (R2 adjusted) in general should be greater than 
0.90.  Any value less than 0.90 may be used at the pharmacokineticist's best 
knowledge and judgment. 
• An appropriate number of decimal places should be used for λz to enable the reported 
value of half-life (t½) to be calculated. 
• Half-life (t1/2) will be calculated as ln2/λZ. 
• AUC will be calculated as follows: 
• The linear trapezoidal method will be employed for all incremental trapezoids arising 
from increasing concentrations and the logarithmic trapezoidal method will be used 
for those arising from decreasing concentrations. 
• 
AUC(0-t)= ∫0  C(t )dt . 
 
t 
∞ 
• AUC(0-inf) = ∫0  C(t )dt ＋ ∫t C ( t )dt = AUC(0-t)＋Ct/λz. 
• C(t) is last observed quantifiable concentration. 
7.7.2. 
Pharmacokinetic Concentrations and Variables 
The analysis of the PK data will be based on the PK analysis set. 
Bupivacaine plasma concentrations will be listed by treatment group, subject, nominal time, 
and actual time.  Concentrations that are BLOQ will be indicated by BLOQ in this listing. 
Plasma concentrations will be summarized by treatment at each time point.  The following 
descriptive statistics will be presented for plasma concentrations obtained at each nominal 
time point: n, geometric mean, arithmetic mean, SD, %CV, minimum, median, and 
maximum. 
Pharmacokinetic parameters will be summarized by treatment. Descriptive statistics for 
calculated PK parameters will include: n, arithmetic mean, SD, %CV, geometric mean, 
median, minimum and maximum values.  Geometric mean will not be presented for Tmax. 
Values of %AUC extrapolated > 20% will be flagged in the listings. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 26 of 152 
09 December 2013 
 
 
 
Individual plasma concentration versus actual times will be plotted by treatment in linear and 
semi-logarithmic scale. 
At the 15 minute time point, unbound bupivacaine will be evaluated.  The percentage of 
unbound over the total (unbound/total*100) will be summarized for subjects who have both 
values. 
 
7.8. 
Safety Analyses. 
All summaries of the safety data will use the safety analysis set. 
 
7.8.1. 
Adverse Events 
All AEs will be coded and summarized by system organ class (SOC) and preferred term based 
on the Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary. 
An AE will be considered treatment-emergent if the onset is any time on or after study drug 
administration through Day 30. 
Only treatment-emergent AEs (TEAEs) that were not solicited from the Neurological 
Assessment or from the Opioid-Related Adverse Event Questionnaire will be summarized in 
the tables.  All other AEs, those that occur after randomization but prior to study drug 
administration, AEs that occur after Day 30, or AEs that were solicited from the Neurological 
Assessment or from the Opioid-Related Adverse Event Questionnaire will appear in listings 
only. 
Tables of AEs will show Part 1 and Part 2 data separately and combined. 
Treatment-emergent AEs will be summarized [n (%)] and grouped by SOC and preferred term 
for each treatment group and for all subjects.  If a subject experiences more than one episode 
of a particular TEAE, the subject will be counted only once for that event at each level of 
summarization (overall, by SOC, and by preferred term). 
Similarly, TEAEs will be summarized in terms of maximum severity (‘Mild’, ‘Moderate’, and 
‘Severe’), study drug related TEAEs, and serious AEs. 
 
7.8.2. 
Laboratory Parameters 
Not applicable. 
 
7.8.3. 
Vital Signs 
Descriptive summaries of actual value and changes from Baseline will be calculated for 
systolic blood pressure, diastolic blood pressure, and heart rate. These summaries will be 
presented by treatment group at each time point for Part 1 and Part 2 separately and 
combined. 
 
7.8.4. 
Other Safety Parameters 
Neurological Assessments 
The proportion of subjects who are oriented will be summarized by treatment group at each 
time point, for Part 1 and Part 2 separately and combined.  Subjects who were ‘not assessable’ 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 27 of 152 
09 December 2013 
 
 
 
will not be included in the calculation of the proportion. The proportion of subjects who have 
at least one of the neurological events and the proportion of subjects who have each of the 
neurologic events will be summarized by treatment group, for Part 1 and Part 2 separately and 
combined. 
20-Meter Walk Test 
The proportion of subjects able to walk 20 meters, unassisted, with the optional use of a four- 
legged walker, will be summarized by treatment group for Part 1 and Part 2 separately and 
combined.  For Part 2, the proportion in the liposome bupivacaine group will be compared to 
placebo using a chi-square test. 
Physician’s Satisfaction with Return of Sensory/Motor Function 
The physician will rate his/her satisfaction with return of sensory/motor function as Extremely 
dissatisfied, Dissatisfied, Neither satisfied nor dissatisfied, Satisfied, or Extremely satisfied at 
72 hours and on Day 30.  The categories will be summarized by treatment group at each time 
point for Part 1 and Part 2 separately and combined.  For Part 2, a Wilcoxon Rank Sum test 
will be used to compare liposome bupivacaine to placebo. 
Transfusions 
The proportion of subjects who had a transfusion (after study drug administration) will be 
summarized by treatment group for Part 1 and Part 2 separately and combined. To determine 
if a subject had a transfusion a review of the concomitant medications will be done. 
Medications such as Packed Red Blood Cells will indicate that a subject had a transfusion. 
 
7.9. 
Interim Analysis 
After all subjects have completed the 72-hour assessments, or discontinued prior to the 
72-hour assessment from Part 1 of the study, an analysis will be conducted in order to select a 
single therapeutic dose from the three liposome bupivacaine dose levels tested. The 
committee will determine the apparent efficacy and safety of each of the three liposome 
bupivacaine dose levels tested and will recommend a dose level for Part 2 of the study. 
In order to make their assessment, the following tables will be produced by an unblinded 
statistician: 
 
Table # 
Table Title 
14.1.1-1 
Subject Disposition (All Subjects) 
14.1.2.1-1 
Demographic and Baseline Characteristics (Safety Analysis Set) 
14.2.2.1-1 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
(Efficacy Analysis Set) 
14.2.2.2-1 
Total Postoperative Consumption (mg) of Opioid Rescue Pain 
Medication Through 72 Hours (Efficacy Analysis Set) 
14.2.2.3.2-1 
Time to First Opioid Rescue (Efficacy Analysis Set) 
14.3.1.2-1 
Incidence of Treatment-Emergent Adverse Events (Safety Analysis 
Set) 
14.3.4-1 
20-Meter Walk Test (Safety Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 28 of 152 
09 December 2013 
 
 
 
In addition, blood plasma samples for PK analysis will be sent to a laboratory for analysis 
from approximately 100 subjects. The samples from those subjects who received liposome 
bupivacaine and who did not receive conventional bupivacaine HCl postsurgically will be 
assayed.  The liposome bupivacaine concentrations will be sent to the unblinded statistician. 
The unblinded statistician will determine the Cmax for each of these subjects. The maximum 
Cmax will be provided to Pacira. Depending on the maximum Cmax, Pacira will determine if 
ECG data at Tmax need to be provided to the committee. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 29 of 152 
09 December 2013 
 
 
 
 
8. 
SAMPLE SIZE CALCULATIONS 
Part 1 
The sample size for Part 1 of the study was not based on formal statistical power calculations. 
Part 2 
A study population of approximately 180 subjects is planned with approximately 90 subjects 
in each treatment group (liposome bupivacaine and placebo). The sample size was estimated 
based on the results of a Phase 3 hemorrhoidectomy study of liposome bupivacaine versus 
placebo where the mean (SD) AUC of the NRS-R pain intensity scores through 72 hours was 
141 (101) and 202 (104) for the liposome bupivacaine and placebo groups, respectively. 
A two-group t-test with 0.05 two-sided significance level will have >97% power to detect a 
difference in means of 61, assuming that the common SD is 104, when the sample size in each 
group is 90. 
After the data from Part 1 are evaluated, the sample size for Part 2 may be increased. The 
evaluation of the data did not indicate that the sample size should be increased. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 30 of 152 
09 December 2013 
 
 
 
 
9. 
REFERENCES 
1. US Federal Register. International Conference on Harmonisation; Guidance on Statistical 
Principles for Clinical Trials. Department of Health and Human Services: Food and Drug 
Administration [Docket No. 97D-0174]. Federal Register Volume 63, Number 179, pages 
49583-49598.  16 September 1998. 
2. American Statistical Association.  Ethical Guidelines for Statistical Practice. Prepared by 
the Committee on Professional Ethics, 07 August 1999. 
http://www.amstat.org/profession/ethicalstatistics.html 
3. Royal Statistical Society.  The Royal Statistical Society: Code of Conduct, August 1993. 
http://www.rss.org.uk/about/conduct.html. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 31 of 152 
09 December 2013 
 
 
 
 
 
10. 
LAYOUT OF TABLES, LISTINGS, AND FIGURES 
The following are planned summary tables for Protocol 402-C-323. Tables will be numbered 
according to the nomenclature used to support the CSR.  The final table numbering may be 
different from the SAP.  No amendment will be made for changes in table numbering.  All 
headers, titles, footnotes, and footers specified in the table templates will be displayed in the 
produced output unless otherwise specified. Notes to programmers will not be included in the 
tables. There will be a footnote in all tables that includes the program name, SAS version 
number, and the date that the output was produced. 
Study Part 1 Planned Tables 
 
Table 
Number 
Table Title 
14.1.1-1 
Subject Disposition 
Study Part 1 (All Randomized Subjects) 
14.1.2.1-1 
Demographic and Baseline Characteristics 
Study Part 1 (Safety Analysis Set) 
14.1.2.2-1 
Demographic and Baseline Characteristics 
Study Part 1 (Efficacy Analysis Set) 
14.1.3.1-1 
Prior Medications 
Study Part 1 (Safety Analysis Set) 
14.1.3.2-1 
Concomitant Medications 
Study Part 1 (Safety Analysis Set) 
14.2.1.1-1 
Study Drug Administration 
Study Part 1 (Safety Analysis Set) 
14.2.1.2-1 
Surgery 
Study Part 1 (Efficacy Analysis Set) 
14.2.2.1-1 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.2-1 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication 
Through 72 Hours 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.3-1 
Time to First Opioid Rescue 
Study Part 1 
(Efficacy Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 32 of 152 
09 December 2013 
 
 
 
Study Part 1 Planned Tables Continued 
 
Table 
Number 
Table Title 
14.2.2.4-1 
NRS-R Pain Intensity Scores 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.5-1 
NRS-A Pain Intensity Scores 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.6-1 
AUC of NRS-R Pain Intensity Scores Through 24, 36, 48, and 60 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.7-1 
AUC of NRS-A Pain Intensity Scores Through 24, 36, 48, 60, and 
72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.8-1 
AUC of NRS-R Pain Intensity Scores 24-48 and 48-72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.9-1 
Percentage of Subjects who are Pain Free at Each Time Point 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.10-1 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication 
Through 24, 36, 48, and 60 Hours 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.11-1 
Subjects who Received Rescue Medication Through 72 Hours 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.12-1 
Overall Benefit of Analgesia Score Questionnaire (Total Scores) 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.13-1 
Subject Satisfaction with Postsurgical Pain Control 
Study Part 1 
(Efficacy Analysis Set) 
14.2.2.14-1 
Time to Sensitivity to Cold 
Study Part 1 
(Efficacy Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 33 of 152 
09 December 2013 
 
 
 
Study Part 1 Planned Tables Continued 
 
Table 
Number 
Table Title 
14.2.2.15-1 
Incidence of Predefined Treatment-Emergent Opioid-Related Adverse 
Events 
Study Part 1 
(Efficacy Analysis Set) 
14.2.3.1-1 
Bupivacaine Plasma Concentrations (ng/mL) 
Study Part 1 
(PK Analysis Set) 
14.2.3.2-1 
Bupivacaine Plasma Pharmacokinetic Parameters 
Study Part 1 
(PK Analysis Set) 
14.2.3.3-1 
Percentage of Unbound Bupivacaine Plasma Concentrations (ng/mL) 
Study Part 1 
(PK Analysis Set) 
14.3.1.1-1 
Overview of Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
14.3.1.2-1 
Incidence of Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
14.3.1.3-1 
Incidence of Study Drug Related Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
14.3.1.4-1 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 1 of 
2) 
Study Part 1 
(Safety Analysis Set) 
14.3.1.4-1 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 2 of 
2) 
Study Part 1 
(Safety Analysis Set) 
14.3.1.5-1 
Incidence of Serious Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
14.3.2.1-1 
Vital Signs 
Study Part 1 
(Safety Analysis Set) 
14.3.2.2-1 
Vital Signs Change from Baseline 
Study Part 1 
(Safety Analysis Set) 
14.3.3-1 
Neurological Assessment 
Study Part 1 
(Safety Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 34 of 152 
09 December 2013 
 
 
 
Study Part 1 Planned Tables Continued 
 
Table 
Number 
Table Title 
14.3.4-1 
20-Meter Walk Test 
Study Part 1 
(Safety Analysis Set) 
14.3.5-1 
Physician Satisfaction with Return of Sensory/Motor Function 
Study Part 1 
(Safety Analysis Set) 
14.3.6-1 
Incidence of Transfusions 
Study Part 1 
(Safety Analysis Set) 
 
 
 
 
Study Part 1 Planned Figure 
 
Figure 
Number 
Table Title 
1-1 
Sensitivity to Cold 
Study Part 1 
(Efficacy Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 35 of 152 
09 December 2013 
 
 
 
Study Part 2 Planned Tables 
 
Table 
Number 
Table Title 
14.1.1.1-2 
Subject Disposition 
Study Part 2 
(All Randomized Subjects) 
14.1.1.2-2 
Subject Disposition by Site 
Study Part 2 
(All Randomized Subjects) 
14.1.2.1-2 
Demographic and Baseline Characteristics 
Study Part 2 
(Safety Analysis Set) 
14.1.2.2-2 
Demographic and Baseline Characteristics 
Study Part 2 
(Efficacy Analysis Set) 
14.1.3.1-2 
Prior Medications 
Study Part 2 
(Safety Analysis Set) 
14.1.3.2-2 
Concomitant Medications 
Study Part 2 
(Safety Analysis Set) 
14.2.1.1-2 
Study Drug Administration 
Study Part 2 
(Safety Analysis Set) 
14.2.1.2-2 
Surgery 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.1.1-2 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.1.2-2 
AUC of NRS-R Pain Intensity Scores Through 72 Hours by Site 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 36 of 152 
09 December 2013 
 
 
 
Study Part 2 Planned Tables Continued 
 
Table 
Number 
Table Title 
14.2.2.1.3-2 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores Excluding Subjects with 
PCA Interval Data 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.2-2 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication 
Through 72 Hours 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.3.2-2 
Time to First Opioid Rescue 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.4-2 
NRS-R Pain Intensity Scores 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.5-2 
NRS-A Pain Intensity Scores 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.6-2 
AUC of NRS-R Pain Intensity Scores Through 24, 36, 48, and 60 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.7-2 
AUC of NRS-A Pain Intensity Scores Through 24, 36, 48, 60, and 
72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.8-2 
AUC of NRS-R Pain Intensity Scores 24-48 and 48-72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.9-2 
Percentage of Subjects who are Pain Free at Each Time Point 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.10-2 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication 
Through 24, 36, 48, and 60 Hours 
Study Part 2 
(Efficacy Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 37 of 152 
09 December 2013 
 
 
 
Study Part 2 Planned Tables Continued 
 
Table 
Number 
Table Title 
14.2.2.11-2 
Subjects who Received Rescue Medication Through 72 Hours 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.12-2 
Overall Benefit of Analgesia Score Questionnaire (Total Scores) 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.13-2 
Subject Satisfaction with Postsurgical Pain Control 
Study Part 2 
(Efficacy Analysis Set) 
14.2.2.14-2 
Time to Sensitivity to Cold 
Study Part 2 
(Efficacy Analysis Set) 
14.3.1.1-2 
Overview of Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
14.3.1.2-2 
Incidence of Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
14.3.1.3-2 
Incidence of Study Drug Related Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
14.3.1.4-2 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 1 of 
2) 
Study Part 2 
(Safety Analysis Set) 
14.3.1.4-2 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 2 of 
2) 
Study Part 2 
(Safety Analysis Set) 
14.3.1.5-2 
Incidence of Serious Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
14.3.2.1-2 
Vital Signs 
Study Part 2 
(Safety Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 38 of 152 
09 December 2013 
 
 
 
Study Part 2 Planned Tables Continued 
 
Table 
Number 
Table Title 
14.3.2.2-2 
Vital Signs Change from Baseline 
Study Part 2 
(Safety Analysis Set) 
14.3.3-2 
Neurological Assessment 
Study Part 2 
(Safety Analysis Set) 
14.3.4-2 
20-Meter Walk Test 
Study Part 2 
(Safety Analysis Set) 
14.3.5-2 
Physician Satisfaction with Return of Sensory/Motor Function 
Study Part 2 
(Safety Analysis Set) 
14.3.6-2 
Incidence of Transfusions 
Study Part 2 
(Safety Analysis Set) 
 
 
 
 
Study Part 2 Planned Figure 
 
Figure 
Number 
Table Title 
1-2 
Sensitivity to Cold 
Study Part 2 
(Efficacy Analysis Set) 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 39 of 152 
09 December 2013 
 
 
 
Planned Listings 
 
Listing 
Number 
Listing Title 
16.1.1 
Eligibility 
16.1.2 
Unblinding 
16.1.3 
Subject Populations and Discontinuations 
16.1.4 
Hospital Discharge 
16.2 
Demographics 
16.3.1 
Medical History 
16.3.2 
Physical Examination 
16.3.3 
Electrocardiogram Recording (Holter Monitoring) 
16.3.4 
Prior and Concomitant Medications (Except for  Rescue Pain 
Medications) 
16.3.5 
Transfusions Post Study Drug Administration 
16.4.1 
Study Drug Exposure 
16.4.2 
Surgery 
16.5.1.1 
Pain Intensity Scores at Rest and with Activity 
16.5.1.2 
AUC of NRS-R and NRS-A Pain Intensity Scores 
wWOCF + LOCF Imputation for the Pain Scores 
16.5.2.1 
Postoperative Consumption of Opioid Rescue Pain Medication 
16.5.2.2 
Postoperative Consumption of Rescue Pain Medication via PCA Pump 
(Interval Data) 
16.5.2.3 
Postoperative Consumption of Conventional Bupivacaine HCl Rescue 
Pain Medication 
16.5.3 
Overall Benefit of Analgesia Score Questionnaire 
16.5.4 
Subject Satisfaction with Postsurgical Pain Control 
16.5.5 
Sensitivity to Cold 
16.5.6 
Predefined Treatment-Emergent Opioid-Related Adverse Events at 
72 Hours (Study Part 1) 
16.6.1 
Scheduled Bupivacaine Plasma Concentrations (Study Part 1) 
16.6.2 
Bupivacaine Plasma Pharmacokinetic Parameters (Study Part 1) 
16.6.3 
Unscheduled Bupivacaine Plasma Concentrations 
16.7.1.1 
Adverse Events (Part 1 of 2) 
16.7.1.2 
Adverse Events (Part 2 of 2) 
16.7.1.3 
Serious Adverse Events (Part 1 of 2) 
16.7.1.4 
Serious Adverse Events (Part 2 of 2) 
16.7.1.5 
Deaths 
16.8 
Height, Weight, and Vital Signs 
16.9 
Neurological Assessment 
16.10 
20-Meter Walk Test 
16.11 
Physician Satisfaction with Return of Sensory/Motor Function 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 40 of 152 
09 December 2013 
 
 
 
STUDY PART 1 TABLES 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 41 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.1-1 (Page x of Y) 
Subject Disposition 
Study Part 1 
(All Randomized Subjects) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
  
n (%) 
n (%) 
n (%) 
n (%) 
n (%)  
 
 
 
Safety Analysis Set [1] 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Efficacy Analysis Set [2] 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
PK Analysis Set [3] 
00 (00.0) 
00 (00.0) 
00 (00.0) 
NA 
00 (00.0) 
Subjects Who Completed the Study 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Subjects Who Terminated Early 
Reason for Early Termination 
Subject Death 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Adverse Event 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Lack of Efficacy 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Lost to Follow-up 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Withdrawal by Subject 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
[1] The safety analysis set includes all subjects who received study drug. 
[2] The efficacy analysis set includes all subjects in the safety analysis set who underwent the planned surgery. 
[3] The PK analysis set includes all subjects in the safety analysis set who received liposome bupivacaine, provided sufficient samples to allow for 
calculation of PK parameters required for analysis, and who did not receive conventional bupivacaine HCl postsurgically. 
 
Reference: Listing 16.1.3. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 42 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.1-1 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 1 
(Safety Analysis Set) 
 
LB 
LB 
LB 
All 
67 mg 
133 mg 
266 mg 
Placebo 
Subjects 
  (N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
Age (years) 
 
n 
00 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
00, 00 
Age Category 
<65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
>=65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Gender 
Male 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Female 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Ethnic Group 
Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Not Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Race [1] 
American Indian/Alaskan Native 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Asian 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Black or African American 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Native Hawaiian/Other Pacific Islander 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
White 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 43 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.1-1 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 1 
(Safety Analysis Set) 
 
LB 
LB 
LB 
All 
67 mg 
133 mg 
266 mg 
Placebo 
Subjects 
  
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
ASA Class 
 
1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Height (cm) 
 
n 
00 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
00, 00 
Weight (kg) 
 
n 
00 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
00, 00 
ASA = American Society of Anesthesiologists; LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 44 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.2-1 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
LB 
LB 
All 
67 mg 
133 mg 
266 mg 
Placebo 
Subjects 
  (N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
Age (years) 
 
n 
00 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
00, 00 
Age Category 
<65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
>=65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Gender 
Male 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Female 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Ethnic Group 
Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Not Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Race [1] 
American Indian/Alaskan Native 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Asian 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Black or African American 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Native Hawaiian/Other Pacific Islander 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
White 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 45 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.2-1 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
LB 
LB 
All 
67 mg 
133 mg 
266 mg 
Placebo 
Subjects 
  
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
ASA Class 
 
1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Height (cm) 
 
n 
00 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
00, 00 
Weight (kg) 
 
n 
00 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
00, 00 
ASA = American Society of Anesthesiologists; LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 46 of 152 
09 December 2013 
 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.3.1-1 (Page x of Y) 
Prior Medications 
Study Part 1 
(Safety Analysis Set) 
 
ATC Class 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
All 
Subjects 
(N=XX) 
WHO-DD Preferred Term 
n   (%) 
n   (%) 
n   (%) 
n   (%) 
n  (%) 
Any Prior Medication 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
…. 
ATC Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
ATC = Anatomical Therapeutic Chemical classification system; LB = liposome bupivacaine; WHO-DD = World Health Organization Drug 
Dictionary. 
Note: Prior medications are defined as medication with a stop date/time prior to study drug administration. 
At each level of summation (overall, ATC class, and preferred term), subjects are only counted once. 
 
Reference: Listing 16.3.4. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 47 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.3.2-1 (Page x of Y) 
Concomitant Medications 
Study Part 1 
(Safety Analysis Set) 
 
ATC Class 
WHO-DD Preferred Term 
LB 
67 mg 
(N=XX) 
n  (%) 
LB 
133 mg 
(N=XX) 
n  (%) 
LB 
266 mg 
(N=XX) 
n  (%) 
Placebo 
(N=XX) 
n  (%) 
All 
Subjects 
(N=XX) 
n  (%) 
Any Prior Medication 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
ATC = Anatomical Therapeutic Chemical classification system; LB = liposome bupivacaine; WHO-DD = World Health Organization Drug 
Dictionary. 
Note: Concomitant medications are defined as medications (other than rescue pain medication) taken on or after the start of study drug 
administration. This table does not include rescue pain medications. 
At each level of summation (overall, ATC class, and preferred term), subjects are only counted once. 
Reference: Listing 16.3.4.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 48 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.1.1-1 (Page x of Y) 
Study Drug Administration 
Study Part 1 
(Safety Analysis Set) 
 
LB 
LB 
LB 
67 mg 
133 mg 
266 mg 
Placebo 
  
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
Duration of Injection (min) 
 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
Volume of Study Drug Administered (mL) 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
LB = liposome bupivacaine. 
 
Reference: Listing 16.4.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 49 of 152 
09 December 2013 
 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.1.2-1 (Page x of Y) 
Surgery 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
LB 
LB 
67 mg 
133 mg 
266 mg 
Placebo 
  
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
Duration of Surgery (min) 
 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
Type of Anesthesia 
 
General 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Spinal 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Incision Length (cm) 
n 
00 
00 
00 
00 
Mean 
00.00 
00.00 
00.00 
00.00 
SD 
00.000 
00.000 
00.000 
00.000 
Median 
00.00 
00.00 
00.00 
00.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
LB = liposome bupivacaine. 
 
Reference: Listing 16.4.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 50 of 152 
09 December 2013 
 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.1-1 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
Statistics 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
n 
00 
00 
00 
00 
Mean 
000.0 
000.0 
000.0 
000.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
0000 
0000 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
000, 000 
000, 000 
 
LSM (Standard Error) [1] 
00.0 (00.00) 
00.0 (00.00) 
00.0 (00.00) 
00.0 (00.00) 
LSM Difference (Standard Error) [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0 (00.00) 
95% CI for Difference [2] 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
P-value [2] 
0.0000 
0.0000 
0.0000 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; 
LSM = least squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. 
[2] Difference from placebo. 
 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 51 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.2-1 (Page x of Y) 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication Through 72 Hours 
Study Part 1 
(Efficacy Analysis Set) 
 
 
Statistics 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
  
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX)  
 
 
n 
00 
00 
00 
00 
Mean 
00.00 
00.00 
00.00 
00.00 
SD 
00.000 
00.000 
00.000 
00.000 
Median 
00.00 
00.00 
00.00 
00.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
 
Geometric LSM [1] 
00.00 
00.00 
00.00 
00.00 
Geometric LSM Ratio [2] 
00.00 
00.00 
00.00 
95% CI for Ratio [2] 
00.00, 00.00 
00.00, 00.00 
00.00, 00.00 
P-value [2] 
0.0000 
0.0000 
0.0000 
 
CI = confidence interval; LB = liposome bupivacaine; LSM = least squares mean, 
If the total amount of opioid used was 0 mg, the value was set to the lesser of 1 mg or one half of the smallest total amount observed 
in the study prior to being transformed into the natural logarithm. 
[1] From an analysis of variance with treatment as the main effect on natural log transformed opioid amount. 
Results are presented in the original, non-transformed scale. 
[2] Geometric LSM ratio is the anti-log LSM difference (LB/placebo). 
Reference: Listing 16.5.2.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 52 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.3-1 (Page x of Y) 
Time to First Opioid Rescue 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
 
 
Subjects Administered an Opioid Rescue [n (%)] 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Censored Observations [n (%)] 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
 
Quartiles (hours) [1] 
First Quartile (25% Administered an Opioid) 
000 
000 
000 
000 
Median (50% Administered an Opioid) 
000 
000 
000 
000 
Third Quartile (75% Administered an Opioid) 
000 
000 
000 
000 
Minimum,  Maximum 
00, 00* 
00, 00* 
00, 00* 
00, 00* 
95% CI of Median 
(000, 000) 
(000, 000) 
(000, 000) 
(000, 000) 
 
P-value from Log-Rank Test 
0.0000 
0.0000 
0.0000 
0.0000 
 
 
* indicates a censored observation. 
CI = confidence interval; LB = liposome bupivacaine, 
[1] Estimates from a Kaplan-Meier Analysis. 
 
Reference: Listing 16.5.2.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 53 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.4-1 (Page x of Y) 
NRS-R Pain Intensity Scores 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
Baseline 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
First Request 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
2 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
   Etc.  
 
 
CI = confidence interval; LB = liposome bupivacaine; NRS-R = numeric rating scale at rest. 
Pain scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
 
Reference: Listing 16.5.1.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 54 of 152 
09 December 2013 
 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.5-1 (Page x of Y) 
NRS-A Pain Intensity Scores 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
Baseline 
N 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
First Request 
N 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
2 Hours 
N 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
   Etc.  
 
 
CI = confidence interval; LB = liposome bupivacaine; NRS-A = numeric rating scale with activity. 
Pain scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
 
Reference: Listing 16.5.1.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 55 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.6-1 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores Through 24, 36, 48, and 60 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
24 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
36 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
48 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
Etc. 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; NRS-R = numeric rating scale at 
rest. 
Pain scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 56 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.7-1 (Page x of Y) 
AUC of NRS-A Pain Intensity Scores Through 24, 36, 48, 60, and 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
24 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
36 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
48 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
   Etc.  
 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; NRS-A = numeric rating scale 
with activity. 
Pain scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
Reference: Listings16.5.1.1 and 16.5.1.2 . 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 57 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.8-1 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores 24-48 and 48-72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
24-48 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
48-72 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; NRS-R = numeric rating scale at 
rest. 
Pain scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
 
Reference: Listings16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 58 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.9-1 (Page x of Y) 
Percentage of Subjects who are Pain Free at Each Time Point 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
LB 
67 mg 
(N=XX) 
n/ N (%) 
LB 
133 mg 
(N=XX) 
n/ N (%) 
LB 
266 mg 
(N=XX) 
n/ N (%) 
Placebo 
(N=XX) 
n/ N (%) 
2 Hours 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
4 Hours 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
8 Hours 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
12 Hours 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
24 Hours 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
36 Hours 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
   Etc  
 
 
 
LB = liposome bupivacaine. n/N = Number of subjects with a pain score of 0 or 1 / Number of subjects with a pain score 
at the time point. 
Pain Free is defined as an NRS-R pain intensity score of 0 or 1. 
Reference: Listing 16.5.1.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 59 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.10-1 (Page x of Y) 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication Through 24, 36, 48, and 60 Hours 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
24 Hours 
n 
00 
00 
00 
00 
Mean 
00.00 
00.00 
00.00 
00.00 
SD 
00.000 
00.000 
00.000 
00.000 
Median 
00.00 
00.00 
00.00 
00.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
36 Hours 
n 
00 
00 
00 
00 
Mean 
00.00 
00.00 
00.00 
00.00 
SD 
00.000 
00.000 
00.000 
00.000 
Median 
00.00 
00.00 
00.00 
00.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
   Etc.  
 
 
LB = liposome bupivacaine. 
Reference: Listing 16.5.2.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 60 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.11-1 (Page x of Y) 
Subjects Who Received Rescue Medication Through 72 Hours 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
  
n (%) 
n (%) 
n (%) 
n (%)  
 
 
 
Received No Rescue Medication 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Received Only the First Rescue 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Received the First Rescue and a Second Opioid 
Rescue 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Received all Three Rescues 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
LB = liposome bupivacaine. 
Reference: Listings 16.5.2.1 and 16.5.2.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 61 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.12-1 (Page x of Y) 
Overall Benefit of Analgesia Score Questionnaire (Total Scores) 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
24 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
48 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
95% CI about the Mean 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
   Etc.  
 
 
CI = confidence interval; LB = liposome bupivacaine. 
Note: The lower the score, the better the overall analgesic treatment. 
Reference: Listing 16.5.3. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 62 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.13-1 (Page x of Y) 
Subject Satisfaction with Postsurgical Pain Control 
Study Part 1 
(Efficacy Analysis Set) 
 
Time Point 
Assessment 
LB 
67 mg 
(N=XX) 
n/N (%) 
LB 
133 mg 
(N=XX) 
n/N (%) 
LB 
266 mg 
(N=XX) 
n/N (%) 
Placebo 
(N=XX) 
n/N (%) 
72 Hours 
Extremely Dissatisfied (1) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Dissatisfied (2) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Satisfied (4) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Extremely Satisfied (5) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Day 30 
Extremely Dissatisfied (1) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Dissatisfied (2) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Satisfied (4) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Extremely Satisfied (5) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
 
LB = liposome bupivacaine. n/N = Number of subjects with a subject satisfaction score of 1, 2, 3, 4, or 5 / Number of subjects with a subject 
satisfaction score at the time point. 
Note: Percentages are based on number of subjects with a score at the time point. 
Reference: Listing 16.5.4. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 63 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.14-1 (Page x of Y) 
Time to Sensitivity to Cold 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
 
 
Subjects with Sensitivity to Cold [n (%)] 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Censored Observations [n (%)] 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
 
Quartiles (hours) [1] 
First Quartile (25% with Sensitivity to Cold) 
000 
000 
000 
000 
Median (50% with Sensitivity to Cold) 
000 
000 
000 
000 
Third Quartile (75% with Sensitivity to Cold) 
000 
000 
000 
000 
Minimum,  Maximum 
00, 00* 
00, 00* 
00, 00* 
00, 00* 
95% CI of Median 
(000, 000) 
(000, 000) 
(000, 000) 
(000, 000) 
 
 
* indicates a censored observation. 
CI = confidence interval; LB = liposome bupivacaine, 
[1] Estimates from a Kaplan-Meier Analysis. 
 
Reference: Listing 16.5.5. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 64 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.15-1 (Page x of Y) 
Incidence of Predefined Treatment-Emergent Opioid-Related Adverse Events 
Study Part 1 
(Efficacy Analysis Set) 
 
LB 
67 mg 
(N=XX) 
n   (%) 
LB 
133 mg 
(N=XX) 
n   (%) 
LB 
266 mg 
(N=XX) 
n   (%) 
Placebo 
(N=XX) 
n   (%) 
Subjects with at Least One Event 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Diffuse Pruritus 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Overt Respiratory Depression 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Urinary Retention [1] 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Constipation 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Sedation 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Confusion 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Delirium 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Vomiting 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Need for Antiemetic Medication 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
LB = liposome bupivacaine. 
[1] Urinary retention was measured by need for postsurgical bladder catheterization. 
Reference: Listing 16.5.6. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 65 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.3.1-1 (Page x of Y) 
Bupivacaine Plasma Concentrations (ng/mL) 
Study Part 1 
(PK Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Baseline 
n 
00 
00 
00 
Mean 
000.00 
000.00 
000.00 
SD 
0.000 
0.000 
0.000 
%CV 
000.00 
000.00 
000.00 
Median 
0.00 
0.00 
0.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
15 Minutes 
n 
00 
00 
00 
Mean 
000.00 
000.00 
000.00 
SD 
0.000 
0.000 
0.000 
%CV 
000.00 
000.00 
000.00 
Median 
0.00 
0.00 
0.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
30 Minutes 
n 
00 
00 
00 
Mean 
000.00 
000.00 
000.00 
SD 
0.000 
0.000 
0.000 
%CV 
000.00 
000.00 
000.00 
Median 
0.00 
0.00 
0.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
   Etc.  
 
 
LB = liposome bupivacaine. 
Reference: Listing 16.6.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 66 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.3.2-1 (Page x of Y) 
Bupivacaine Plasma Pharmacokinetic Parameters 
Study Part 1 
(PK Analysis Set) 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Parameter 
Statistics 
(N=XX) 
(N=XX) 
(N=XX) 
Cmax (ng/mL) 
n 
00 
00 
00 
Mean 
000.00 0 
000.00 0 
000.00 0 
SD 
0.0000 
0.0000 
0.0000 
%CV 
000.00 
000.00 
000.00 
Geometric Mean 
00.0 
00.0 
00.0 
Median 
0.000 
0.000 
0.000 
Minimum, Maximum 
00.00, 00.00 
00.00, 00.00 
00.00, 00.00 
Tmax (hours) 
n 
00 
00 
00 
Mean 
000.00 0 
000.00 0 
000.00 0 
SD 
0.0000 
0.0000 
0.0000 
%CV 
000.00 
000.00 
000.00 
Geometric Mean 
00.0 
00.0 
00.0 
Median 
0.000 
0.000 
0.000 
Minimum, Maximum 
00.00, 00.00 
00.00, 00.00 
00.00, 00.00 
AUC0-last (h*ng/mL) 
n 
00 
00 
00 
Mean 
000.00 0 
000.00 0 
000.00 0 
SD 
0.0000 
0.0000 
0.0000 
%CV 
000.00 
000.00 
000.00 
Geometric Mean 
00.0 
00.0 
00.0 
Median 
0.000 
0.000 
0.000 
Minimum, Maximum 
00.00, 00.00 
00.00, 00.00 
00.00, 00.00 
   Etc.  
 
 
LB = liposome bupivacaine. 
Reference: Listing 16.6.2. 
 
Programmer Note: The other parameters should be AUC0-inf (h*ng/mL), and half-life (t1/2) (hours). 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 67 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.3.3-1 (Page x of Y) 
Percentage of Unbound Bupivacaine Plasma Concentrations (ng/mL) 
Study Part 1 
(PK Analysis Set) 
 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
15 Minutes 
n 
00 
00 
00 
Mean 
000.00 
000.00 
000.00 
SD 
0.000 
0.000 
0.000 
Median 
0.00 
0.00 
0.00 
Minimum, Maximum 
00.0, 00.0 
00.0, 00.0 
00.0, 00.0 
 
LB = liposome bupivacaine. 
Reference: Listing 16.6.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 68 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.3.1.1-1 (Page x of Y) 
Overview of Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
  
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%)  
 
 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Maximum Severity: Mild 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Maximum Severity: Moderate 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Maximum Severity: Severe 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
At Least One TEAE Related to Study Drug 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
At Least One Serious TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Subjects Discontinued Because of a TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Deaths on Study 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
Reference: Listings 16.7.1.1 and 16.7.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 69 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.1.2-1 (Page x of Y) 
Incidence of Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
 
System Organ Class 
Preferred Term 
LB 
67 mg 
(N=XX) 
n  (%) 
LB 
133 mg 
(N=XX) 
n  (%) 
LB 
266 mg 
(N=XX) 
n  (%) 
Placebo 
(N=XX) 
n  (%) 
All 
Subjects 
(N=XX) 
n  (%) 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once. 
Reference: Listings 16.7.1.1 and 16.7.1.2.. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 70 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.1.3-1 (Page x of Y) 
Incidence of Study Drug Related Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
 
System Organ Class 
Preferred Term 
LB 
67 mg 
(N=XX) 
n  (%) 
LB 
133 mg 
(N=XX) 
n  (%) 
LB 
266 mg 
(N=XX) 
n  (%) 
Placebo 
(N=XX) 
n  (%) 
All 
Subjects 
(N=XX) 
n  (%) 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
…. 
System Organ Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once. 
Reference: Listings 16.7.1.1 and 16.7.1.2.. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 71 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.3.1.4-1 (Page x of Y) 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 1 of 2) 
Study Part 1 
(Safety Analysis Set) 
 
LB 
67 mg 
(N = XX) 
LB 
133 mg 
(N = XX) 
System Organ Class 
Mild 
Moderate 
Severe 
Mild 
Moderate 
Severe 
Preferred Term 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
Subjects with at Least 
One TEAE 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
System Organ Class 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 2 
… 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
System Organ Class 2 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 3 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 4 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
   …  
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once using the highest severity. 
Reference: Listings 16.7.1.1 and 16.7.1.2.. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 72 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.3.1.4-1 (Page x of Y) 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 2 of 2) 
Study Part 1 
(Safety Analysis Set) 
 
LB 
266 mg 
(N = XX) 
Placebo 
(N = XX) 
All 
Subjects 
(N = XX 
System Organ Class 
Mild 
Moderate 
Severe 
Mild 
Moderate 
Severe 
Mild 
Moderate 
Severe 
Preferred Term 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
Subjects with at Least 
One TEAE 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
System Organ Class 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 2 
… 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
System Organ Class 2 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 3 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 4 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
   …  
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once using the highest severity. 
Reference: Listings 16.7.1.1 and 16.7.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 73 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.1.5-1 (Page x of Y) 
Incidence of Serious Treatment-Emergent Adverse Events 
Study Part 1 
(Safety Analysis Set) 
 
System Organ Class 
Preferred Term 
LB 
67 mg 
(N=XX) 
n  (%) 
LB 
133 mg 
(N=XX) 
n  (%) 
LB 
266 mg 
(N=XX) 
n  (%) 
Placebo 
(N=XX) 
n  (%) 
All 
Subjects 
(N=XX) 
n  (%) 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
…. 
System Organ Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once. 
Reference: Listings 16.7.1.3 and 16.7.1.4. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 74 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.2.1-1 (Page x of Y) 
Vital Signs 
Study Part 1 
(Safety Analysis Set) 
 
Parameter 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
Heart Rate 
Screening 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
Baseline 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
30 Minutes 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Etc. 
Etc. 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
 
LB = liposome bupivacaine. 
Reference: Listing 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 75 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.2.2-1 (Page x of Y) 
Vital Signs Change from Baseline 
Study Part 1 
(Safety Analysis Set) 
 
Parameter 
Time Point 
Statistics 
LB 
67 mg 
(N=XX) 
LB 
133 mg 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
Heart Rate 
30 Minutes 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
1 Hour 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
2 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
   Etc.  
 
 
LB = liposome bupivacaine. 
Reference: Listing 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 76 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.3-1 (Page x of Y) 
Neurological Assessment 
Study Part 1 
(Safety Analysis Set) 
 
Time Point 
Assessment 
LB 
67 mg 
(N=XX) 
n/ N (%) 
LB 
133 mg 
(N=XX) 
n/ N (%) 
LB 
266 mg 
(N=XX) 
n/ N (%) 
Placebo 
(N=XX) 
n/ N (%) 
All 
Subjects 
(N=XX) 
n/ N (%) 
Baseline 
Oriented [1] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
At Least one of the Events 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Numbness [2] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Metallic Taste in Mouth 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Hearing 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Vision 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Muscles Twitching 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
 
15 Minutes 
Oriented [1] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
At Least one of the Events 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Numbness [2] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Metallic Taste in Mouth 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Hearing 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Vision 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Muscles Twitching 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
   Etc.  
 
 
LB = liposome bupivacaine. n/N = Number of subjects with an event / Number of subjects with a neurological assessment at the time point. 
[1] The denominator does not include subjects who were not assessable at the time point. 
[2] Numbness of the lips, the tongue, or around the mouth. 
 
Reference: Listing 16.9. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 77 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.4-1 (Page x of Y) 
20-Meter Walk Test 
Study Part 1 
(Safety Analysis Set) 
 
Time Point 
Completed Status 
LB 
67 mg 
(N=XX) 
n (%) 
LB 
133 mg 
(N=XX) 
n (%) 
LB 
266 mg 
(N=XX) 
n/ (%) 
Placebo 
(N=XX) 
n (%) 
All 
Subjects 
(N=XX) 
n (%) 
24 Hours 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
72 Hours 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Day 30 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
Reference: Listing 16.10. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 78 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.5-1 (Page x of Y) 
Physician Satisfaction with Return of Sensory/Motor Function 
Study Part 1 
(Safety Analysis Set) 
 
Time Point 
Assessment 
LB 
67 mg 
(N=XX) 
n (%) 
LB 
133 mg 
(N=XX) 
n (%) 
LB 
266 mg 
(N=XX) 
n (%) 
Placebo 
(N=XX) 
n (%) 
72 Hours 
Extremely Dissatisfied (1) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Dissatisfied (2) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Satisfied (4) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Extremely Satisfied (5) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Day 30 
Extremely Dissatisfied (1) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Dissatisfied (2) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Satisfied (4) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Extremely Satisfied (5) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
Note: Percentages are based on number of subjects with a score at the time point. 
Reference: Listing 16.11. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 79 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.6-1 (Page x of Y) 
Incidence of Transfusions 
Study Part 1 
(Safety Analysis Set) 
 
LB 
67 mg 
LB 
133 mg 
LB 
266 mg 
Placebo 
All 
Subjects 
 
Transfusion 
(N=XX) 
n (%) 
(N=XX) 
n (%) 
(N=XX) 
n/ (%) 
(N=XX) 
n (%) 
(N=XX) 
n (%) 
 
 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
LB = liposome bupivacaine. 
Reference: Listing 16.3.5. 


 
Pacira Pharmaceuticals, Inc. 
Liposome Bupivacaine 
402-C-323 TKA 
Statistical Analysis Plan Amendment 3 
 
 
STUDY PART 2 TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 80 of 152 
09 December 2013 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 81 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.1.1-2 (Page x of Y) 
Subject Disposition 
Study Part 2 
(All Randomized Subjects) 
 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
  
n (%) 
n (%) 
n (%)  
 
 
 
Safety Analysis Set [1] 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Efficacy Analysis Set [2] 
PK Analysis Set [3] 
00 (00.0) 
00 (00.0) 
NA 
00 (00.0) 
Subjects Who Completed the Study 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Subjects Who Terminated Early 
Reason for Early Termination 
Subject Death 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Adverse Event 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Lack of Efficacy 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Lost to Follow-up 
Withdrawal by Subject 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
[1] The safety analysis set includes all subjects who received study drug. 
[2] The efficacy analysis set includes all subjects in the safety analysis set who underwent the planned surgery. 
[3] The PK analysis set includes all subjects in the safety analysis set who received liposome bupivacaine, provided sufficient samples to allow for 
calculation of PK parameters required for analysis, and who did not receive conventional bupivacaine HCl postsurgically. 
 
Reference: Listing 16.1.3. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 82 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.1.2-2 (Page x of Y) 
Subject Disposition by Site 
Study Part 2 
(All Randomized Subjects) 
 
LB 
XXX mg 
Placebo 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
Site 
  
n (%)  
n (%)  
n (%)  
 
 
 
101 
Safety Analysis Set [1] 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Efficacy Analysis Set [2] 
PK Analysis Set [3] 
00 (00.0) 
00 (00.0) 
NA 
00 (00.0) 
Subjects Who Completed the Study 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Subjects Who Terminated Early 
Reason for Early Termination 
Subject Death 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Adverse Event 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Lack of Efficacy 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Lost to Follow-up 
Withdrawal by Subject 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
  Etc  
 
 
LB = liposome bupivacaine. 
[1] The safety analysis set includes all subjects who received study drug. 
[2] The efficacy analysis set includes all subjects in the safety analysis set who underwent the planned surgery. 
[3] The PK analysis set includes all subjects in the safety analysis set who received liposome bupivacaine, provided sufficient samples to allow for 
calculation of PK parameters required for analysis, and who did not receive conventional bupivacaine HCl postsurgically. 
 
Reference: Listing 16.1.3. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 83 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.1-2 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 2 
(Safety Analysis Set) 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
All 
Subjects 
  
(N=XX) 
(N=XX) 
(N=XX)  
 
 
Age (years) 
 
n 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
Age Category 
<65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
>=65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Gender 
Male 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Female 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Ethnic Group 
Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Not Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Race [1] 
American Indian/Alaskan Native 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Asian 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Black or African American 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Native Hawaiian/Other Pacific Islander 
00 (00.0) 
00 (00.0) 
00 (00.0) 
White 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 84 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.1-2 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 2 
(Safety Analysis Set) 
 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
 
All 
Subjects 
  
(N=XX) 
(N=XX) 
(N=XX)  
 
 
ASA Class 
 
1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Height (cm) 
 
n 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
Weight (kg) 
 
n 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
ASA = American Society of Anesthesiologists; LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 85 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.2-2 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 2 
(Efficacy Analysis Set) 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
All 
Subjects 
  
(N=XX) 
(N=XX) 
(N=XX)  
 
 
Age (years) 
 
n 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
Age Category 
<65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
>=65 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Gender 
Male 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Female 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Ethnic Group 
Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Not Hispanic or Latino 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Race [1] 
American Indian/Alaskan Native 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Asian 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Black or African American 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Native Hawaiian/Other Pacific Islander 
00 (00.0) 
00 (00.0) 
00 (00.0) 
White 
Other 
00 (00.0) 
00 (00.0) 
00 (00.0) 
LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 86 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.2.2-2 (Page x of Y) 
Demographic and Baseline Characteristics 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
 
All 
Subjects 
  
(N=XX) 
(N=XX) 
(N=XX)  
 
 
ASA Class 
 
1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Height (cm) 
 
n 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
Weight (kg) 
 
n 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
Median 
00 
00 
00 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
ASA = American Society of Anesthesiologists; LB = liposome bupivacaine. 
[1] Subjects may be counted in more than one category. 
Reference: Listings 16.2 and 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 87 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.3.1-2 (Page x of Y) 
Prior Medications 
Study Part 2 
(Safety Analysis Set) 
 
 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
 
 
All 
Subjects 
ATC Class 
(N=XX) 
(N=XX) 
(N=XX) 
  
WHO-DD Preferred Term 
n  (%) 
n  (%) 
n  (%)  
 
 
Any Prior Medication 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
ATC = Anatomical Therapeutic Chemical classification system; LB = liposome bupivacaine; WHO-DD = World Health Organization Drug 
Dictionary 
Note: Prior medications are defined as medication with a stop date/time prior to study drug administration. 
At each level of summation (overall, ATC class, and preferred term), subjects are only counted once. 
 
Reference: Listing 16.3.4. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 88 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.1.3.2-2 (Page x of Y) 
Concomitant Medications 
Study Part 2 
(Safety Analysis Set) 
 
 
LB 
XXX mg 
Placebo 
 
 
 
 
 
 
 
 
All 
Subjects 
ATC Class[1] 
(N=XX) 
(N=XX) 
(N=XX) 
  
WHO-DD Preferred Term 
n  (%) 
n  (%) 
n  (%)  
 
 
Any Prior Medication 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
ATC Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
ATC = Anatomical Therapeutic Chemical classification system; LB = liposome bupivacaine; WHO-DD = World Health Organization Drug 
Dictionary. 
Note: Concomitant medications are defined as medications (other than rescue pain medication) taken on or after the start of study drug 
administration. This table does not include rescue pain medications. 
At each level of summation (overall, ATC class, and preferred term), subjects are only counted once. 
Reference: Listing 16.3.4.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 89 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.1.1-2 (Page x of Y) 
Study Drug Administration 
Study Part 2 
(Safety Analysis Set) 
 
LB 
XXX mg 
Placebo 
  
(N=XX) 
(N=XX)  
 
 
Duration of Injection (min) 
n 
Mean 
SD 
Median 
Minimum, Maximum 
 
00 
00.0 
00.00 
00 
00, 00 
 
00 
00.0 
00.00 
00 
00, 00 
 
Volume of Study Drug Administered (mL) 
n 
Mean 
SD 
Median 
Minimum, Maximum 
 
00 
00.0 
00.00 
00 
00, 00 
 
00 
00.0 
00.00 
00 
00, 00 
 
 
LB = liposome bupivacaine. 
 
Reference: Listing 16.4.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 90 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.1.2-2 (Page x of Y) 
Surgery 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
  
(N=XX) 
(N=XX)  
 
 
Duration of Surgery (min) 
n 
Mean 
SD 
Median 
Minimum, Maximum 
 
00 
00.0 
00.00 
00 
00, 00 
 
00 
00.0 
00.00 
00 
00, 00 
 
Type of Anesthesia 
General 
Spinal 
Other 
 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
Incision Length (cm) 
n 
Mean 
SD 
Median 
Minimum, Maximum 
 
00 
00.00 
00.000 
00.00 
00.0, 00.0 
 
00 
00.00 
00.000 
00.00 
00.0, 00.0 
 
 
LB = liposome bupivacaine. 
 
Reference: Listing 16.4.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 91 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.1.1-2 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
  Statistics 
(N=XX) 
(N=XX)  
 
 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
LSM (Standard Error) [1] 
LSM Difference (Standard Error) [2] 
95% CI for Difference [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0, 00.0 
00.0 (00.00) 
   P-value [2] 
0.0000  
 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; LSM = least 
squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. 
[2] Difference from placebo. 
 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 92 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.1.2-2 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores Through 72 Hours by Site 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
Site 
Statistics 
(N=XX) 
(N=XX) 
101 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
   Etc.  
 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine, LSM = least 
squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 93 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.1.3-2 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores Through 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores Excluding Subjects with PCA Interval Data 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
  Statistics 
(N=XX) 
(N=XX)  
 
 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
LSM (Standard Error) [1] 
LSM Difference (Standard Error) [2] 
95% CI for Difference [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0, 00.0 
00.0 (00.00) 
   P-value [2] 
0.0000  
 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; LSM = least 
squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. 
[2] Difference from placebo. 
 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 94 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.2-2 (Page x of Y) 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication Through 72 Hours 
Study Part 2 
(Efficacy Analysis Set) 
 
 
Statistics 
LB 
67 mg 
Placebo 
  
(N=XX) 
(N=XX)  
 
 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
00.00 
00.000 
00.00 
00.0, 00.0 
00 
00.00 
00.000 
00.00 
00.0, 00.0 
 
Geometric LSM [1] 
Geometric LSM Ratio [2] 
95% CI for Ratio [2] 
00.00 
00.00 
00.00, 00.00 
00.00 
   P-value [2] 
0.0000  
 
 
CI = confidence interval; LB = liposome bupivacaine; LSM = least squares mean. 
If the total amount of opioid used was 0 mg, the value was set to the lesser of 1 mg or one half of the smallest total amount observed 
in the study prior to being transformed into the natural logarithm. 
[1] From an analysis of variance with treatment as the main effect on natural log transformed opioid amount. 
Results are presented in the original, non-transformed scale. 
[2] Geometric LSM Ratio is the anti-log LSM difference (LB/placebo). 
Reference: Listing 16.5.2.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 95 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.3.2 (Page x of Y) 
Time to First Opioid Rescue 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
(N=XX) 
(N=XX) 
 
 
Subjects Administered an Opioid Rescue [n (%)] 
00 (00.00) 
00 (00.00) 
Censored Observations [n (%)] 
00 (00.00) 
00 (00.00) 
 
Quartiles (hours) [1] 
First Quartile (25% Administered an Opioid) 
000 
000 
Median (50% Administered an Opioid) 
000 
000 
Third Quartile (75% Administered an Opioid) 
000 
000 
Minimum,  Maximum 
00, 00* 
00, 00* 
95% CI of Median 
(000, 000) 
(000, 000) 
 
P-value from Log-Rank Test 
0.0000 
0.0000 
 
 
* indicates a censored observation. 
CI = confidence interval; LB = liposome bupivacaine. 
[1] Estimates from a Kaplan-Meier Analysis. 
 
Reference: Listing 16.5.2.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 96 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
Time Point 
Table 14.2.2.4-2 (Page x of Y) 
NRS-R Pain Intensity Scores 
Study Part 2 
(Efficacy Analysis Set) 
Statistics 
LB 
XXX mg 
(N=XX) 
Placebo 
(N=XX) 
Baseline 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
First Request 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
LSM (Standard Error) [1] 
00.0 (00.00) 
00.0 (00.00) 
LSM Difference (Standard Error) [2] 
00.0 (00.00) 
95% CI for Difference [2] 
00.0, 00.0 
P-value [2] 
0.0000 
2 Hours 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Etc. 
Minimum, Maximum 
000, 000 
000, 000 
CI = confidence interval; LB = liposome bupivacaine; LSM = least squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. 
[2] Difference from placebo. 
Reference: Listing 16.5.1.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 97 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
Time Point 
Table 14.2.2.5-2 (Page x of Y) 
NRS-A Pain Intensity Scores 
Study Part 2 
(Efficacy Analysis Set) 
Statistics 
LB 
XXX mg 
(N=XX) 
Placebo 
(N=XX) 
Baseline 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
First Request 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
LSM (Standard Error) [1] 
00.0 (00.00) 
00.0 (00.00) 
LSM Difference (Standard Error) [2] 
00.0 (00.00) 
95% CI for Difference [2] 
00.0, 00.0 
P-value [2] 
0.0000 
2 Hours 
n 
00 
00 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Etc. 
Minimum, Maximum 
000, 000 
000, 000 
CI = confidence interval; LB = liposome bupivacaine; LSM = least squares mean; NRS-A = numeric rating scale with activity. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-A pain intensity score as the covariate. 
[2] Difference from placebo. 
Reference: Listing 16.5.1.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 98 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.6-2 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores Through 24, 36, 48, and 60 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
LB 
XXX mg 
Placebo 
Time Point 
Statistics 
(N=XX) 
(N=XX) 
 
 
24 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
LSM (Standard Error) [1] 
LSM Difference (Standard Error) [2] 
95% CI for Difference [2] 
P-value [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0, 00.0 
0.0000 
00.0 (00.00) 
 
36 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
Etc. 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; 
LSM = least squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. 
[2] Difference from placebo. 
Reference: Listings16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 99 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.7-2 (Page x of Y) 
AUC of NRS-A Pain Intensity Scores Through 24, 36, 48, 60, and 72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
Time Point 
Statistics 
(N=XX) 
(N=XX) 
 
 
24 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
LSM (Standard Error) [1] 
LSM Difference (Standard Error) [2] 
95% CI for Difference [2] 
P-value [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0, 00.0 
0.0000 
00.0 (00.00) 
 
48 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
Etc. 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine; LSM = least 
squares mean; NRS-A = numeric rating scale with activity. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-A pain intensity score as the covariate. 
[2] Difference from placebo. 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 100 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.8-2 (Page x of Y) 
AUC of NRS-R Pain Intensity Scores 24-48 and 48-72 Hours 
wWOCF + LOCF Imputation for the Pain Scores 
Study Part 2 
(Efficacy Analysis Set) 
LB 
XXX mg 
Placebo 
Time Point 
Statistics 
(N=XX) 
(N=XX) 
24-48 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
LSM (Standard Error) [1] 
LSM Difference (Standard Error) [2] 
95% CI for Difference [2] 
P-value [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0, 00.0 
0.0000 
00.0 (00.00) 
 
48-72 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
000.0 
00.00 
0000 
000, 000 
00 
000.0 
00.00 
0000 
000, 000 
 
LSM (Standard Error) [1] 
LSM Difference (Standard Error) [2] 
95% CI for Difference [2] 
P-value [2] 
00.0 (00.00) 
00.0 (00.00) 
00.0, 00.0 
0.0000 
00.0 (00.00) 
 
AUC = area under the curve calculated using the trapezoidal method; CI = confidence interval; LB = liposome bupivacaine, LSM = least 
squares mean; NRS-R = numeric rating scale at rest. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
[1] From an analysis of covariance with treatment as the main effect and the baseline NRS-R pain intensity score as the covariate. 
[2] Difference from placebo. 
Reference: Listings 16.5.1.1 and 16.5.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 101 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.9-2 (Page x of Y) 
Percentage of Subjects who are Pain Free at Each Time Point 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
(N=XX) 
(N=XX) 
  Time Point 
n/ N (%) 
n/ N (%) 
P-value [1]  
 
 
2 Hours 
00/00 (00.0) 
00/00 (00.0) 
0.0000 
4 Hours 
00/00 (00.0) 
00/00 (00.0) 
0.0000 
8 Hours 
00/00 (00.0) 
00/00 (00.0) 
0.0000 
12 Hours 
00/00 (00.0) 
00/00 (00.0) 
0.0000 
24 Hours 
00/00 (00.0) 
00/00 (00.0) 
0.0000 
36 Hours 
00/00 (00.0) 
00/00 (00.0) 
0.0000 
   Etc  
 
 
. 
LB = liposome bupivacaine. n/N = Number of subjects with a pain score of 0 or 1 / Number of subjects with a pain score 
at the time point. 
Pain Free is defined as an NRS-R pain intensity score of 0 or 1 
[1] P-value is from a chi-square test. 
 
Reference: Listing 16.5.1.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 102 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.2.2.10-2 (Page x of Y) 
Total Postoperative Consumption (mg) of Opioid Rescue Pain Medication Through 24, 36, 48, and 60 Hours 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
67 mg 
Placebo 
Time Point 
Statistics 
(N=XX) 
(N=XX) 
 
 
24 Hours 
n 
Mean 
SD 
Median 
Minimum, Maximum 
00 
00.00 
00.000 
00.00 
00.0, 00.0 
00 
00.00 
00.000 
00.00 
00.0, 00.0 
 
Geometric LSM [1] 
Geometric LSM Ratio [2] 
95% CI for Ratio [2] 
P-value [2] 
00.00 
00.00 
00.00, 00.00 
0.0000 
00.00 
   Etc.  
 
 
CI = confidence interval; LB = liposome bupivacaine, LSM = least squares mean. 
If the total amount of opioid used was 0 mg, the value was set to the lesser of 1 mg or one half of the smallest total amount observed 
in the study prior to being transformed into the natural logarithm. 
[1] From an analysis of variance with treatment as the main effect on natural log transformed opioid amount. 
Results are presented in the original, non-transformed scale. 
[2] Geometric LSM ratio is the anti-log LSM difference (LB/placebo). 
Reference: Listing 16.5.2.1. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 103 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.11-2 (Page x of Y) 
Subjects Who Received Rescue Medication Through 72 Hours 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
(N=XX) 
(N=XX) 
  
n (%) 
n (%) 
P-value [1]   
 
 
Received No Rescue Medication 
00 (00.0) 
00 (00.0) 
 
Received Only the First Rescue 
00 (00.0) 
00 (00.0) 
 
Received the First Rescue and a Second Opioid 
Rescue 
00 (00.0) 
00 (00.0) 
 
Received all Three Rescues 
00 (00.0) 
00 (00.0) 
 
 
 
LB = liposome bupivacaine. 
[1] P-value is from a chi-square test 
Reference: Listings 16.5.2.1 and 16.5.2.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 104 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.12-2 (Page x of Y) 
Overall Benefit of Analgesia Score Questionnaire (Total Scores) 
Study Part 2 
(Efficacy Analysis Set) 
 
Time Point 
Statistics 
LB 
XXX mg 
(N=XX) 
Placebo 
(N=XX) 
P-value [1] 
24 Hours 
n 
00 
00 
0.0000 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
48 Hours 
n 
00 
00 
0.0000 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
72 Hours 
n 
00 
00 
0.0000 
Mean 
000.0 
000.0 
SD 
00.00 
00.00 
Median 
0000 
0000 
Minimum, Maximum 
000, 000 
000, 000 
CI = confidence interval; LB = liposome bupivacaine. 
Note: The lower the score, the better the overall analgesic treatment. 
[1] P-value is from a Wilcoxon Rank Sum test. 
 
Reference: Listing 16.5.3. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 105 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.13-2 (Page x of Y) 
Subject Satisfaction with Postsurgical Pain Control 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
 
Time Point 
Assessment 
(N=XX) 
n/N (%) 
(N=XX) 
n/N (%) 
P-value [1] 
 
 
72 Hours 
Extremely Dissatisfied (1) 
00/00 (00.0) 
00/00 (00.0) 
Dissatisfied (2) 
00/00 (00.0) 
00/00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00/00 (00.0) 
00/00 (00.0) 
Satisfied (4) 
00/00 (00.0) 
00/00 (00.0) 
Extremely Satisfied (5) 
00/00 (00.0) 
00/00 (00.0) 
 
Day 30 
Extremely Dissatisfied (1) 
00/00 (00.0) 
00/00 (00.0) 
Dissatisfied (2) 
00/00 (00.0) 
00/00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00/00 (00.0) 
00/00 (00.0) 
Satisfied (4) 
00/00 (00.0) 
00/00 (00.0) 
Extremely Satisfied (5) 
00/00 (00.0) 
00/00 (00.0) 
 
 
 
LB = liposome bupivacaine. n/N = Number of subjects with a subject satisfaction score of 1, 2, 3, 4, or 5 / Number of subjects with a subject 
satisfaction score at the time point. 
Note: Percentages are based on number of subjects with a score at the time point. 
[1] P-value is from a Wilcoxon Rank Sum test. 
 
Reference: Listing 16.5.4. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 106 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.2.2.14-2 (Page x of Y) 
Time to Sensitivity to Cold 
Study Part 2 
(Efficacy Analysis Set) 
 
LB 
XXX mg 
Placebo 
(N=XX) 
(N=XX) 
 
 
Subjects with Sensitivity to Cold [n (%)] 
00 (00.00) 
00 (00.00) 
Censored Observations [n (%)] 
00 (00.00) 
00 (00.00) 
 
Quartiles (hours) [1] 
First Quartile (25% with Sensitivity to Cold) 
000 
000 
Median (50% with Sensitivity to Cold) 
000 
000 
Third Quartile (75% with Sensitivity to Cold) 
000 
000 
Minimum,  Maximum 
00, 00* 
00, 00* 
95% CI of Median 
(000, 000) 
(000, 000) 
 
P-value from Log-Rank Test 
0.0000 
0.0000 
 
 
* indicates a censored observation. 
CI = confidence interval; LB = liposome bupivacaine, 
[1] Estimates from a Kaplan-Meier Analysis. 
 
Reference: Listing 16.5.5. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 107 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.3.1.1-2 (Page x of Y) 
Overview of Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
XXX mg 
Placebo 
All 
Subjects 
LB 
XXX mg 
Placebo 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
  
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%)  
 
 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Maximum Severity: Mild 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Maximum Severity: Moderate 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Maximum Severity: Severe 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
At Least One TEAE Related to Study Drug 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
At Least One Serious TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Subjects Discontinued Because of a TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Deaths on Study 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
Reference: Listings 16.7.1.1 and 16.7.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 108 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.1.2-2 (Page x of Y) 
Incidence of Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
XXX mg 
Placebo 
All 
Subjects 
LB 
XXX mg 
Placebo 
All 
Subjects 
System Organ Class 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
Preferred Term 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once. 
Reference: Listings 16.7.1.1 and 16.7.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 109 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.1.3-2 (Page x of Y) 
Incidence of Study Drug Related Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
XXX mg 
Placebo 
All 
Subjects 
LB 
XXX mg 
Placebo 
All 
Subjects 
System Organ Class 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
Preferred Term 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once. 
Reference: Listings 16.7.1.1 and 16.7.1.2.. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 110 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.3.1.4-2 (Page x of Y) 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 1 of 2) 
Study Part 2 
(Safety Analysis Set) 
 
 
 
 
 
System Organ Class 
Preferred Term 
 
 
 
 
Mild 
n (%) 
 
LB 
XXX mg 
(N = XX) 
Moderate 
n (%) 
 
 
 
 
Severe 
n (%) 
 
 
 
 
Mild 
n (%) 
Part 2 
 
Placebo 
(N = XX) 
Moderate 
n (%) 
 
 
 
 
Severe 
n (%) 
 
 
 
 
Mild 
n (%) 
 
All 
Subjects 
(N = XX 
Moderate 
n (%) 
 
 
 
 
Severe 
n (%) 
 
 
Subjects with at Least 
One TEAE 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
 
System Organ Class 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 2 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
… 
 
System Organ Class 2 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 3 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 4 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
   …  
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once using the highest severity. 
Reference: Listings 16.7.1.1 and 16.7.1.2.. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 111 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Table 14.3.1.4-2 (Page x of Y) 
Incidence of Treatment-Emergent Adverse Events by Severity (Part 2 of 2) 
Study Part 2 
(Safety Analysis Set) 
 
 
LB 
XXX mg 
(N = XX) 
Part 1 and Part 2 Combined 
 
Placebo 
(N = XX) 
 
All 
Subjects 
(N = XX 
System Organ Class 
Preferred Term 
Mild 
n (%) 
Moderate 
n (%) 
Severe 
n (%) 
Mild 
n (%) 
Moderate 
n (%) 
Severe 
n (%) 
Mild 
n (%) 
Moderate 
n (%) 
Severe 
n (%) 
 
 
Subjects with at Least 
One TEAE 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
 
System Organ Class 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 1 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 2 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
… 
 
System Organ Class 2 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 3 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
Preferred Term 4 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
00 (00.00) 
   …  
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once using the highest severity. 
Reference: Listings 16.7.1.1 and 16.7.1.2. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 112 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.1.5-2 (Page x of Y) 
Incidence of Serious Treatment-Emergent Adverse Events 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
XXX mg 
Placebo 
All 
Subjects 
LB 
XXX mg 
Placebo 
All 
Subjects 
System Organ Class 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
Preferred Term 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
n  (%) 
Subjects with at Least One TEAE 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 1 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 2 
…. 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
System Organ Class 2 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 3 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Preferred Term 4 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
 
 
 
 
 
LB = liposome bupivacaine, TEAE = treatment-emergent adverse event. 
At each level of summation (overall, system organ class, preferred term), subjects are only counted once. 
Reference: Listings16.7.1.3 and 16.7.1.4. . 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 113 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.2.1-2 (Page x of Y) 
Vital Signs 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
Parameter 
Time Point 
Statistics 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
LB 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
Heart Rate 
Screening 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
Baseline 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
30 Minutes 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Etc. 
Etc. 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
 
LB = liposome bupivacaine. 
Reference: Listing 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 114 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.2.2-2 (Page x of Y) 
Vital Signs Change from Baseline 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
 
LB 
 
Parameter 
Time Point 
Statistics 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
266 mg 
(N=XX) 
Placebo 
(N=XX) 
Heart Rate 
30 Minutes 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
1 Hour 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
2 Hours 
n 
00 
00 
00 
00 
Mean 
00.0 
00.0 
00.0 
00.0 
SD 
00.00 
00.00 
00.00 
00.00 
Median 
00.0 
00.0 
00.0 
00.0 
Minimum, Maximum 
00, 00 
00, 00 
00, 00 
00, 00 
   Etc.  
 
 
LB = liposome bupivacaine. 
Reference: Listing 16.8. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 115 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.3-2 (Page x of Y) 
Neurological Assessment 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
All 
LB 
All 
XXX mg 
Placebo 
Subjects 
XXX mg 
Placebo 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
Time Point 
Assessment 
n/ N (%) 
n/ N (%) 
n/ N (%) 
n/ N (%) 
n/ N (%) 
n/ N (%) 
Baseline 
Oriented [1] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
At Least one of the Events 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Numbness [2] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Metallic Taste in Mouth 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Hearing 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Vision 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Muscles Twitching 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
 
15 Minutes 
Oriented [1] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
At Least one of the Events 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Numbness [2] 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Metallic Taste in Mouth 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Hearing 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Problems with Vision 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
Muscles Twitching 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
00/00 (00.0) 
   Etc.  
 
 
LB = liposome bupivacaine.  n/N = Number of subjects with an event / Number of subjects with a neurological assessment at the time point. 
[1] The denominator does not include subjects who were not assessable at the time point. 
[2] Numbness of the lips, the tongue, or around the mouth. 
 
Reference: Listing 16.9. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 116 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.4-2 (Page x of Y) 
20-Meter Walk Test 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
XXX mg 
Placebo 
All 
Subjects 
LB 
XXX mg 
Placebo 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
Time Point 
Completed Status 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
24 Hours 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
72 Hours 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Day 30 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
Reference: Listing 16.10. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 117 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.5-2 (Page x of Y) 
Physician Satisfaction with Return of Sensory/Motor Function 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
Time Point 
Assessment 
LB 
XXX mg 
(N=XX) 
n (%) 
Placebo 
(N=XX) 
n (%) 
P-value [1] 
LB 
XXX mg 
(N=XX) 
n (%) 
Placebo 
(N=XX) 
n (%) 
All 
Subjects 
(N=XX) 
n (%) 
72 Hours 
Extremely Dissatisfied (1) 
00 (00.0) 
00 (00.0) 
0.0000 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Dissatisfied (2) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Satisfied (4) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Extremely Satisfied (5) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Day 30 
Extremely Dissatisfied (1) 
00 (00.0) 
00 (00.0) 
0.0000 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Dissatisfied (2) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Neither Satisfied or Dissatisfied (3) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Satisfied (4) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
Extremely Satisfied (5) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
Note: Percentages are based on number of subjects with a score at the time point. 
[1] P-value is from a Wilcoxon Rank Sum test. 
 
Reference: Listing 16.11. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 118 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Table 14.3.6-2 (Page x of Y) 
Incidence of Transfusions 
Study Part 2 
(Safety Analysis Set) 
 
Part 2 
Part 1 and Part 2 Combined 
LB 
XXX mg 
Placebo 
All 
Subjects 
LB 
XXX mg 
Placebo 
All 
Subjects 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
(N=XX) 
Transfusion 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
Yes 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
No 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
00 (00.0) 
 
LB = liposome bupivacaine. 
Reference: Listing 16.3.5. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 119 of 152 
09 December 2013 
 
 
 
 
LISTINGS 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 120 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.1.1 (Page x of Y) 
Eligibility 
  Study Part: X  Treatment Group: YYY  
 
 
 
Date Informed 
 
Randomization 
 
Randomization 
 
Met Inc./Exc. 
 
Criteria Not 
Waiver 
Subject ID 
Consent Form Signed 
Date/Time 
Number 
Criteria? 
Met 
Granted? 
Date 
 
 
 
 
 
 
 
Inc./Exc. = inclusion/exclusion. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 121 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.1.2 (Page x of Y) 
Unblinding 
 
  
Study Part: X Treatment Group: YYY  
 
 
  
Subject ID 
Blind Broken? 
Date of Unblinding 
Reason  
 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 122 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.1.3 (Page x of Y) 
Subject Populations and Discontinuations 
 
  Study Part: X  Treatment Group: YYY  
 
 
  
Subject Included in:  
 
 
Safety 
Efficacy 
PK 
Date of Completion or 
Reason for Early 
Subject ID 
Analysis Set [1] 
Analysis Set [2] 
Analysis Set [3] 
Complete the Study? 
Early Discontinuation 
Discontinuation 
 
 
 
 
 
 
[1] The safety analysis set includes all subjects who received study drug. 
[2] The efficacy analysis set includes all subjects in the safety analysis set who underwent the planned surgery. 
[3] The PK analysis set includes all subjects in the safety analysis set who received liposome bupivacaine, provided sufficient samples to allow for 
calculation of PK parameters required for analysis, and who did not receive conventional bupivacaine HCl postsurgically. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 123 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.1.4 (Page x of Y) 
Hospital Discharge 
 
Study Part: X Treatment Group: YYY  
 
 
Hospital Discharge 
 
Subject ID 
Date 
Time 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 124 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.2 (Page x of Y) 
Demographics 
 
Study Part: X  Treatment Group: YYY 
 
Subject ID 
Initials 
Date of Birth 
Age 
Gender 
Ethnicity 
Race 
 
ASA 
Class 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 125 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.3.1 (Page x of Y) 
Medical History 
Past and/or Concomitant Diseases and Past Surgeries 
 
Study Part: X  Treatment Group: YYY  
 
 
 
Subject ID 
Visit Date 
Body System 
Condition 
Onset Date 
Currently 
Active? 
 
 
 
 
 
 
 
 
Programmer note:  Sort categories as on the CRFs, not alphabetically. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 126 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.3.2 (Page x of Y) 
Physical Examination 
 
Study Part: X Treatment Group: YYY  
 
 
  
Subject ID 
Performed? 
Date  
 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 127 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.3.3 (Page x of Y) 
Electrocardiogram Recording (Holter Monitoring) 
 
  
Study Part: X  Treatment Group: YYY  
 
 
Subject ID 
Performed? 
Start Date 
Start Time 
Stop Date 
Stop Time 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 128 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Listing 16.3.4 
Prior and Concomitant Medications (Except for Rescue Pain Medications) 
 Study Part: X  Treatment Group: YYY  
 
 
Anatomical Main Group/ 
Prior / 
Preferred Term / 
Concomitant 
Reason for 
Start Date / 
End Date / 
Subject ID 
Verbatim Term 
[1] 
Use 
Time 
Time 
Dose / Unit 
Route 
Frequency 
 
 
 
 
 
 
Prior medications are defined as medication with a stop date/time prior to study drug administration. 
Concomitant medications are defined as medications (other than protocol defined and other rescue pain medication) taken on or after the start of study drug administration. 
 
 
 
Programmer note:  If a subject has no medications, then put “NONE” in the 2nd column. 
If the medication is Ongoing, then put “Ongoing” in the “End Date / Time” column. 
Use formatted terms as much as possible.  If you have to use codes, then add footnotes to explain the codes. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 129 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Listing 16.3.5 
Transfusions After Study Drug Administration 
Study Part: X  Treatment Group: YYY  
 
Anatomical  Main Group/ 
 
Preferred Term / 
Reason for 
Start Date / 
End Date / 
Subject ID 
Verbatim Term 
Use 
Time 
Time 
Dose / Unit 
Route 
Frequency 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 130 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
 
Study Part: X  Treatment Group: YYY 
Listing 16.4.1 
Study Drug Exposure 
 
 
 
 
Study Drug 
 
 
Date 
Study Drug Administration  
Time of Femoral 
Nerve Catheter 
Subject ID 
Administered? 
Administered 
Start Time 
End Time 
Duration (minutes) 
Volume (mL) 
Insertion 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 131 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
Listing 16.4.2 
Surgery 
  
Study Part: X  Treatment Group: YYY  
 
 
Surgery 
Duration 
Type of 
Incision Length 
Subject ID 
Date 
Start Time 
Stop Time 
(minutes) 
Anesthesia 
Other Type 
Procedure 
(cm) 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 132 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.1.1 
Pain Intensity Scores at Rest and with Activity 
  
Study Part: X  Treatment Group: YYY  
 
 
  
NRS-R 
NRS-A  
 
 
Actual 
Actual 
Subject ID 
Time Point 
Date 
Time 
Hours Since End of Surgery 
Actual Score 
Imputed Score 
Actual Score 
Imputed Score 
 
 
 
 
 
 
NRS-R = numeric rating scale at rest. NRS-A =  numeric rating scale with activity. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 133 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Study Part: X  Treatment Group: YYY 
 
 
Listing 16.5.1.2 
AUC of NRS-R and NRS-A Pain Intensity Scores 
wWOCF + LOCF -  Imputation for the Pain Scores 
 
AUC 
 
 
 
Subject ID 
NRS Pain 
Intensity: 
0-24 
0-36 
0-48 
0-60 
0-72 
24-48 
48-72 
At Rest 
With Activity 
 
 
 
 
 
AUC = area under the curve calculated using the trapezoidal method, LB = liposome bupivacaine, LSM = least squares means, 
CI = confidence interval, NA = not applicable. 
Scores are based on a numeric rating scale where 0 = no pain and 10 = worst possible pain. 
wWOCF + LOCF = imputation using the worst observation prior to the use of rescue medication within a medication window and 
last-observation-carried-forward for missing values. 
 
 
 
Programmer Note: The Time Intervals should be 0-24, 0-36, 0-48, 0-72, 24-48, and 48-72.  For the intervals 24-48 and 48-72 put NA in the ‘With Activity’ column. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 134 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.2.1 
Postoperative Consumption of Opioid Rescue Pain Medication 
Study Part: X Treatment Group: YYY  
 
 
First or Second 
Date/Time 
Hours from End 
Amount Taken 
Converted 
Cumulative 
Subject ID 
Rescue 
Medication 
Administered 
of Surgery 
(Units) 
Amount (mg) [1] 
Amount (mg) 
 
 
 
 
 
 
[1] Opioids are converted to a morphine-equivalent amount. 
 
 
 
Programmer note: If subject took no postoperative opioid pain medications, put ’NONE’ in the 2nd column. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 135 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.2.2 
 
Postoperative Consumption of Rescue Pain Medication via PCA Pump (Interval Data) 
 
Study Part: X  Treatment Group: YYY  
 
 
Date/Time 
Hours from End 
Date/Time 
Subject ID 
Medication 
Started 
of Surgery 
Stopped 
Total Dose (units) 
 
 
 
 
 
 
Ropivacaine used as a rescue pain medication is also included in the listing. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 136 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.2.3 
 
Postoperative Consumption of Conventional Bupivacaine HCl Rescue Pain Medication 
Study Part: X Treatment Group: YYY  
 
 
Date/Time 
Hours from End 
Date/Time 
Rate 
Subject ID 
Started 
of Surgery 
Stopped 
Concentration (%) 
(mL/Hour) 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 137 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.3 
Overall Benefit of Analgesia Score Questionnaire 
Study Part: X  Treatment Group: YYY  
 
 
 
 
Date/Time of 
 
 
Current Pain 
Distress and Bother with [2]:  
Satisfaction 
with Pain 
Subject ID 
Time Point 
Assessment 
at Rest [1] 
Vomiting 
Itching 
Sweating 
Freezing 
Dizziness 
Treatment [2] 
Total Score 
 
 
 
 
 
 
 
[1] 0 = Minimal Pain, 4 = Maximal imaginable pain. 
[2] 0 = Not at all, 4 = Very much. 
Total score is the sum of the first six questions plus 4 minus the score of the seventh question. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 138 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.4 
Subject Satisfaction with Postsurgical Pain Control 
 
Study Part: X Treatment Group: YYY  
 
 
Date of 
Time of 
     Subject ID 
Time Point 
Assessment 
Assessment 
Assessment  
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 139 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.5 
Sensitivity to Cold 
 
Study Part: X  Treatment Group: YYY  
 
 
Subject ID 
Time Point 
Date of 
Assessment 
Time of 
Assessment 
Sensitivity to Cold 
 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 140 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.5.6 
Predefined Treatment-Emergent Opioid-Related Adverse Events at 72 Hours (Study Part 1) 
 
Study Part: X Treatment Group: YYY  
 
 
Overt 
Urinary 
Need for 
Subject 
Date of 
Diffuse 
Respiratory 
Retention 
Antiemetic 
ID 
Assessment 
Pruritus 
Depression 
[1] 
Constipation 
Sedation 
Confusion 
Delirium 
Vomiting 
Medication 
 
 
 
 
 
 
[1] Urinary retention was measured by need for postsurgical bladder catheterization. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 141 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.6.1 
Scheduled Bupivacaine Plasma Concentrations (Study Part 1) 
  
Treatment Group: YYY  
 
 
Unbound Bupivacaine 
Dose Time 
Date of 
Time of 
Elapsed Time 
Total Bupivacaine Plasma 
Plasma Concentration 
Subject ID 
[1] 
Sample 
Sample 
Time Point 
(hours) [2] 
Concentration (ng/mL) 
(ng/mL) 
 
 
 
 
 
 
[1] Dose time is the start time of study drug administration. 
[2] Elapsed time is the time the sample was collected relative to the time of dose. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 142 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.6.2 
Bupivacaine Plasma Pharmacokinetic Parameters (Study Part 1) 
Treatment Group: YYY  
 
 
Cmax 
Tmax 
AUC 0-last 
AUC 0-inf 
t1/2 
   Subject ID 
(ng/mL 
(hours) 
(h*ng/mL) 
(h*ng/mL) 
(hours)  
 
 
 
 
 
 
 
[1] Dose time is the start time of study drug administration. 
[2] Elapsed time is the time the sample was collected relative to the time of dose. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 143 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.6.3 
Unscheduled Bupivacaine Plasma Concentrations 
Study Part XX Treatment Group: YYY  
 
 
Dose Time 
Date of 
Time of 
Reason for 
Elapsed Time 
Bupivacaine Plasma 
Subject ID 
[1] 
Sample 
Sample 
Collection 
(hours) [2] 
Concentration (ng/mL) 
 
 
 
 
 
 
[1] Dose time is the start time of study drug administration. 
[2] Elapsed time is the time the sample was collected relative to the time of dose. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 144 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.7.1.1 
Adverse Events (Part 1 of 2) 
  Study Part: X  Treatment Group: YYY  
 
 
 
SOC / 
Preferred Term / 
 
 
Start Date / 
 
 
End Date / 
Solicited From: 
 
 
Relationship 
Subject ID 
Verbatim Term 
Time 
Time 
Neuro. [1] 
ORAE [2] 
Serious 
Severity 
to Study Drug 
Outcome 
 
 
 
 
 
 
 
* Indicates that the event is not treatment-emergent. 
[1] Neurological assessment. 
[2] Predefined treatment-emergent opioid-related adverse events questionnaire. 
 
 
 
 
Programmer note: If the subject has no adverse events, then put ‘NONE’ in the “SOC/Preferred Term/Verbatim Term” column. 
Use formatted terms as much as possible.  If you have to use codes, then add footnotes to explain the codes. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 145 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.7.1.2 
Adverse Events (Part 2 of 2) 
  Study Part: X  Treatment Group: YYY  
 
 
Action Taken with Subject 
SOC / 
Preferred Term / 
Start Date / 
End Date / 
Non- 
Pharmaceutical 
Discontinued 
Subject ID 
Verbatim Term 
Time 
Time 
None 
Medication 
Therapy 
from Study 
Other 
 
 
 
 
 
 
* Indicates that the event is not treatment-emergent. 
 
 
 
 
Programmer note: If the subject has no adverse events, then put ‘NONE’ in the ”SOC/Preferred Term/Verbatim Term” column. 
Use formatted terms as much as possible.  If you have to use codes, then add footnotes to explain the codes. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 146 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.7.1.3 
Serious Adverse Events (Part 1 of 2) 
  Study Part: X  Treatment Group: YYY  
 
 
 
SOC / 
Preferred Term / 
 
 
Start Date / 
 
 
End Date / 
Solicited From: 
 
 
Relationship 
Subject ID 
Verbatim Term 
Time 
Time 
Neuro. [1] 
ORAE[2] 
Severity 
to Study Drug 
Outcome 
 
 
 
 
 
 
 
* Indicates that the event is not treatment-emergent. 
[1] Neurological assessment. 
[2] Predefined treatment-emergent opioid-related adverse events questionnaire. 
 
 
 
 
Programmer note: If the subject has no adverse events, then put ‘NONE’ in the ”SOC/Preferred Term/Verbatim Term” column. 
Use formatted terms as much as possible.  If you have to use codes, then add footnotes to explain the codes. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 147 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.7.1.4 
Serious Adverse Events (Part 2 of 2) 
  Study Part: X  Treatment Group: YYY  
 
 
Action Taken with Subject 
SOC / 
Preferred Term / 
Start Date / 
End Date / 
Non- 
Pharmaceutical 
Discontinued 
Subject ID 
Verbatim Term 
Time 
Time 
None 
Medication 
Therapy 
from Study 
Other 
 
 
 
 
 
 
* Indicates that the event is not treatment-emergent. 
 
 
 
 
Programmer note: If the subject has no adverse events, then put ‘NONE’ in the ”SOC/Preferred Term/Verbatim Term” column. 
Use formatted terms as much as possible.  If you have to use codes, then add footnotes to explain the codes. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 148 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.7.1.5 
Deaths 
Study Part: X Treatment Group: YYY  
 
 
Autopsy 
Report 
   Subject ID 
Date of Death 
Primary Cause 
Performed? 
Obtained?  
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 149 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Study Part: X  Treatment Group: YYY 
 
 
 
 
 
 
Date of 
 
 
Listing 16.8 
Height, Weight, and Vital Signs 
 
 
Time of 
 
 
 
 
 
 
Heart Rate 
 
 
 
 
 
Blood Pressure (mmHg) 
Subject ID 
Time Point 
Assessment 
Assessment 
Height (cm) 
Weight (kg) 
(bpm) 
Systolic 
Diastolic 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 150 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.9 
Neurological Assessment 
Study Part: X  Treatment Group: YYY  
 
 
Metallic 
Problems 
Date of 
Time of 
Numbness 
Taste in 
with 
Problems 
Muscles 
Subject ID 
Time Point 
Assessment 
Assessment 
Oriented 
[1] 
Mouth 
Hearing 
with Vision 
Twitching 
 
 
 
 
 
 
[1] Numbness of the lips, the tongue, or around the mouth. 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 151 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.10 
20-Meter Walk Test 
Study Part: X Treatment Group: YYY 
Subject ID 
Time Point 
Date of Assessment 
Time of Assessment 
 
 
 
 
 
 
Able to Perform the 
Test? 
If No, Provide Reason 
 
 
 
 
 
 


Pacira Pharmaceuticals, Inc. 
402-C-323 TKA 
Liposome Bupivacaine 
Statistical Analysis Plan Amendment 3 
DOCUMENT NO. 040-00173.004 
CONFIDENTIAL 
Page 152 of 152 
09 December 2013 
 
 
 
 
Pacira Pharmaceuticals, Inc. 
402-C-323 
 
 
Listing 16.11 
Physician Satisfaction with Return of Sensory/Motor Function 
 
Study Part: X Treatment Group: YYY  
 
 
Date of 
Time of 
     Subject ID 
Time Point 
Assessment 
Assessment 
Assessment